var title_f2_11_2224="Typical hypergranular APL peripheral smear";
var content_f2_11_2224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Peripheral smear from a patient with the typical hypergranular type of acute promyelocytic leukemia (APL)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 494px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The white cell count in this type of APL is usually low with only a few circulating malignant promyelocytes. The abnormal promyelocytes frequently have bi-lobed or dumbbell shaped nuclei with granular cytoplasm. They can be difficult to recognize due to their scarcity, but when seen they should immediately raise the possibility of APL.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2224=[""].join("\n");
var outline_f2_11_2224=null;
var title_f2_11_2225="RP dynamic collapse CT";
var content_f2_11_2225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic scan shows tracheal narrowing and wall thickening that spares the posterior wall. Dynamic collapse is present during expiration (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2225=[""].join("\n");
var outline_f2_11_2225=null;
var title_f2_11_2226="Foreign bodies ear";
var content_f2_11_2226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Foreign bodies in the ear canal and on the tympanic membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) A pearl in the ear canal (a foreign body - not a squamous pearl). Panel B) Sand on the tympanic membrane after swimming in the ocean.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2226=[""].join("\n");
var outline_f2_11_2226=null;
var title_f2_11_2227="U-S cervix in PTL";
var content_f2_11_2227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Endovaginal ultrasound image of the cervix in a woman with preterm labor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jay D Iams, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2227=[""].join("\n");
var outline_f2_11_2227=null;
var title_f2_11_2228="Metastatic cancer marrow";
var content_f2_11_2228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clump of tumor cells in the bone marrow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with carcinoma metastatic to the bone marrow, illustrating the presence of a large clump of tumor cells (arrow), surrounded by normal marrow elements. Note that the cellular outlines within the clump of tumor cells are indistinct. This is not a characteristic of any group of cells normally seen in the bone marrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD and Anna J Mitus, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2228=[""].join("\n");
var outline_f2_11_2228=null;
var title_f2_11_2229="VISA A questionnaire";
var content_f2_11_2229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    The VISA-A questionnaire: An index of the severity of Achilles tendinopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 792px; background-image: url(data:image/gif;base64,R0lGODlhNgIYA8QAAP///wAAAIiIiICAgERERLu7u0BAQMDAwCIiIjMzM93d3ZmZmREREWZmZu7u7szMzFVVVXd3d6qqqjAwMCAgIGBgYJCQkBAQEIeHh9DQ0ODg4HBwcKCgoPDw8GVlZQAAACH5BAAAAAAALAAAAAA2AhgDAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PKxgBAQ0Akw8ACwEkCJOeAgELIpoAoJQAEZ4NDiUNnyIBBaMImZ6nqZMNpramlQoEkwiiBQEIrA0EAMACAAqxIqmiypMLxMGyzp60Jq62BALbAAjMnZ4KItm2BeWTv54QIsDn0/Ow1yISp6W5lgGYpCR4iWAXwJ2ndbYMBoAH4EGCSQmkiXAALAADZrvgaVLV8GExAb36feLnAIKnCPj0/zmr16ASqgQiHvhDZ2tSgQIeE2AKeA9VKBEhL9UiYY2WUIADawog4NJZgXTFTDyst6BcggLgRowrCqDliJUjulGjOOkiJ6ViQ4FiOE7cu3k4IWJaO5DZiF0Jzm3k96AiJbI/4wbQuY+t3RJLYSGghXQEsRE/h5ZKJoHBOYf1UCHAVMDss0yMwwGofDlvvMOJASRIwArUA2IIKiFT1kmBUwAOGBBIdhoAsXMRYIJl8TlrXXESTaRGToJpMwYSpqHMlvmnAAbxCDBgNVkx400BReVjJay5y4HJnSuArhplqfMvRyXLqmBcVRLrXQqAlzoyUN6rsYJTdts1U1BYLjnQVv8C7pGQWn7xGBNeKdjltttdvBXzXQmPWbKYZESBp0xTsQxnQmcJ2JWPNLoYJw4zHXpFE0vwBSffiSLKCBQDDIjSVnm/GAMhbQ5c1+OLDm7DIGgk5MYQTud885xLBBhjpI+HOZjhdQI0JkKHlkgDUGKVyXICe0DB9Nl9941QpglS/tdQANwBAEEExGhSwGxM7XbbApYdqAyMB0IAj4kqFBfOj8khxhtzIzgnEya7bReBPBPKZJs/5XVnCZdeWocdpPHA12mpc2KSwKMlBJeZcRA00GaaymWYXGIy1UnTA0AK2tV5nUUgoaO0joAmLKJoCuhw/YEq4pfgBeAsjpGS+JT/r61A0OadiC1KqAg6mqjjS5lxmCN84FynIDkSQScATMZKkO52bd1Fy7pM2nuClO+S4O449GaJIbKggEKtPbbIWcpDZgVkJpNrfsfRuxYdFmd3jbX0W5V8NkAMKLIQgFKcUloTAAHnQCWaCcUp5ZY5xCZlTkUN9wmoJtWJ0gAt/abW3wIFPyvSVTK341cyBBnU8APdELDTRA0wMJgoWT3Q416UCACfwgIlto5yMCUmLnyuPKwluKyeGmZXtIg8KNdASyt0h2rJffA06qjcJHS5hdzoLpN8++tXvqa1gANRT3234eDktjO7kWqdNtDGMPC4gxzVospsIkXJDOfoNW55/70xh6LgJHdHNiarDR0LwLH9FgfTrCVYHd3bcuY6wp2/yXTyiHbapPfbvy1rYLkoKKoV5CgspzZTDiw5oiYQ/MZTMZgk7anp5ZQQiu3omcdJeqtIT0ID8JqgSZEc0e7iwGsPrGkJSY8dYvO89Rvv9ZsN//Ppc4vW4bpnrmrR5FrI0xw/YtWt5fkGPOEq3NZGsL4CggtdPAscqdyVvtfJK4PSSlJX4OW+cICFXx381z5CWCtkaS51YgJPYrTGCquZTVicOdKqcJOASrhvFa0z08VSgwDW7OM1B3JFMtRjE/3lJjolO1BwHIAodbHMTC5iVAqcR77niMI5DLgJtvxDDP/uuO1nL5xQZbLXRa10cT2iiAjaSAABuwCqSKKh3XoYsp/t3QpApsFJGeMRAfs5RmjwcwaVhuXCYj3Rj2k8pAs3cjfnGAiB+3JPGfNhlxZ564EXJByN6GjHAt0vlPpyC+SCZKBF4jEpWTJOD/OFDt3U8EBSUmSEXqnKrjxKEqeITCdgOIpN9EIwLDzfKzoyCQKwAmse80gy4xQSg5THes5YokvKRroGQKAi1RCUn2xBizqeQHnH0d7ZilYQSxKjAJZ8YM7CwpBMXIQfwhRaZMBRn4TE82VGc8k7cTGYV5UDAbJ4HzR9kxOQ4FMi1aRZBLxJwUB5ginqAFPMGCoX70n/pJt1fGhSQhSVfFbSWsMz0NPacp1mYsVbXDGcNxh3ULNBKyy2oFwxyfEO7giGMMbRRCy3UZ8u2aISfVEFYIaRk7lsQ6i+lML83JAbXUHiqljNKg66kUCtevWrYA2rWMdK1rKa9axoTata18rWtrr1rXCNq1znSte62vWueM2rXvfK17769a+ADaxgB0vYwhr2sIhNrGIXy9jGOvaxkI2sZCdL2cpatg6fEYRGe5BZIfRTANawaREudoPOQkaMY/jsZWuQjxWY7HctMK0WSJuCzb7AtjuQLQ46lJhLiSBFO1gOCkgmMBXkY4KwMJuUYoHbHDQ3B759bnJjwNv8sQ4H/+lALiQq4lpsxVa0aJCuCsRrA93eYLPmfB14g0DcF1TKqtO9InmvkF7irLe2MryuDyYFVvFa70tSO9I3qhQQj4hCAR5BCXB31yDaNLMTlnnZZixh4NsMEihW8QgUmTEYakQVOQcN3mAcACgNOoYdzUgwfp5RRlPo5E8r6/BPxLIAZ3CGTqaYcEUDd9Cl7KUi41jMiEXMGodMAgKAGZWcCOAR+OxlAUzmB4L5sWJeScMkFqGwh5eL2imfosTJHFSVvOwLaXZZxeDohBEdE2CqCXnNCiTFUlzjkVjBDB1mJjIAj5qYKJ/Cy51ty0qI8RAdH6+/iDTXQcxyRyaXK4RZMf9UECMADzA+TRnJ0BOStIISSNPCK+PipzM+t0QOY+TTvBEGb42YIreZwCyPkbQNzyebBvAXGTD23qnPBxPnxMpqmKB0cxpUXdw9g5+5ARqrQZK+C5/tQv/tDablycD1XLpn80FAPTz9NuZuotoM6EuDI2UacD8AAvDytp3gYUNkH8lYzLiju9PzLXAktIOmRXdy38WKFBW7O9AuiL4tYTZBF4QYmJA0hRqVVf8KajjtLO4z7tMpAiygMsquTAmieBrEcWTitOhMFTOU0FITnEmcUzUEjxoXp4kSlBVPjsgL0qZ15NphTGppVGauAKyJpuVIXLJdjp3qBaSlAQowiRz/U9EwoR86cr1ZCUGSk7RxgbzbqJ060Jtjl6l3St0xJ6JEIK4AsXMdlA9SuihM+/U9sTy/Tpe6NALNjEHLcBtq8yqYQHfIephFXbQ9+X1k/QwelZ0B9exNh75RwVleXRkJSPz2So71nIe8R4PktwkYCO99rHtONmUyu2fyzbURGOdVcUZ0hDUQBCQD2CqIVeZNfnKxa76BMfFVn+uOLVfnUuDIvbDI+HlaJnE51sjlvLSV/3mZoJbwWCm6vzCyHbND/THCLYVRbre70WMFzpmH1+6PB33xgUIBHZolWf2is+tGuzMW+aLEZXEfL7un9A7wj+LB8w0vx0bw25APNtUf/5THZUzSTwnQI9ETFVgWCkB2aRvxECk2CeM2Gi0zGHMBETFGf20TDE91gfoQD8HwAAs4DrRHdOHTgHFDDSaDLiaHKBsBZbxnG9LEEvUEKHiDHVd3fJsAaNZ0aXHig7xSDOpmf56iNvB3JNa3f56yCzrTDiMwhJ0gCypYglaTNS9YEFLYWdYwFSZjGqSyWjeQfV5AhpU1VVuAhjeghncjhj2wHtz3BXC4WiZTXFVQh7u1TPjlhnzYh374h4AYiII4iIRYiIZ4iG2wAQawiIzYiI74iJAYiZI4iZRYiZZ4iZiYiZq4iZzYiZ74iZS4AYj4AgNQE6Z4irYwAGdgABZwAP+u+IqwGIuxWAEVIIu2eIsHQIu4uIuvqIu8uIsWMAG/CIzCOIy3GIzGeIzFmIyyGADMaIvO+IyxGI3SCIsWYACj6AIDoIozsI2reAA04I01II7hyI00cADYWAPoaAPrqI7pWAOJBgPx+ALz+ALtmI0rQI4xoI9jYADg2I3mCJA2wI8xcI8zYJAygJAF+Y40UI+xVVo4oJD4aAIEqY0B2Y//KAMVSYoXuY8dCQMSaY8MmZAjuZAQWV4nyY4lOZElsJEs4JIu0Fp45mF4o137Yoco4I/lOJAfyZEq+ZPuCJTwmJINGZElWRE2CSc46VbaIFq4NV8iAJMqIJUrwF0iIGn/49E4c+gDOimQ49iTFimUB7mSIimWM+CQxEGU5ziSWuk6giUqt4WWI0CVKECX4yUiaBIL3II7GAYRGtZtBuYTQiECXamRYNkCdlmXh8kCIekCjdkCj8mYZEmPaikDcrkCCLmXpAUOfjkJG6ZlP0FQl2ZWP6EpFeFM2PdmALQZdfZAZpOYLbmYLAAmn+GAdvFPohZCfGJq2mcJcUiYGemRPDmcQVmca2mWllmZMXCZKoCQJINBm0Jq3bZrAfCbaDVjQeYA0QNaxqRtybZqIfKasqmY54WXt6OX7rGZJAdwHMaB2vcXI1CYwvmVxHmcxjmWyLmcyimPRlkCmhlL6zl+/1fHmUCUVtrANPrhMcZUdB2SdIpzArBJAhF6N1iJY0LiOgTIngDoLxIhnzAwoRI6nikAoiMQmZg5mZCJopK5n5SJkjeAkG0ZhxkqoO5pLAxHVv7ROOuCfQxKJyL0TiG6kzXAfhMYGUhZOgXYnqCRGxBRJx7qk/QZpfY5pfh5n2fJoi7AnCmgkEe6TihogFXBpENmoOnRTA7Ao+hRgk7omkHqlWXwpGEppW5apVRKkvnJny46lC+qohNJoiQ6BXCKmCJKnnJqp1Zqkoeqn3lalHvKklM5qLH5jUI6qXNqqHWKqJeqqHq6qYnqqFEJqW36psH5oaAaqYWKqXSaqpbKqP+ceqWN6qkQWqqfuooT0IkUQAGfeKu5iqueOAEX8Im+Cqy/2qvD6okBAIrH+onJCqx8io8DYADbGK3SOq3UCq1nkAHVmK3auq3c2q3e+q3gGq7imgGwegIHQK3omq4DMKrl2q7u+q7wGq/yOq+C5WLwFZNaSgJGFoIwYDL65QL18a8rABVLqQItJbAqMHUygBABUIEtgBDvJgPr8TBdSq+KwF/mAwNWKQMLgBL8RQNbGQMLiLApgCgxoAk3GgNs2AJLkg9dpQKw5qMxYApYdKHWabGEoD9m+LD5agL5N5owsLIs2xIkiwLpIHkusGA38E8vgD6vwUgukH924Zb0aCb//4mzieAzKxOXS+uwLtAJBZsCF8J3MmA1YXtOUgNbM0AaM4ATrnC2J2AKUnOz3yVtTIu1g6CzRYsCUHkC0ZOULaAgKVuyNbG3Ygu3JRBGXkQDpBMD7PFINPCxlmm16Ym4eJsHGOu1s9mzADa4LKALz2G53GC4iOGxihsD4Ea3K2BFM8AApqu6A7tDDVmzVES1lxsI9joDRBoDR8ex5YC0MEC2LsCwmqsCRigDuSG6HJK2xZsCG4FkM7ALVEJlt1u91nu92Ju92ru93Nu93vu94Bu+4ju+5Fu+5nu+6Ju+6ru+7Nu+7vu+8Bu/8ju/9Fu/9nu/+Ju/+ru//Nu//vu//+jbtzhiXoc7s6SbPPdVWgkMBTubBIE3pMqbArplgEJAwM2DOsTywGAAGHB2Aj8FtH8gwCWgtCzQXjDQwFm6wPCows7FuSjMtfZ1k+vkXrdpuceFwM+mpC6gwYnCwiOQf+A1fmbwC9rZuCUwJFVyr30gwv7iw7jDw/ijwEBgwQx8wHsYw0q5tDXsXtpxrxOswy0AxTj8AjIRxWIMBiSMGCn0QWrWGp7wtDQ5R8pQSCqWcsmxF5UwZwLXpG6iZHPicVu2FEHWmdXpG+UwDChGOO7pZ2QTDEaox/PwZIxcpFuzC8lAYxYms/iRZ6dZJ5nMPhh4c5ARmJg8Ey02gkkiNf+skQ6skZpt/MMzES9pNmRY1sodFm76Wmc1FQt1gz1iUXZvPMl91mRFmlmSTMxkdsScIg27IBOBSaN6tq836AnVcMiQJ2WcbKagSXW5YHBlV2p3tDCbTIFI8kQMK3+nhwT6gwJ8Jwzz5nw2Ohp+vBIrIWthZMcnsD72tjD9dhg/m3p9FBa9Zhq5KZ1HonExu2KLPHqX9gz2/FKhd5vJ8BvmFoUoKNCDMy67Q3I6SsKgZmszgWuPBxm7htG+Zmu4LGz2UsSHoXqpqQDJRgIpUh8LYDXaB9M9onn+9gy42Wzg8TGtE2zw8AzwnB3y1GcTLXDpplwSTW2+gMt3ETavl1n/3EajOs1sMvw64oEdAZd0HG0M2/kpvSlJSLIS41ceavPQWZEVB83VYIgE6KPExSIC7lJ0swIVvScAEwUpFofPFFSDqdG7I5AiEeFN1BcMuDOjKFMTYKFRuRYn+vcMYXdd7SV1OUVB2zBDaXt5Jhs+BCcjWkMUgdJz22BzIz1d96FznE1z5LROTJFULLigng0NsSIB48AfRXd0MQIfDhoRHdIhPrehUGfWWUjT8WW3M6iwWpEQtDOgJhcLR9fb9GYg/pTcc7cnCSrcN1XWBTF+S2Hb9CMNFtc3EYHXvxDBN4BgZHNdukQkYlfUWs23CIDL0JcVnUF1KOGyPtPBd2E5/68TbqqnGYkdoMkQsa+DEfr0RW3DDC6Lc/VN2ZVLfsjFX98U4KwHed5HR96no0YseqliJ8nwE+mM2tpWyBe+GK8H1cQCR+iDG6GApmFoNeX0d0V3e6A0OMqBUD7aIbAHGdEB37/3zW9TzxkeKRFez8EnsyID386NdTaeSoRE19NN5KDH4UpKO4uXx91tcrmRxuW3MwVi4GfcA8EtvByFgUdINW/MsFsru0aIgAaeY1u+O9Ssr89w4UC24FxDeWyuORKIOYPRgSZWfI98XTEY5D6oTIOxRB6YEpSnr2rG09pMAgIIFB3lYhtofI1eC1iUOZZ+ZL4hNZ0QTmmeuAx+IP9mp4K7DeimU2hgIr1d0Q7NHOTjtxJbaDaHPoOJDi43iB3N3OQGqIJrSkEsGGJBPoQPETLafNq/DRFzHicRYEpfoWIGYhd9PuZp0Dd4gO1MkBpEUwMvPAThjgdCe1XcHgg2su3obQQhawPtrgTjTgd4CFbjAcD2fu/4LohMfEVLq7ZJYNtBhwT7Lu7/Wh+wm+9u0Ow4QMUrUBlyrQLYbhVWhQDRMfDbDcM9EO5mKFxg0hkPj/BsoPBSDO5WDHUvgC9/ffFGYPEGW/Lwo/JyBPJ0sMsMk4HYM85/lmcNiOA3P+0UmA4SgcdNQjNPds7bPD7no0mbwCvMUMus4PTgoMr/Z9qdr2zJ98P0s2xEOZZwfDwCoqkKeiz0XoNiWb+atC3z8v7TPI3SQk1HT31uHB1h3wB7Kn2V7BZGO1tB0FIncdLWYn0do6B+kSINCIdQ/KwazNbPVv7SySYT0cHxnJJQ3tkjdF9HyxYQ3Ke1uI5jBY4SjI95zwJlaD8HIt8Swb3c1Nx2MsJ4re1G8QA0rLMANUgCTMcMv5cQLJZEE2Rx0OK64HJUR5caTAHjwtAmkO/7ae5zgt2Xq+AzvCH75rAUjS3byKFRoj/6cTBIu93j/gkf9Q3W48D9Gl7lrIMA+e1dc/IL7mHgd761SQ8tnYERcGbjYgP6aU7hrPJONI4e/9wPAkLiAKV5MotYCkSJRIAUKC3ACIAQ6C6ALAoBUikCOSGTyiWz6XxCo9IptWq9YrPaLbdrciQCCGGp0dAF0meTIpxWPBCBcAGcRuR26lM7HbOd6MkpmAjtLaQFyYkBpIkVlK2dLCSUkD0wnEE4LgBsJuoFHJEBAgE03PlY8mA2lHaGanJ+MaSNYAa4+gjS2CCK8bzaIZQkdHohJysvMzc7P0NHKzuYSjMFQEIhSFgBSkFIWksJEDsVMBCJq6+zt7u/wy87qr5jR0kgPFR5OxHYEsZDoodBNiYKtgVMqHAhw4YOH0KMKHEixYoWL2LMqHEjx44eP4IMKXIkyZImT/+iTKlyJcuWLl/CjClzJs2UHQ7gzKlzJ8+ePn8CDSp0KNGiRo8iTap0KVOhHWpW1MBUA9QtBy4YyKp1K9euAbqCDZv1q9iyWsmaLXthQlq1bNuGXQs37tu5XClQsNsVr967eftyvXCg6sQBf/tSGEA4ywEDWHhkgfxYi4HBWCpnwXzZ8pUBirF4zhKaMufFDkdXQW2aSuPJkbVIvqJZdukqs63cTv25824rqmmvfvhbyvDgT1pfiW1FeRXmVHI/rx09s/QpxYn31r0FuvF4159830cvpD0myJfDTk99/Wb2vEVnpxI+CncvBHKkdDQmCRn+zpfMx0SA44zH0nnNqef/WnsLAsegb/FZByF221XX3TWwMCBFf1AMqESHSyxQSwCxtLCDAv4EQAAJcyQCQAGLxOYAihm+mEiILFQiiD4BLIBAAzXyeIIQYeTzwx07FjBkAAzoY8KBVPwnRZRRTAlFffRViKV7D8LXJWlJsBhkHwHEcEKYnaDS4n2NuHGMSEE+QAOKKpKCgBwjLJKPG6OUV8KHSPyZBAFl9sDCfuQ4AEYOI+pADAMxbOjiECakIAM6laaAiT5GNHLEDZ1IkGEhAegDgacvxICNEJAQEM6TU1T5RKxOzNrElVZmieuW2oEmYRSBKgEdo+R4cgQmBTWSh6hlVLLmsOW8iSYeCCSa/4AAdSrgQAr9rTAqssD66SsUBYRBwAOAAGIGC2fY06MCNEiKRARLCvCuI70QgA8Av9zRCCT2OgJQvI06kGYu/vanrpOOJZdgw7tO56BtuYInbsVeQtwuMdUQ4Ka/ktYgIjHOQtIjSfo9oLAAPwbjAxD9KbCJMQBaLGDNUIDTLbrUUrNoyY7m4VycClTKhhg5aGpmNkUj0V8CDSBCwtMIQ6ZwCa9K6TB6EE9x6xNeOwF2E+CaQHa4FIL5c7EAxImsPREg8C43cANA8r7Qkucmoj2T4nIQk5pA7KonkG123UfioosJc66o9i9yCOnIGUCW0wA6LEj+sYt5Rv7PmD5SHf/JCVhTqTWCXEshNhOqL8G6hzfbjLHEH5s8JqEl6MfqHSP7fPfJHjPe9wsLDBNKJ4OXDXsShidDrDiRWkE6FLVeY3rEDWKPG8VOGN698qtv30SfFnJR+PfMDIRsNNBXIb2s1sP65exdhw++7Ly+J39y6pN//4T9H4dhW1PQw+aXuvq1DoHBUuDyzgcoBxIOgkhwHQCbYb4KOsF9tIJf1lCnJQN+MH8i5JL+MNiOC5pwCQeYwFIC0BQXMgWGS5mABZhCQxvWcIY5VEoFKsCUHv7Qh01hYQrdgcIiIiEDgFkiE5voxCdCMYpSnCIVDZABJLJjAPfaIhe7KEEsgjGMYhz/IxnLaMYzojGNalwjG8k4Jo9RwVpXmJcYmkSFGfFvHOOTgsGoxwcU5dEJ/GJEFT6RADtO4RMqmqMqzlHHNkIyIqaSAeCmYAj8FLJUp7JCBCphhV8E0glWswICRrAFcFQhVISYGhUQVbfbSSlFlMpBJyNpy4YwgBuaq8KassApLKAylbncYxTStB8qhCodWBCCwKTwrhz0cgpwI0G3xFOCOJGAfbfcZjvKEyQrRNMK52jmFBARtyqs6l2hhILl9iEigmAhAbD8BgQSkAByQmFMDPCkNQfGTG4C1B25xN06mxBOKvQIkd3AWzG3WNAmaNMJgKDbJy+3D09W0wqT7IYP/7A5sICCVByTnIEyp3BQKRDAlFZoAyEisKwqqNMKhzxFgZ6QtFpWoWdXEAADCNEAfu6DmFHwBg4AgNOQIhUabxSnfmC6RXw6wQGfOOZKhfoEQyp0qLbIKhRceQUUzbQKcqhGcwLmoloUKalqXStb2+rWt8I1rnKdK13rate74jWvet0rX/vq178CNrCCHSxhC2vYwyI2sYpdLGMb69jHQjaykp0sZStr2ctiNrOa3SxnO+vZz4I2tKK9iD9qugXhSeMgI/LjMqBniIduhB/IkO1EItpV067DqgHV1j+cMK9jJHOXXUAtC3C7hQi4QJu0ZQb05KjVNOBHDyp9wkmVYP9bAqHPuMiorqySBBno6XZgy+UCbemYVhOEdwqLmC4W5dkEbRFgFz5ILzpbZg0I5EC52vUC9OCJzCHESR/uRcZ1h7rfnR44Hv0psH+Km90kQECTSKDvFHQKRmrAEQkhepcCAHavGhypET2SxC9xBLARCK9HBbBBSvcwpvE5slLkuFM6+IWIfUkOYOEIhQvuQ4C4uSEGDfAbm1oEpNgY03Y9MFESiKUzepDDFm7ghrPa9IMccJhzhnRAiKC7BB6fdUkeG3IJBqXkG59ix3aagwNOXDBPmdkN4ShykAzWiSq3yAShOgE2sZEnJTGJamEItAnyNGM2o+GRgVuzKbfM0w7/pyBzSSgx7qwc407gAQAcXtWIZnQCshYRFdodVN3yMF9I3PQIokDCnsmMX6NJoG+UIASLk0uDehIUBTkIkQPIkS2mlfqjOO71eOLEDRbfc23HIvMPOvGsG+RXOfaY5LHIwT97QWJngYjbM2ka7GdnetOQEYHUWjBPPtvDBkXltdE6fGtjEQTNo/S1ttwkN2YODZVEQ+SwXvrTb+cBbw4glbsEoGrvroJV7PKuwiNnqF8vINXbhji5ASDHTspxvOOccMChvS90hJsGQoi2MikxZyQGUwkeJgYg2nUvYuxx4BIYVIge8AAU8YgUtdAli7FMg2r0icO4qwGRFxftfbkB/18aLkfPh1fmBTDbFBoTOnghwTEV4HZoTw7EqQtlN5OFXAEJu9ePysVVk/VA6I1o5n0icIary3vHfrv5LNr+9nt5zB7M5Gm/vs5QaxmjAa9W1XertvCEhYNbfhsk3l7RxzWU0sFJSGja7qb2n/tc7JKZV1HTDMYFeCoBR2B2IDypLQm0nBtJQy//IJApBmTo3wP/mw6Mke4eZ57a4ysqT4ntdKPHCwaUrAFQ2UYqT+C+BLpfMTHO4Wy18V7akFg+bQkAiRnY/PgDlvztv622VqFB89Rkr/I1QY8AI9/jvRcSAgK9fGa2Qe7Dk32QQgTPlE8YEnCTm1F5RzuG8tQZwP8ekghBNhle6HjeqFDT3BGaQPhNxZkAcmVaRpUZ+eWayfAeOoCfiUDP0IzRA7hBspFeoWGS4KXLG8SCcLHA5UyNI8kB7fkCjzQdh8UBMCDLpRVKs53AmpDCHdBA4pyAMSWfpgWZpt1JpWgMjrFI/hGhH+RgIDhCdNmCMrVctiVfEhpCGGQLkXgCJ6BIkfiXCaRJAiRXLQBbMfiAkh3OPslfs7ngNyFAGiZdM+XO4YiB/yUhuulfOWDDMCAeAo5S8RBZCgYOkX2CDFJLnERcLUiCh8EL6/kODmahyBXeHiQgZ3ngOuBfd8xcFmgLbDUDhY3WGRkCo4gDWEFVGh1VN4H/4ii64ivCYizKYmWx0g7KEhaE03gpg91kgWrtADy4Vhq0YkToojjoAUiUFhUwGDD2VApRAu68QXBlQS4a1zJCAS9iAXIJWyFKQ3Nh0hOU4i5MYRRwV9OwVjFKw8ANY7C1A4rMmTSCY+ExITP0Ujk6YAohRK6h4zV+YzFaI3X1Tha8mn51o3KEoTPlEvpt33CdY4I5Q5xcBKIQjS5J3rjIozXY4xIMXCoGx7ukAzYAjJtE3d8Mmj7YWd3IWaEAicfkiRqWwMAhUi6dJMmAwSYp2aFNl43xAL80gI5BYRrg3o+d2QGeyeY4QhDegZJxWoZpHUbRgxDIAQN8QgzgWZ35/42WTSEIpsEmkUMtjMCYnMGYQICbxZ2MpAGNLAIcMc4ihENRzuSiWJkS0BGpiKUd0gk2yGCImQAElEk0haR07ciIFdodABqSaOWqsUHSFUDcGSWPmKWYeWHQzMGOxKXFfSP5vIjSPGEZ+M3ggJ8YNouxkIq6gcpL9Qe1HaS1HMQiBmGzLIoEONdewhvzQdwOHp0JRI1sGZvXJRtqLiZRdlxRVZ2yEcTIKYEcmJqhRI7VucCNOUvHjSS3mJK1UKChJAoe6BuTQECByE3cFSCllOa2Vcu1MEe/tSbANcoSBABFbueijadxShzw1Y38oR+ZIeaoJNx8+kt1pp+/MGalhP/Kd5YZftxHfbrAs5XBZVpIZkKibEXnAfIdI/SSDBKAIwpMf1zdCRhBA+CDwemAyHzbPiXB1b2CbcYLJQSMbKFd0+lg3SwAY04dvAzn1dkWhm0dfgYbGfidt7lh1ZBdzMyBxwBCq8AIj5AV3dnIAXJevTyVGK7ByrCP3vUCiO6oEkRZA2CYk65LfzDeCfDlgHKd72yOCi4YURYAkM5MoR0DNsSdhS4pO94H2mVmHp6CgnaHRzboeAjOthge/9HNmswA0X2KdU3K8vEZAxCD6zHp3OAhJYwH9RUdmJKB8AUqBaJfe/bS+9FA/P2f+kmfshFeEriCpuGAQt5Of/AgD+z/6J7+zfiVVHpyI9GAXji0J7MAwOzBXy0OzRlaJ9+U5x76KR6qTdsoQQrUKsH46jU1oHhOZJhe6oGqz3f+YZ84j/KJpnd12NTw6tCQWqk9a6cWQw6MYHfkY4qOh2olAJ+KzheOTBSqJOd8AZG45CwNnx3aifeBwXTdZKTmaDD4IBwwIlKKwRCqoT+wYaf+QhgwoVIyR49sJeYgGo6mqvf5DrqmwDB0ISjMQuA4whG8WLZu5Rve2ZI8TSlODrwuDlA6QJQSpr0Kq+/wA2+xWV0Gj2QQYsoeTJgm2kzFHJFM64pt7DWNlT0YbAv+Web8wgKsCWCC60byKPk8YxttYmCJ/yISJMA6ekTVasE+rkYtnhEqGpbW0oTYXsHGzeLZom3aqu3asm3buu3bwm3cyu3cjsQGVNHd4m3e6u3e8m3eboBeaVEXCS4XfdFiGMAOHQUQLYXi8pAQKYUFsNBSQC5TTK7kRm4LvVDmNoUFCNBdHVEYUVDy+E+EMEbnto/psgbqToEGvc9ruG7pAq4EMU9VhO7Z9MroSgHrNoHumofq5q7vdhABDRAW8C5bfS4Y1S4AeA/uRkHxKoHzJgH0IoH0ThgHlY4WUG9IHW8WcC1GhFfyLu/tEi/wQkH2Xg35BpD1To/6li/6ZsE/dkQdmiOh/g/+bEH3jgT4Fm74XoH5Av+A/wKw+27Q6xbQ+JZRkPCUhlDP9paTiJDIfciJytLZ8cDICTwmWtqIqKyAjoiYj6xk5BCJPuQJAbLIsuov83JI4QYw7BowAQ/vC0eP6eIkNW3VtnllmzkCigUDo73qR8BJBKfIyu4wjY3wnkjKt8hu4XZrDlobssrRsz2KsAnooCYTpizipqiapwCoaR7fRqEK1TScCZyw+I7Q6bJw/wpw77LvAAtvDAtE3NSbgYqnhWnaemJLvZVEnU3Le+4wxEnnckZQGSuj2aGLD6jMwlmejCrHklpoC+hLl9qDheIoohjM4R2gGDOQ6JIxCaHxGbtxC7cxlKxxBsnw4pUDg0r/Xqsgac7ZV4uOBMocMmq9DGSgaYbZrv0Ckys4Za9mWhJGnxLsqse8S6atXq4NaoNZHNRMytSE6iUCwBgLMumC8id38jTDsCi7MDVLHhB8a6ymAP3BIL/mjXsm6ytMcXoizy3LhxIjDiN6A+MgrA92zsFQThlYVAqWRz2Piue4Aeg08yhBMycLtBlbc+p68jXHTzYTNDfqINNy7MOKrCzbctYCj8pKdPHMQjorbxIrRLUWZAlJczTXrzYvNEkbtEIndCifNEdxEwOrQ/qoA/wukEj/yv6qcBqrEE4/r05HL0+DyShXD/b6NEPfkkunUEDj8jof9Eqb9OoOtZkAtXpa/8VTg5RRmxBSK/Uml/RWMzVXY7NKB29B05VVY5AB1IVe8AUTpfUSrTVgTABWMNFbN5FcxzVcMxFaLBFeA4ZeuzVVB9QAGIBnCPZgE3ZhBzYZZUBTKPZiM3ZjO/ZjQ3ZkL8UV5dUBFPZlY/YAZDLdcnZne/Zng3Zoi/ZsjaMVzMAVHObJWSRQYsFBOCQf3IudPgHfvfZgBq2GLMK5gWNUTvQTEE1BuONov4SpglMaXMECxAD6XUGz5lS5VBVHPgEi9LYUZOIUuFegVoFwVpIelYdEDpRws8SN1pcWwCQWVLd1m0FtlwDAbJIUxOY0qvYT/NQDvEgPv5cpfndzZMOXsv8jeKuEtjGVFiyxWJniHbnAuFIBJsi2+IiIeutZM6LT0xT4FAzEeu4PmOqnf//3Lgf4FYBBfEtBlk6BIzq4fE4BPMnqFWSaFQzU6Zn38S3Hfvflgmt4SBB3h6MTr/IRlnWeFSB4VyX3QUZBdlIkhVtUdgd5kY84GT5GNni3ktd4SUiXfffDbTeUpJXTIrQ3Ffz4bjshTBVhTvV4jn85Qm0llTcBIQZ3lLN5m7v5m8N5nMv5nNN5ndv5neN5nuv5nvN5n/v5nwN6oAv6oBN6oRv6oSN6oiv6ojN6ozv6o0N6pMc0a8UDNgo4jUNERloD2XIBp/u3PzSBh+k2F8g0FuD/r0EFpDHzEqYr8BKUusPVI6tLg9ay6IVrmJXXeJqEuoyKHnNROjxY+jTKukU+Q6wnBKdruviEUgK3eSf9okE8IjbNK7utAOPEFNqtQkkaSR3dSO1lLHu12MHwJG9a4kvCeAnIZN35TE0K2pLoA5h5qbsC5p6ZADaF+xl02Yi0ZA4L8ZKRihGbwHvzpRDY2L0jwUmOirYzrZEO2SL82JIQwggL15Ep4cG0gI3Fu5hdzgp8QoZMW2mLaZRjQNyg2RKonb/45qdhmgrwjGrS6RFnOKrgcQpU3HsTgGjaUW72mK01k2pys7+5ZiPAJn4QnsLtJj/4mrce35DBZMEdQXyB/8wSQ8+97XC2FV8RPL0A0reqEijPK8G/ect8yjFiQj0iWN03Ct/uQUps6Hx/P5yaNlvSE1TN50DBnFeNF2mUqB02ZWgh6sshXzveIF7BZI4jE8PjmaiIoSgKJt/JGxU4dOgRRCgeiihBId6K0oPCxOkpEwPgQd2rrcmmmV1/rHI4r7fMeEyoqEAC7JmOEmjmBQKI4qgZyCnMZcPElhrh70HQKTLSmavbO7PhOzM2IL7jt7m8cSeva8K1WvA+Bdx1LsqdCb7hRU0y1/EEWmCwBSqlKl3oP6KyJioOBOu3OarlG14387IAfGsA3kCgeb/AgMN3gjNxKScK9BRP8ckrgf/pyY8/CABiEYhN8wQPABFAUIiEAJCysAQOkDRvLAIwaIISIgKQBBQCFwEZBAgQiqCDkSBSgzBBYhcNi8fksvmMTqvX7Lb7DY/DcyZXWBHIB2gARSIPFRXBAEaQR7BTFJCAEGUDcOKXh+ADSSgCobcQZZhHNLnUBDDTtxQ2lGTaidBICuOQ8AXzeAI5aScCG8CA8Lm4khIT0ThKg6ew+qCLUMAQgBCwYCMqpRnWAuAQXVOSE016zDlJPFIC6aOYsAJzw30j+ezDHuQNXf0c6uK9GdTJIDKoUJ5/7DLl2RROjsKFDBs6fAgxokROfCaiIWVxIYRKGTt6lDhlIcaPJEv/mjyJMuUYJWBUjlRJplOCKjBrplTEAEgcljZ7+vwJNKjQoUSLGj2KNKnSpUybOn0KNarUqVSrWr2KNavWrVy7ev0KNqzYsWTLmj2LNq0IDgPaun0LN67cuXTr2r2LN6/evXz7+v0LOLBdDmqbcjCAOLHixYwNEC680ECFv4gDVwZ8+W8FCoE3d+YM2HPgAIJJjxY8oIIByEtTH3gNO7Zs2ZNZKzRwAE5bObvj9IZzYHWc4HKIDxcex1xyhcqP2076u030521w6x7AG7tv7cCRvzHevbj3N83JM18InjrR6WvYq09j/Y379tzl13eTHv/4Nvn5729TnhsBAojef+/5/zQfGgm6QU1W85ARnxsLKnifdBWy0R+GBqqR4RodrjEgGyGCWKBFj4ClBzNinOjIiGJMWAaMazRIVoQWZoejczqGtyMcLqbxIxpBovHhgWVsI8A/arB4hoxjOEnGAs7soUcDTRSBzCE7LHJQDdDkEYUD/nh5kJQieHEPAussQEkBX/JTzh9qAvDlnLNwycAKQdjIBpRPXkifeIL2qN95cgxpBqJm5DcFNF/co04UUzjzBR55fDENK4u0hNU2KWQZACKZOupAnQ/8EQAE3OgEgJ9RuBrGE0FQM0UMUzgACw17SNEIA0iwSEJLDGwiASHDCrHAA3kCEIGqqYpwbLEtrv8AgapBHPEDCTEQwBEAfAa6XY48jvvdhmkUCaShyynEKBVXJKsCJLjwimsvQeAhQaYKvLvVNg30ggCuWej77iNoBqHtq4BSKEcBfxDwAK121CKFPDGwGQ6TEewigKV6MEGABI14M8kPpehhSjlnBtxAldmaQ7EI36oBq8LiljsouYUeqq6PJUpqBwILsDkCOVLYwe0DnUQzTdBwdjrJAxQL0EDTIgj9iAKZJPC0zfYxtNHBtAZcqq4X9/rJGJ8ee+8zNCirpwjzsB3GIz3ksEMPL5vQ7cxp1BwE4CIIDgC6Zxi+qLlEKi5kz+axOx41QqdA7byiKDBsAwlkw3QJknf/bdU2K9crgNV0SqODpI0kHPjCTbp+UdTKBmAlLp0gYjLR9TRHQh4+uFmyJWAoQrvJZD7T4qUKwEPJ3udE4TfD4U6vs38548xz9utef/TVm6QT9z3PNoMP6t2f3u/TtztgutDLEL8J64PDHiP9JYVkEpNuRP/6zRLaXwbEBZBxieOegBx3QMjFgUZGcgjgCNcQnLDqI/qrTm6+Rj0MVk9DBuSg9nz2wQ2qgYENZMgDAVhC/pmBcCxE4RgESAYYvpCAA0QggUKIvRL+5IQ6hM8F/+e/GxHKekP04PZAeEQR9hAlPFyiGSRDGQNYRoqYoaJmQHPFz2jxNFwEjGk6Q0Mn/2ZkAFbkixTFWAa2oGaNbGyjG98IxzjKcTBorMkBAvPDOupxj3zsox//CMhACnKQhCykIQ9JknRwig1KgMOpfPeG3oUqDgpAwLzW4LFdMcgZl1TDl7rUBuAFIBBsAB7d2oA5nXSiW4hsZVEoxwNSrqETc0ACLOGAOQm8QRedTENC3pAD0LnhU25IABKUQBM2oCJYDMoDEG6VS1dKkyhi62UaKsgGbYSvDcQs5gmseQaPWasNWWAIt96guQe4aZFo0AYfGKBL8gABAlB4yTTvaZOxwQGbs5QlG6BRETYQwAUNAGcalBVQNeziEDthQDJL2QNNtgEnAYingICAkXPic/+jNanmPhUlBliw0g2lEqYZMjnJONgzDTnpwyn/mdA1wDMbM3VkvOSJiXrGlKM8/QgsjfnRfb6UDVZy6U7VUNA3CMCWLW3DRlxqUTYkiZ1q8BUAlBVVNvjBoGeYBzRr2tOwJvJSVI0dKImKspGigU15GCc6uUoGUfrTl6iaaztRIVRAALOtZT0D8SqxSrEKdrCELaxhD4vYxCp2sYxtrGMfC9nISnaylK2sZS+L2cxqdrOc7axnPwva0Ip2tKQtrWlPi9rUqna1rG2ta18L29jKdra0ra1tb4vb3Oo2svyESW+fstJrgpQbD5ooXCWCOZOmgYQt8iUCsvpbMRTXRM7/tIghDDFBhvQuu1T5JDgzaVftDneBx3VHV7mrkOi6wRXZxaZ6o1BO5qKBufI9QzllAMkwNGCuwRVDfc2LhmZw6r1cQK8Y+puG+06kWFtq73jhe1QzkEy5NhEaGjKWALc+hMAl4XBSEOze4bb0v2Ug8Rp6x4evRhUPfV2uQQnMteaKyMAPaepEqDFdAL/BxpssypdmUoaEpMAB8CCllBKxufXh4Wwt+sOyTGUmKWzOII/qB6p8QDJ0OOHKdfukvLynrWjcyckrIN4l1/cCNnEkU5dClS4J8CU476IKVN6BQXYFA499oU4sIKsN7HUFi+rZAS1DGe1EuYkZwFlSenAB//mOJQoubQMeOcYIPdtBj81lY0yuQFX8vCwKRDcXHj6gNBCa1eRdlDlqaVoHqxRNCWvMQEwDOd4mNpaHuBW6FzNYwvpIAA0GGESWpmrbQfKshz0HDyB6kJrTwpyiLPcBVaqqMz2MNhRYaDgKv4RBta7KYwsL7Va5WjIAiIYwdmj0ahHg17C8kLeAEkBVtzy3DkQxUG48dJklSOrpSMCHO20LBRU93+hy9QIN6wsPNEhqvnMQg17AmwcCmEIV2Nu2fJlj4gPrxsiwLQJ8mYwa0foHAYAchGB0DxVHjrQWWKDpSvMho92iWjla4oqXW9VqJW/uUzH3AAjEHAgLmFfCkv+2rGbBjVnOejXKTZDk0qUOWsQiSFblZisVkbvjEddHiLA1Kzs8CF/6K3gdwKzJ4uING2d6VDkJPaej1FfIOrDwKJ7WBJE9r2LmRrfKzkFol+W9EYXOL6ajsQBU5aMYpUhmxvr9bOXciW/optHULFY3z4ndVk6gwSNmUHjaUYy9StMELdJqgys47Gml7xI7LmdoZCS08gRIyOLZQTS7yzynmD4TRzaGCoxjzBRNQ2ky/4wyNvFjHkWX8QlI9gzoN6K4GElSyUgB/I7Ffgq049TrJ1YJqn3e880JvOHPB4PWd86/0GgAoSNf4HMrvpJwCn2pUzaUAiAC4f7mNvH19m3/KmcFWKAFpJNmo2A0tNAAeMMD92cvE3dgNIBM2IJM+GYM+CcEaRMSzWA+WKeAsMR2B2cv02U638d44weB9FI2P6A5nIM6SNYSBpMAShIELagNm/B6mnZK9gSCLoAKUxVpTBaAu0cv0ZRpYfApwoc21bBywmQDTxUEQ3hqbvWByyICSxd//XCBujQMjHeFSzBUyBIFJqiCvTB+OsaAehN2WGeDnVNW77Y6w3Ii7ECBSxCCKZgU8IA7/WdsnhBydSUGAYFfoZIIl5KAMNMAzFMJDXAJfXZWo6AHvgANIMN4v2RvXNIHjiKHklcACmgLz3BmWmI86YZ+nHeC5kAKd7YA/7rAC2ZDPtCwinLiiOvHOQn1itvADrNTNXy2UoWWAI7mDJDmArjXCA8ADdDAKpJEDIHlfzsgST6ghJdoD6HGZ6RIaQpgjPgABDFGis/zV+KDeVo4iKxQDM94PAEzJVWGdQb3a6hIftyGKs2zhtniDLC4DANIVpW0CJsYf4owifBQbdZgiWOBYB9RkCgBhVYhYEbRTegUXmaAPwpBTAu5Wz7BEzBxkCQhEw9FFUCVf5EoB8k1IwNBYwEGkpV0dRWpkivJki3pki8JkzEpkzNJk4a1AY2BkzmpkzvJkz3pkz8JlEEplENJlEVplEeZkxswWQNgaE3plCjjQkZiABYwG/9VWZUVUAFWqZW0kZVb6ZVY6ZVeaQETEJZbOZZlqZVniZZVqZZrORsB4JZVCZdxKRtzSZexYQFhRFhN5EcqVD9B1CdRGQYyJAaEOZh6WZiIKV02JCI/E1l82Ud+SQYtBJgeophRYJiYeZlBkJljyJgkokCSBZl8JJl/Upk0I5ia2UGWuZqgmUQJ1JqKNZpyYGJPkWPQk0eBeZp/k5qcuZki0JnA+ZuFM5wv8JkK5ZgR4WFRkSIONgYENpvkdRal+SK9OT+7uTixmZ1F1Jg4dEPa6URIQoMmCS5AFAdS4glVciW+JoqS9ml6ECZjgmhRhib+uCZt8iapNifFNmaqhpv/14Gd/cOdHDKcwUmcx5ku3klEs6IpjwI+qkMpRJZs7OM5DdpizLkJSaglo7IppkJtq+I15gkHsnImdlArKlhOuxISO8c7UyeGDHYsw7J0qPYsLzqeJEAtboUtAjcKfZOb5alBQbozSnQuBVqcD+aZCmpEK7MvMhovfEhu9hJyFUUwYUgV/gIwAiN1vNKkHXgw5cAq0XliDxMxJgp+vpc7VEB85ZF9xjd4l1gy7GB83XgrhWcxnrgnP4qaAbpC1nmgA1qk4NlVCNo4oTmPQoNubgI0MoACS2M+n9MvUXN57dOBWrMIJiWmTmUlmjY2BkiMGciEYrA2T4MH9oKF6yiG/ytiDneTOnozeXsnM3rKm3z6l4C6nUR6q0ikq4/DPZ/Tg4uaXG34qE6TPgxKOpTKTAwKoq0DoColO85QO/3Qnky2O8lTPKJEDIw4PC4zD9hqrTOhiM4TM94iq9LTrOeaQ+k6pOoKm7varjoDqQ86K3qgKrc4rN5TrNJKiJT6PtYgP63SmxD0EBFJEssZBtQZBpSZQevKsAvKrt/prhCLqxBZXoGUqfdDkidhsP8ppEKErg27pCDLmkqKnCRLoNKJTxfrRAgboh2rm7Z6OEYqqIlCqINqqJClskvEssy6sB77sCM7sQVksoX6miK7WDnbQwYwAURJARRglE37tE5blP8TcAFGSbVWW7VTm7VFGQBH2bVG+bVWW5wbRUaU4ae2kQF3qbZry7Zt67ZvC7dxK7dzmwGTdUeAUa41qbd7y7d967d/C7hOpEhw0Ehv8EjF4waSVLFiUEmL24cSJVWc9AafJDql9CUPWQamRGEnZWPMGLiQ8VOYGxNgAky2dFNvYIRtwEuoi4FtEEwL0ZBrAFTI5Ab8dqFjoAjPFDCp+7lp4VGRhKRWcLrD1Lpq0AN8iEn0+gYKJgfrRlTqsE6qq0lgBSDzpFO9Wxj6BLwKQaKTC7mzRFCOi4R4JSJTIr5BUCwcuSQRFWEQORBmd1GY5rzYaxa/m7jBK1IKUVKoZGj/5yuObdBSIjm57WsGMxVocVBv1ct7Xki/ZxG6QRVJVpoGRYU5BGwGyDtCTFWSY/Bz1DsjjVi7TJWSdOW/xqNiDey7ZPUGjuoG9ucGbFWjcIDB13S5qAuIJEW+iTslojsG3gABt4u7LgOJiIvCRWzER4zESazES8zETezETwzFUSzFU0zFVWzFV4zFWazFW8zFXezFXwzGYSzGY0zGZWzGZ4zGaazGa8zGbfySt/m/I1TCQJGRLubGWAEqBkYCNDHDPfFecNx7dkwVdZx551ObFBFKA+IxanXHbYAA6hhXKdPHTAHIDCzIU0HIuGumbZDJapDAjdwGDGaSfAyMu7CK/8NLvfhAO5dyMptCAmR2ZFIWBei5Bxz6KHdmNo4IyaRgn7MYUI2yKZCyDp7GLM3GaLlWeInGZfRwCWiiZJ8aBbgszBAWzRGwx+ppoUOMCHRwDhOWbnLyAINmyy0xkKC8BhgwJTyWeSjjgzRwZFlAf8oSBrvyL8szdlSqbj4gbuoTCFW6AElycWbDcfImADMKAQBtyRb3LrCUVCpqdaKaYy2Yb3scBfu8ddrHZAwa0Aw9L6h2TnliOgoNh1rKzbVgTzjKAuNEdhXapWciweZ8BhhgB10YyaRsewrQLA0gMgKgYWSYfo7qiW/qCGRKqaNnNi6shdJn1It6Ook6fTGwx//c537XJilT0goX+FBvenl9ZzRG7dRRUCz/nADSEtJOc3klDY22uHFqAtSah6/oA9OGm3Sbg8EU/WU/SAjK0ggQkMMjt3nC6olXwLzRXDVufTpRKtCQrIWnithMPTnxgg3sQNNUl3LzIHJdCA4YKNgFuILbsGjGWja/GgUM4FBJUq+ew6lOg9h77AfQKEt2cwKbc4OUGtcL8aB1LcmlzDaoQLtjaIr0WD54Koji8AzqZNjuE4+5rIqI/Fe64DaO/T2Xsg6TUABXoMLzmmurcNWNFwbDjWbpYDSs+IDSfQ0ucIPuoIuQimaGgAVYdlaSNBP2SttwXdtd0cljsL/6a3f/ILLB3GvBTLGx9Q0WF0keDHUoBj5jGUHgVRHgAu7gDw7hES7hE07hFa5baTu3Ga7hG87hHe7hHw4bHRBId/sXeYtYSsu0UpviUYu1La61Ls61XivjR3kBJu5EZesXZxRZO3udPfuyQVtDMCu0RdudRM4GPP4eSFtYSK6wH+uwRhuoQk6zQ2uzcoDk6qHkRqKoDGJ0LsLkftrkP3uyUh5DR1qzU27lNr5EWS4k/d0UCFZUXC5jEKLmpunjQArluZrnMXvmR9LnZXDl5GkTzamqz6kobH5eZHEF6nvJOiYGX06rk+mnBkrpMkvlaB6xFoQi3zOeZwCdAWudh7sRHxMN/20SjMqcX9LMzJ5AanRCA4HW6rDW6mNIzMnMeO4pAs3H1aPAZdI2Ka5cArMeq07+4y4LtGIe5UDu55e+7GkeBsDsoOTNoBEqzhVKKifhKey5r9beoVHzof+K6JKiaahaoyxHCBMdCg5lyd3bwRHTCCHR7idHZ6VmhXJDBOMp0brycjygS7uO7smEN6tdAu2ep8SO5z6750OO7Hr+rg0vsW/AJyINLysApWQjpaWgcVzKLyaBpRftzzLYImEK6pS0NTgIBHKaMr6G1UuNMGRKuauYEzH28hjx8r6tb9aHPNEoz6XAZJmtAIn3MdTALchnDcNu7Ht652Ou7DM0s82e6f+uGQcR7zRfPY9J09bns98kkSJSE36FjfWVWvKSbvBSNX3xNDf3LiZY3dhisBEJaQIIcAlub2mMLNlqyoXb/akREAievd3HUIeUmFxPqFaQnvSzSuZMf/iJ+edjELxyExm56auQbTkuEKyyvX6QyvFwIvBfn6wrs6w9LqLN1CWFZm41cOqVuATOffFDrCbXWAp8cI0Y4fpcQN2sj/dMVu/gjfpMAAq831buMPvkOvaGP/wMH7JPjvwPr/xFHvWQT6zyeibKK9/HvbkRUbnaTKFf369dAu4j7xP5XRKVTAYSMO4fQfjFL6BLr/iJf5iLv5jMDuh1rsm2Ee7Wj+Dh7+b/NXH+R0/8IACII1mSh2GqK4Cy7+jCrzyzgf3i+brzquHwKwkIwyMyqRQNBsnmMiqdUqus4NOphG61yRoSfBQPyUNfEo1UI7HWNzwO4B7p8js+3xYi7XVvH+BYipIZj2EOYg7bWRTjkJue5KSKH48lZaYmnIHFwSdoqKhoRcXoKepBaSor6Gorq8UEbOwsLarsLa6t7mhA7+kvsKjwcOjsZnIepg2z8jO0zYYBdbX1NXa29jZ3t/c3eLj4OHm5+Tl6d0Y0+9RAAHy8/Dx9gGA7fr7+Pn+//z/AgAIHEixo8CDChAoXMmzo8CHEiBInxhEAL4GDJBIezXiQAF4DJAXi/xlJogBBySEK5AlAIoBBgJQ/EMhbcKQAzQARRNJkYBOJAgYFRhAASfEoUooPAjwAkGDnkaIcYSzYubSpSQYSkDj4KJPHSgVKFgT4uWSp2CFPAWxM+4NBy5EZh1gMMBSAAAQOgm5N6vdvQgEJRBRJMjKKA6ZK0CJJ0KDB1xwr4UFo3FIKgZBHGiR4gHMuj8SXtaa5CwEqgcuAV7P+VxgvAsNTbRCAioSm6h8EjEA+C/dIAJgxlUhg4PZHAccBcvOoC7Mv8LupRWRubf06PsGEI+c4nKSrZiUOEJiVPI87j+lDhAIIWn4mcx6kHZBOcrW0iNPU42Pv7z/PfWuJNBsLBf/4pEQDLQXFXw69HSGAVewNAUFIfLnEAGjrRQidSgmgZ4NdhOll4X8lmihHXRghIVVZm8kTHg8L5FQZgh++gBM8tv2gwEc6cfWbYcLpGCNlGTYXj2ZSwXgik006+SSUUUo5JZVVWnkllllquSWXXXr5JZhhijkmmWWaeSaaaaq5JpttuvkmnHHKOSedddp5J5556rknn336+SeggQo6KKGFGnooookquiijjTr6KKSRSjoppZVaeimY6knhnUs2NsTpEiFaoSmmUZIVT2wvRNDiQq+RugSoKsQ6wmvbUSKqFd7NusZdtDFIwqs37rDrdLiSMFkAS5YKEIUv0LcbQ67//jrEriRUW+smxlKhK4Eg9kpFsAV2C4C2Jdy3bEAjHWfCAsYFIFYRFikAwUWgrTSUXAYGZxMCCr5LQl1M9dveu/G+WxYCDeDYYgA9LoAsZAK0m5F2IzhI3kgfMdDUwjjwaJTBqJ6aLF5GyFhAYQT0WGGPxq4KzwN5waSiVAQ4MNJI8jwgFQMl1HyzXaxSB4/NOSGQcXBN1YVAUwiHhzTT5Dp8LwBy8QzAdAE/0EA8NpE6MsuUGX3YwPRJkBrX8EyM12AihIVuQAKyUBvWLeU1lGAZJZDbYwD0/dvEA78twlK9Cl7w0SIEQOOBxZFrd2zSAkDe5OVdvADOWIf022HN/wYVc+KxkuVAEQskAK8R0KoLQdvGBgBdXg6MJ0DsXQkw0mUhymVC7XvjToRetnM7VGYPbAxABJUtXsJITUGgPOR+h/TY7vsVbgJndaswOgQpcQsb+MXeRTnleB0I9z9rs4BsAJGXlLZRIxgY1uDvHu6WjCTcX2uI7B88VP4kVwQJpMpiJcHYDh7zNrLV5DXeMV08FPCS19lqOmEpn7HykizSlSQzfcOLwnwgqlUBSQQfFEAIsacZFH5PeiNrH7m+VbUd5CWGAMjf/P5FwpakJn+0Ek5svtayk5jle/RJjtdaIqoBFrB86OvH7AzIu7aZ7TV5W4HKGGc3DFVHXiO4Hv91QiIv/t3lfIoDYOTaNh367A14VfOJd/5mNxw0i1Yl2R0CdtIWwZAFb6nz17wqA8YS+KQw7qldvzhFwS/+S0SySyQbEHm7AGQkjg0wHlbOyLwdOMaGPswiCdCSGjCuZCsRCGJu8siWd3VPfpScoQkRgCHtLZKN03piPmInxRIMzIQQqBW91FaCjdxFXwfK2UeOozVkFiwlolpYbEKUP+MlSz0RmOWxaJIAOCYwJKf6SHuG+JqutG9pzbxhWVIGyAfQhCa9ok+9Akajn3EqbWDzGdGApoKfkfNo3cQLkmxorXiczpOpIuYMjZK1eOwMHghAJcAc+q6PLa6f3lnJZab/kzaxXBM0TsSldbDVj3D5gzErEClCqgUwT7WDpCBtDYn8sREj9SNny3kBSg+iUrfV5x8zfSlQgyrUoRK1qEY9KlKTqtSlMrWpTn0qVKMKmMPkVKpWxU6KaPqCovhLhrCEgUtFQFWWXrWsSAnQkMBKEwVQbZMzCCssq2rWuSKlYtjyXwHDuBuq/cxoJIDfAkZmFmRhZKx0PSxgrJjXt4bQIigLnu84kj2SltKwiL3sUewqE7z6LCTBLMAJU0gEIGovlCzCHA7kitnVJgStuqkQPB77yElmqJTIC+KQspcY1JaMtb59SFZfa8IQ8fMjeZXKQ9EpNH3RhLeq/S10oyvd/+lSt7rWvS52s6tdP5GqLjN4bkrRcJKbCmu7TyzKEIqSFvVuVYkFSAzxpoWtnYqVEfRlAQq3lVojRMAIO70vuDLqXk2aF01pS6+PJrMun6lmKTmY77jekN8pgOqXNgDwFF5VrgKXKQJ7UwNngUUADPX3Xz8DQDBvapecRAyg7VMaSfTnUJyVhaD6zIs2b/zQhlEsxrxTFmwu0qOtpIhjOdmvYD22sqodmQgMNaZNNNiwIUtNmAsLbNfQFkHi5hNpx+MwlvKiALKkFzLtIosEIUs7BIhFfN4Z5fGSdz0I1zc3lU0tm+nj3Dz7ZClE3iw9viVmjPqNAPfpDef2q73OVf9oY4kOJa4Ah6FB37Q3N30JABrXM/WI74y9myTxgAzmKB0ZHseax2IzQxYIqCu0H3TzDnooD/Kkis5fbajaLIvA3lbOhzmdMBFKEqLSpQonC1T0dBjYtX+ByocES8s5bVgY3R1MHgrg9IBjGFpLjlpLZBauUNQlSUnG8M0CwCQjnSeT3cVxMLvVtXMPuID7tPLHKnjNsA2tmFb+xiK9TTYdYdRvNAyy35MWth9teMpMl4dutOyLXSTJ7W5j6dvpeZqJ80lOBgzMLuZ2McnS5iESWHRYMGkuvOHtN4cCeh6CRnhvi6xccKoTlhR91zfVsEyYHAjfCUcVvvx6qgVoFB7/fO3yPyl+2Dr6ZcNK77ZUCvoXpz+96la/OtazHqWaiwm8DIGrrCLsrYh4HaQvXCxY5eFVrtsKBr8mqwoaOQls2xDDdoQB1W/g1WDrAewmsPvYoeF3G5Q9qEynjagrmJvCW0HuktDw3gnvqbz3IPJ3z8PgB9p4y8/9ls2BO1DVdepZd3YEVAvgH02PpNQQgDwBTdmSYW+Um+/d8bR6Ms+9lpPWB0csDbNyTrCsNi2rTck5mqHGMgmbmTng24+Bn1twzGOs5RP6FusaxL7Yo8oYrWksvkh+6gWsOb64XYQZTDALq4buO+BqI0gewAbz+xZdGWtLHkH74eEufFGS9zHp/4nvOYxgyZz/8Z5xeARlAIwsTV/6ZUSKtUT3VZnQRIrc5ACLEMDpuU9ptZ3KHMfopIx/nZPqsFLrfAv8EA2k9YqktZ/JhEjHbRHDscWmCVjd0ZEghRtxwYgkOV9IaIuY6dmnCRT2DIZIVQwv7USlsdm9XFEbEcW5xRkE6BnDMeEkrUAeVQ8JOE5vWNilxYamYU0IugUW9k3fQEsfTY4SweB0HFrqtOBQ9IsRKuBsUeFLtFkqIWH0SIr6qB7pAUt4ZOC/LV4HXQYEGV3NhcUh2s9PbJjt3VAB1c+1xUWsDZi6zEMk7kcNVg518Jb0rFQY8aAQth15hFYomo9D8Zrp0f9LAiyAA8BPDyactr3I+J1dyRDQyiEJqLRiQO0Qyb1ObbRL06CR/1zi4IgAL+aQHX5Vp6nLdPgQTizaJM5Lw5SHqzzGi7yaAOiiUUgT2jFKFJUZCbRI6wVi/GHi5OiRCAJSIgYSAAxSOC5YwW1R+0kiJobIwpkR1qCGEm1F5wiSxyWdrbiHuvBID3IIr5EHuS2S21DQwsWhAo6OU7wir0WcipgAnCnfSgzMFdUXCUBkJxGO40FAnzFAzxhUDDrhs5kAY4ASNNbjUCwc3dBb6n2ciHjiIVUkbMyWR0qksz2KLoHj7TWMBpIKNbWYi63VOq4jO7WPsZzgcEQUzEBZS9L/0owx2SkOXdHVWDgd38QRRjzMU3B00kZdHuWc2FgOTfvERlEGZVlQVMJIG8ylWMORH8n4DTbJJai4ZQjFzw/pjWZwo1XCkAXJnU1pBkJNZbFU5dARID3WTcBQ41eGn9qQUznppUlqXTs2YhxQ3lF5HWfmwXi8B2ZuEjx4HhV8JlHFlA5wXh742Ju8Qz3EJj3cw2jWZjQ4Awzgpm3uJiXoJgv45pYAXjJ8ZuahJLWI3Qyg5kAwHtwAZyXQ5g9shPycnPLZAAKWU67QEOid1Fe00D8YS7gUpzkiB3LiHWvqgXK63XY2J3TOgHNikamJwG942I4wwArRiH5VgUh5pz8Q/6dpMthNlOdqRkN64tR62gnQ/Z19Rdh7lkCDhh1IVpIaOCU1tg2wIF1PBNNOyAwD1ovRyF5dPmBHIkn2icDY/N7x1N8ItEtpEhbQZOjxUdSSyJzThKPDaE/ApM6SyWjJeBEmLs0DmB/boFi9xAr7uZ8x4ueQzp9N1J/K8CUA5F/vUVv77R4ASuACQB8BWmnvXaeScqiKNCCRlubkOFTT3KiatAimdQeDtmduuumFDYucLhh+zaiaZQ5KoFNOzg4VegcIzpAEGccGjigHudUMhVoMOg5RpNWdvWELolijZRIbkouSKk70jBIF/enqROrdMBi6JY8UFpKKRJYVRgAWjv+AFhoBF0bPF46gGL6SCU1PSJihC6ah+djQpNLqG9KOhcohn44q7QgqqahSF65Ji4gS0sFGjnXf9h0qCTzoCECroS6FhJYAhSqgta6QaAEcr3nQi/hp6oUFNnakOHWnnMbqMMqPVzwArpXFxymbMImAM0aTVwFmD9VauNpPA0WGrKFKLcbGCYqWCGgjyfAi/vliBACjQQ3jYB7HMbpLMn4ctQEikyGmAEjjKnqi5gQsNhIsT3YjmbRIA/TLneKZAuiZn/Zq5kQrnP5my8IAp8xnr85AUNCIAPxS8EASJhrWTYLG7iRlzt7hKknQzLLbP+GjCVCIbrnrJMLS4aUbihn/QbnY67ntW77Oiw7y6xNiJHZu5FfJ6yt9ZGYeh0jOG0lqUv7gY8OqpIklwDw1ZqctHAXJpMXSSl4ZkqiCxg6G7ccaq5lum6JVzkWpomgywcs+5xKc1hu9GLX0SBvRU9NSVWSOaVn00zpSZi95JVMqwFoOrHFxGzRd6IsxF9PurPEZHVR2RimaZFbmacPenARpLchpRgPcZdfkZY8kTGGOll+ibWyE7trWV/wcJrdSZfsMxUYxpjLSTtdA5fJQLivm7sXmbt+mqVlIXOAiUIbU0MoabhY4BHOyQGiWyNOWiGeeJ2h+1JxMIOQeZPSWU/N27xwcrglI6z6Erwm45nVE/x2d9odq6t0z6G+p2K/98qYBuwP9OmgCHzADI/D3NjAE6wEBL3AEV/APDIABNIEGbzAHd3AGWzAIv8EBdDAJl/AA8EEIp7AKrzALt7ALvzAMx7AMzzAN17AN3zAO57AO7zAP97AP/zAQB7EQDzERF7ERHzESJ7ESw4qA6gH+eskTL/EkpF91DtRFKIBwTkJOUV7AwAM8lWbLUMZStM2q7IRw5MhSxAPSrhJ5qUAaX0QVN4dwLEneWdG6NfEi3EWBFnFxiIXYKmibsRoe48EWs6ZFDMlHZNKqXMYYG6OPwARoNPJSlCQJBBPIZiYRPu+DPCUEGKR6tt0k7DESE5pLif/e3ZyuNwUUi96UmMpPTkzv8UlZAlDZk5JMYVyZlpppRCGyYjgyIzeMI5sxrGIy8pUAfTDAR3gySGYyc6xyZWzELPfqWlWel2USxEif+t2QcORGxxSaidpEA3op9HFZTABN8i3x88xy/wIqeDBae3wZOrWfbVAhCZTQ87SjUFBaS/QGAfhjzBjBF4bIp36pPLRNIr8feb1xPAhzPEiAQuOkV/6SJptLQZdHIx/yRoDfwAaH3mVOdVzeD3JTPqrAo10OHfaqqERcySJqEmNA2zikFfMYvJZFIb5LcsTE1sjiQrpF+RDAAvgcOZLLT2OgJUpTH3olLytyQgMz8jzyMI//8SSvS6lhE0W3zTQj9SolwEZUaqZpZrkBJK+9xq7dtKGpnlgcxuUELMbaREqDlrZ25RFjgKBmj4MM1KtCqv6go1tQiNfWs2rcc+EAdc3tEUCXx9zC8y6XwEH78jIHc1dHMjBbhMrCEJG2BDJDmrtdNTFj9ER7ZUl0cjgWAFxr1jdXmMDNEfgYyE9DdE0ukkrPFrfVdRFHXVPIdn3dNeya07XpslxayzZT1IbCXMrEg934l18lb0CxpRef8WUscmM3NUOjMVN/RHjQC1RshD/lhkKr7yqHxFbf2xyXwD/GaijBRILI22Egl/KdCk20hzYdiFw+5i0eXTnH9oFKcUv9/+dB1NBRZDF+W4d4EoTDUYR//7eBHziC/3DOxPEQJAaDI4SiEgFXK0ETHsG5yEGElzdeTLgVZLgNWBgPeHhAgPg+IHZJ1eVfaKjZUIGIs8OaDgH8/RCK6TcMOLiz9PJoAQwl/0AyqUCMg+Q/z3iI73gO/HgOSEiRV0YJ5UGLHzn6aoKDmUCTH0swAQmuIQDsxBYSkAWNM8TATPkRGHlDVHg9KzMSgLkMroCYu4QsKTOZj4B+9NQMrPkMvDkMUCuPd7kU0Ll1DnMuzWyS3jky+/FNkWTzMXVQxOsQcM2TN4SNb/MIkMbnXGdL6EemfcssN4y/oKB+jMdOBFNuJAZNEP/AUFB6L7ZTRsDPUDyFqMfEt2gUb9jM75G6U0TASvTYU0b6VjjYKQUHVLzM8lDUqoexTqi6U/AQBrI6U9L6KoOYVrSRA1hyYnjFSw4Glt/6mNJlr2T06wi7U2hTS1wnU0ipEWB3snjgYJj6yIR7yzzATPU6A+yElLYxyBWAudPIy5zOtM+DBKSYmr/yDbUNqCvXpcUD3qBgRwafqXsY0QRTUyRATtT2Tgg7t0sAjrCZjN3FqjQAPDWAczvF4tA7W5yYVyxOU8jSyjmPKOMDt2eIog54fuxEatBHS5DZwOD5Ru/EwqEqJRVG9kRAS0jndNqEY9C8nqIqe1i6CCi7xR//yB9Tz0PdS3EQPce/jgQMxtlEKa6shNIMxm44wB5FzeO+pKxDxZsru4y0RGI0PdVnDn1WcmXoh8rMxdRHZK0nBtgPBtCvEnyZgI1jDdmTi87rxVs6DrQsYWfsFglEQAQYvcUhD0YUfs/Q59e3BbSs/cH2ioeJhVaIGRrWvY0LPQuMnPEoAOMjT9CjgYf1vQhkPevP0E84Pg54CNi3CFyIxpBqNeAjj6w3BY/4cYNxtGOzCFRYRANsBIyMhBFYhGXHxkbY+nBYhEOLPETEuJzzfmFUTHHYeBwqKvxJmfNrxbso9I6/xt5o/47H+Gk8gFzOlPnnRgRAxvPzF43szbtH/2GpZZKixvlQgIDEAIkAOMEjBGwAiUDMPMADtYvERrHuCIRYCdKIQXgxwKLlegQcyQhEKEBJYFJna7RCmJKPEWDVgjhjUhgg+zylICYULVkSJHoMR6PVUEtJPAwFACJOCjVtSV0mJTIiElR/NWIONwmDSUlyiA4lWix5eyxFiw4ITHMAR4p3hHkpro5qdnJkLGZiNy1fAAUBYgCnDwkBBQqnEg4MTK0xe5ArAr6kATkBJr4CEM2Z3d7f4OHi4+TdjU5QmSIMhwIIDgoJET7DSDFAVAvsAARTCiwm3KXrtqrWu3j2SJhYQOAYD18PItwpCEsRgyLLBhGIk0KiQiepMv951CcB3ZopDBaMeQJhCqsYJhE87JhABw2PFB8QKFKAAaQYyr7YcYKJH8cHPv7UeedNXyY7Rlzea7UUgEOQ/O74jKUphUCEDe4EdWdVphWTUnwdIsAtib5NDTAGZLdqTNsGUtWN6LTA4MCwJxjw0ofVG4Qg9w7K8zMF3R+dBWC0fNpK8DdlxQDsCVTM1JtrVn9letYpzwqVewqcDg1hX7nXsGPLTtJCAtRuVoASC1BEVQBkmXJqQWAZAAOXDgi0KGocEoxOozKhYIHgkK4EI1ZtVeM2wFrE27PzgBVhl/RTp35QDUj9zjDqCuoqWCaFBXZAY2Zodz7CVwBiA22TBAz/orATnl1GAZBCcsuJgoBKA7JQ0m7V5XTMbwFAIkpDaOXV0wm7UfNfChcig85tjSjHgEyjUWcNC4gt8d8gWxEi4Sn/0cBiFOZ9yCALqtmXgoMqlQdQJg/gGAF0vJ1EBYK7ZaZNDRQqoEOG+sDYjU4uxrAAjjUt0cwyh8QQD4w07HEIcfx4FwNxXywx0Gx01mmnN5LcqSds3O3p55+AdkMAYoEWamigPTHXTZ52LtBWI4feuUmgKCAQ6Te+EHrppndKwBSnf94G6qiRLhMAAXOSquqlZKQkTl13IhBSc6u+ZlKhRva2qSmu1errr8AGK+ywxBZr7LHIJqvsssw26+yz/9BGK+20dvo3K52TMtsnGMDsCSmdxUWaLbdj5HXotuTAERu6xIqKq7nU1qkcvMCGkawuS9a4J7uHCtAtbIyChI+f43pTMEwV5UcnMWV206fAQaj72sHjMFqOILH9ES6nFCdBhDgFT/atNyMbWrLD/3LqbruaRuHSZKt6wZWfFit7sioJdZoyyuDwG5s7+opE73587jzOzeHc+hrSl/osAy/f8NtxxwQn/E3NmzL9K6yZaL0rLKbystV8D7wHWl0Y00FMI/9oWRCLukBd6W9QiJKZPHMTwBw+SyjxCjF6r3EHApAUgF7DOMsQGYYNHGKkC1btNkgCUe4gI2h/2FEA3v8YBm52ZknMJwGktsSztgkeEf4PFGQEYfiRQLUQwZl3n3JOlA/8GETezDlK5ZGXm/A5Uk9EcAoDSDyuqS2Ln+KSkQkogALgsusSAJIjZrYVOrJ3Nbp9mWQpmtlfxL0SkF3bLvxujIBv5m4EXInlMhgngGNIt/0BvQImDXwPKMYThnJO5Qr0GAlq5/NOluq3m23QbW5MIVwvDvc4KxjvF8lrQcteI785qYEAOVvFRoKihOvJTGko4IHx1PEEfAAmAibQgV4GwTXOSaAnKkmArpTwDuIcQwAiyGEROAeP6CkkEydsYQJyVw130CBFg4gAqgKAhJJ5pAQJ2F2GcEiCBpD/0AfBmcIqnBg7FVqKiKMjhBY3h8An8SOKQaDiGnpYBBgMKjQF4KIORZKvhVwvCgkwRR1H4JFBOUAHCnDHIeTRlaJI5BA+UWQwgOiqI8rQG/6iYUNgAZWSJcVcTigSBEjYNxjaCAWKioEcjUfK61lMil2hgS8G0YApBoQb6DDcD6ozSackLgm+gEIWoXDHfxRAIkwsAswSM4dZamaKZixbCkRAwyU9IR6LpGQPnmBIREqSkYCSRNDWsJEg3EYEm3AXY8aAI0s9wjufEI3LjBABG+DABwMbmacEYIcI5EESJbCCZJjAi3RO5CiNqAUTXgCMGZzAbl50Hz4RUxUEdacM/7TCAxpGmSEsjBJHLHjAl+SYCYfaogl/TIMY2ACFWlAUanVoBTohuk5GYgwGlQzaIo7YnBqVIE8OrcSMhEZPNWhnVjhBIED5KdMZMIELv4HaGU5yzuwg8D0Q4F8uksfQqUgnQwig0U9+6hKdigUWJpFDQmHBNX3VRaUb5YQkjjDQXUxJcMYZBE4hNE49nSMRA2LAPr6ymCfU4ykv1cda/HEkgXyjEQxxSC9okrhx9cRSNzDBRtxAPAdorI2nPOyBXLWCSuTlNiYBTFBsYhmc8MAgkbMHCREUrnwCsXhT8ITVzJQwkyzTolW5CizYUtmE+QUsYhEMWRxyljb8oRorSf+V3+Ail/zEBwlK00xeIEtZkmQXP+P8mC9soxgYfip83UIRP8ubUW944TaT6YkEHhO4riHvadZlZHnmtAqTYIUtm1BD0MIVX58sFUoLachng1PFejp3CtAtLaBqszI3/IRJvbkBcDz22hQMpzjHAcoAQecG+PjmP+Kh1bb+oRJ/QeFAUNms+Fqm4Qx16HwIcE+V5EMfMhAjInfwxQKIBoMLEeMnqmgGDC4ngZzE2ATk2UXwMjEfKpqtQh1+QIkypBkYQZI/mfBRiM734y2XRIlP8jE3iCS/GNlHrGaiD5hSMZ3fDMIz6alyQraytjBT5wkYPsGIC0AkBnM20CT4T+j/ynBICYXhF+1D36KaIaNLIOI3bdmKqDZkpZU2BrAldDT9GHEUnNWZlzI2VRCMpAzbrIfMbeEU1lTltHipLA+2NlY8QBvXXB+rY2Szda1ns2tan/dXFfb1pa5zLWWr6hM5I0i0nf2r79KB189KNp2gTe1ue/vb4A63uMdN7nKb+9zoTne5qaYsiSXLoc9ywg7VTe9623tfYhh2OWaxM8GwexxpQ9ZUeTaO+IDiC1z6DSQuB7nZLAHb9464xCc+TyftadYE3zaojZVsjMOEAUYkhgkE6wAxraQIG45NaijO8pZLXH6jO50RYJeEdrZjF7WRB3xr8gTZjQ3ei8LRQlph/74pM+98LRtpNcgnOBjp4on30wwPaLc4Cb2OlzUHXXm8uIwGlEez1fBMSCQwQFRVihhLCsYI2BSMY7v87XCn9iZSOMc1xPCPuMkQGTlrYV/4TQFXLB8PNvvYIIQB8Cq8u0gCSWKyu6EoQgaKZfo2TB2oxN+g6SQkAifFTWCTp4gARnkG3z3jENTP5ryGL6ZQHgn8IwjK+QGJ40772lPLXlxhwxbCFyXRkeuUVnCVTecgRf/lnQbo0O0W9MCHlXjBMy1IBayqGmAx+GQWjFfBQnFvPdDEwBfAEAYxjIEMX1iqbQ17xkr4Cd0bWCnzKUDAvG1P//or6za2dWw3/gGNEf/UthUeEQyQ01zpsA6Ioxcg0hdecV6qFS6EsVtGQCiENQ+eJleNoTeScVqVAVqYQUtylBFitwJBoAOWkgSkgR0MsiZQpRJLICD294IwaCxX0mRZ9iMkBn0JMAVMNoN1AQFMgQ56ZmE1lxCPgw17MWg+NiRdUoRIoiSBdmCdtBzl8ju/8X7zoyVIMkAP4iVgsnlMQAAhQTtg2HahAXtu8g9pAxgxuIZsaG954jtdA3HA8m+zUSmqEg1tmId6mG6eMhCy0g19RSzWdnHRwSm+EGt7mIiKuIiM2IiO+IiQGImSOInOtgJGIxteIyzDpm/CciFySCq4pypYMwOhGCkeh0n/9BIOnFgsQMdxqXgs8sYppnJDvSIpEHgoG/MajOIvePKKcQgsIHQsxndtiNBsR+MmJAM1LXEGwygOq0iMsOFu5cAGxlgodPgNA3cs0hg71cgjhZhwEsRO1NGN3/BwnPIPN+GL63KJxZKJmXiNhgKPo8I13GgnQINksYRJEzFt4HCKBnOL4RCI4ZCJgfKMlKEsfVVrpaEhkENyJpdZgpZK47BymwIDnzAH+TNKZWdR0hhA99U2BLQ9XGY+EeI8oaElPmA//wE1fHM9bzEigcNItuAEgMMcr3MNuxFIG0mCkHOTvGASfbg//aMpurANxJAS9DM5DUQMx6Z0C8B0EuF0/yEFQVAgQa2TaP9xRerjNy2wfz6RULpAOCPSOFbgdcFQOIfjkxFidYfDO1wpGgs0OVu5aA7AdFM2PFq5klRIYmJIlVzJQExARdYDDioJC2Z5dWsCH2qJmOGDIwsQlySwlA+EIQfRBq1TZzxAks7gfSSIGV53DTqQigaXI4k2LzqydmKAAG7HQS0wJ5LAZWDwBLpUTMWAF47QNaiCSBGSHCbAIqZ0SWhgRPqSFHewSiXIhbzyQ0HURVawd8u5R9BocbR5TMI5OqDlE8qgArzkBb7ENVBBd85US3RnPNKUCpEXGH5EArkJXYJBTab2BI6HSgA1HmbkTAHoMWI0eIEUnP9MZA2dkAzXFHJ20EaeJ6B61AChdBLhGUdmpA6BNHl4JziCFAuMZJxfBFiwhAfVtKB0Z0kR+o+3RAKuJ6De8y2f9y3nyaHGWZ7uSVd3EJ/FACm/GaHLMAc6cAcjxgN7wIGqqQCZYhzuREWv1yayJ5F38ldzYgVhlVYpgKT5CAPuQB0nsULx1C2QEkntBAhTxSj71E//5BIl4AP6cmBucQqZKTxtoFZf4BMjlTNDMHJjJQDihI+rYFRctU5KM31NVX2OMFcUCH0hpS7NtVEf80tesn2AtVZAJgd1BRBtiiS5QFC2tVRvZQYplRdSQH005WmDSlUl6C5YBXgvIwV32lD/NCBUluYN2CcH3ScAjtICCvCorcphtHoSeIpb9CQFgJoCDlWlJVUROzp+F9Jk0NUUcuQEetMkp6ED7JEk86cnBkUy9/VfjJcMxAVMl6pY/KCDIcVO0kVd2toPzflqwLQivqFZR+ER4bJZB4OOIkkDAGaYuoKOIgFy+OUvCLEGoKZpRDcF8gWF3HAYilBet9oJCSaqhXGb+LQeO9EL+jJbQ0FimQEDi0FIKNFG9OpVxqGMWSZeGVJgruZGVDCBDbheZTEPaKYQywVO3eAFkNUQIItaoGabvVgDGOh/vMB/CsNbYQBaAhsVDjtfYBqiL7trCds/q5lofhQEICgM5YEY/33QHZmpd9CVGqvRgoh4J/7BEtF2n5yGYwmhXh+Gpl9gg0XRZpcGJ+iQE1QWYbh2IKvAZAdyUaDRZ5yGtlOmF2VSaYMwHLjUBnXxaJahqIZaA044ZgB7amuBOuZxOvvIWf4BIB6jZCNQIDcWSVOQajCSt9t0hSEJZv6RHoJrAmxLG7kzZkmoZeihd48rB0YGmyfpAoo7CZD2S3o2ZzpLB1I4JTOGgxAwZTPWhDswuke0CUcwu1EGEHpmttJhPXHShZtZiEkwQAmAGm7CJspxCGiICWp4jq1YK/7YLOELetJikORwR3voYj3Djq9hlvmILOZLDgwzKnhYKwS5bPwYLf/02I/quCzaNhuqJl0vyGzh8L+vcQxzMojCYsB1ciXHGSmHSIkSPMEUXMEWfMEYnMEavMEc3MEe/MEgHMIiPMIkXMImfMIonMIqvMIs3MIu/MIwHMMyPMM0XMM2fMM4nMM6vMM83MM+/MNAHMRCPMREDG5ksCezl2tJPAYbRCd+RyeEdyhRnAnF0IyBssQF3MThgMXEohxa3A1cXA5hLG4C8KzmVh4QAg5kEFFGKhtjXCtT/BqzV8VfHBtPDA53LChQ88Z4Uqx6nAmbRcewwcdg3MaYVMfeIMigEsfrK8DfQMjgAMksMw553LKGPA6EN8Ygacajogzom8WI8CeSzCz/S2zFs1HJ3YDKMcDIseHJTczKiizGl5zIs6wIiFzIqsLKhzzItRzJvTzJdWI4d6LLSQOQoKJYyKjGQYAjvWFMkyV7OdI3mrFD2aMS7fQANAtCN5nGWREdPfEL3Aw0/1FyzbcRh/gLqfAwPbcbKiHIZPCHvDUIX6Ig7DxBXfnODzBLTPAg5WwCYWFM7mA7RSSFbsEObuKTbBEdgawaqfcbZdNAJgir15EcY0Y7xfDNrpLQTWLLZKZlLRBIFs3Q9MwCKnGTESo+QDBmGN3OSgcQEL1/OFB2DqDPaVzNHb2L3FAMtKOf0RHSwQEKl1MEGr1DtbTKEbDSzjzPvDUK5aSa/+Pod0PtDNgwIrICBKfRfD6JAzrdQLQzr8kMx4MHcfhQyXExzVhRS9Jc1rQREA8sE2phCK7SJ3ekFpOHa4nhAKYwGNwkDZnRsNz4JYkEYWytIAwdBum4aPJsKZlnKZYBEQ6VFqBRyXKyEUVN2IqkDEPWCrMXjJu1rq7jHQsNBIZNVYgoJftZAnPtHT9bDHWdHJ/dMKJtmITCf6st0ottHDMByPbQD8XY2g23WQaMDwJhsNkAxmx91vFTuRGzxwUwGWFQAKkdH5pdFJIUPtz02oumAP8wHwvhVImNWKtsREMI1a+NAlAAEaoAB2Fl3bOVIIT9s6pQBMHmL9y8KiD5G//iMNYf2hPbrdSGk9bUnNjMp9By2jiB2TCbtd3ImMwDsxOvygIKYM5/pNZUUL14AWXfTccMd5xJrdiJvd2TteFP/MQPDtqCVSaK/CBbSNiL1gLVkcwJDtoYDgQbbnDVS8UeyAcxfgwQUg0LHuEmAOL3QAD+LSsj9iU9btsfftARujmnohNf4OMo7swJYuP1PeTTfA8NgMqZgeQlqEsZAkKEgeMrTuQ7vuIkRuElDuShgTgbEQEGPuVd/sANHgcQBdVB7h139cTuMDBrDuNR/t9ZhwPBcOWqggGt0GpUDt6ozBafRgOHoRbxEOA8JCdd5DcYU0l/vN2Wob5YPh9fwgP/iCThzrBD/oIRDjXnlg2G36tKKkEAHs5DG7sSo/19fxRMwSDqoA3nvJTiQ/Zp1J3oPrGuec7mdFzrT/HAXEYL01vszs3ac8GbbW7LWHEYqlUNz67kst7pH2oEtXR33J0fqGTUya4Ky2NO75DXXJ7Y1R4xKREG/1IM2b7j2T6wZcIio17sYUYcNNDpr/DqdN4KMtYGOoTnbV4Tti4EDTAw+O4d64oE8k4ohWosMuMMWZXEa4zKOoAJPgavvwCdqvThFNIbCIAYN/nAO77ST4FR7yzjT0zhiBBFJajq7tx8imAfsT7PlXY9trDlfwQdXvBnbN4AsuLrSYIhRVHx2vXN/9ew46Hd0LxhC9wsCqNZDTt+9OOn8jvO0R3/zafwlLYjyKouI6cAyOM4YkYIziwealKfV+DdJqcy092u6h0v7peO4ztd5fC0uswxQIIh9FuPm99HPy2G85DKGwk+8gbvrthqH4mEGC3vo2EjI0tgDFzde4XebaYsjLc8cYbQhmQBDsS8b51fLJ8PrQEna/agyvTne86y+RO3tZ/4dq3SxqPvbbJPM1kLKqxfxL7/+8Af/MLfcgMQmMZ//EwwAMO//EA8AMpPJ87P/NLPw9EP/c/P+dOf/WxY/bPB/XTiY44s+qBhTH4H+7IxH0YKnLRj6JjS7bHCBOy/MFCToVsyZv9kFv7dYP7ElvrFDQKAOJKlSS5MECxjRJzFGsCAsCbOeQr1/v8iK8RjlBAAk6ZHsSRb1W6BnFLUq2IBhBWjAFAkVq0suWwWDQZnQHoNeASKiQiZgAgoFAGv1ee2rvCVbAWMQEAASATo/DXCKTSKPCGJQJ0s0MExxQHMRa5JCT6oUEZGtAgwVNIAKTBIaHbSfZpBFB0CTNK+JSQIkrjCcnrunkUkAOAqMhYDzCD8ShaayGS1nV2fCSDb+OnNBCAMNhAQ6BVUX+3u7VSLvFb+hq804OQWCiDc5TyEBSCO+PZsB4EGxQiU6gbEQZxtfUjIuMMAwgo6Vwj4M5hiRcIF4AL/GDTB7guDBQgSfpKg6uGPRw4VjogYYGJFhRjpAdgYoOPHkCYiANSCMtKCXmNGuOSmTppEigEswrgJMqeKnSh67oBgEJ6zaLRY2FhZxV2VbGXMllGXr04DGTfQ4fMTaeQdsPdGjLRbCUkDBHn2pPProOTLMyoh7UJIQp1AxFqgWhEXkx0CGB5twpChgMCsM+wUnAQQehdoCSMYz0B8B4laydK8VM4ZV0tmPJzdFGDgWHEz2aVWw1w7Gbbl2eXube5cxqPfrpWOFgP7iBABB4H3OahLxB8iGb/QWlMDSqm3j65FFEwWKJ3cRiOpTQPA9b1zdYBni16ggGIC6AKHnDBa/2IJLVWCAwmE9FKB7ijGnlBf4FFAGAQ0IYJH4PhEAjsXzjDUGqNAV6AJ2S2goB8MIuGgYnooICENFcqGoQkmwcjbLkX1ZyACJZIH0TQNGocEiy5SeJWMPIgzn1efgNVXPg4cKEBgCgy2gDuF3fOdeGaAl0UsxGCR3jdwwfTVkneJoMwiGnphH5nq7HjaeVWkwgwtNpYJUUlIDaMcinddJCQehmSIBX2ieagNESWIKEIDQjIgwJd+/phikBA6plUdVJCApyO9/PIoSZL26SN6ltokaKaFtpIAJBGooqad6wzxQAMJtoXfju7sNwV0JHRZ1pba4DBrEukBUM+b7YEyA/+rhIAFhhglsOOmg/lJoVcVgyW6xhPhrLKCY47KKAWn0pwKaFSqErJoFtlmKGAjdU0Lzrg51QWQuXb+qSK7tWbxX4QDfcLEjPkCMgW/lar7IIvtwpiEA05B84U/v65z1JPZSamrlWvKmSWww5IRbG8no5yyyiuz3LLLL8Mcs8zNaEuddR4fGE62LXg38homzxy00EMTXbTRRyOdtNIlAA1E00tDHbXUU1NdtdVX//D0Dlpj3bXXX4Mdtthgc21C2WOjnbbaa7Pddskkh+e23HPTXbfdXg9gQBp7892333rfHbjggxNeeDMH+J244gMcYLjjj0MeueSTU1655Zdjnrn/5ptz3rnnn4Meuuijk1666aejnrrqq7Peuuuvwx677LPTXvvXLk5RRLau2t6777/T4kpIdjggHJjAI5+88idgwM07EqzF8fLTU4+8B37sCG/123M/e/MkvLJWA853X775p+sxPALFS4bg+e/DHzruCeguGWjdxp+//vvz37///wMwgAIcIAELaMADIjCBClwgAxvowAdCMIISnCAFK2jBC2IwgxrcIAc76MEPgjCEIrzHoc5AlsGdcDIDcoOnelPCrqTwZC/8QaOAEMOk1fATLdzet6yyAykY5Ai0uOHVZmjD+MSDiGfYYacShScjBkFbbGoiDJGoBCYCAYomyGE7//DTMiwyillTXMy6fgDGuZwJXZfTTFiAoI4uDNGKgbuhEs1wRiaeUQmDOc4JXnifOuBvB1oMIxnqiLI8suQHM8QiIt0ARUMajo1AcSMM6gEuCzFABw6x2Tnw5aMwMKAI2nlACqyADKecCwBCWMEDpPUUG9SlFyswTQHqAh0ZhGFRo6wiKGEkRENEAJczKcIfXZmhTpoElthRD0dsADAW0AuaAFPM+M4hzFA60xIo0M2gmKmKKUxLMcXMCFWaaaEZlOiZF7PYDArgSjpcE0ZXyM1MWmBJsNRyBjYhJzN9iEmO5EMFVLCZM0wCjh5w4YcIEKgDLpOsW6XmNATgEHScYv8Vc+muVg4ghFju0cts0u+ejtFJPgBkM2G6a44YMpZE41GCOGVvfVFC5nl6hiwRICACVZIPj3Twy0qYJk2IGEUB8vEXvsBgTyrx0S2CIho63McLN1UlItITSpsa5I+ackWFaApLKhGmOQgZRREm+Y90kSCnQiFHEtlREDiYRkS3UYxR8cIacYiTTFsN5W1MoBiyUtUZd01GDfaAC6JilYzyQUIKmDG+xTbsOJpJBSTw1FdYQukkGxPiWR8kA5bKKbMCcOitnKNYT9V1rJwgB2CB8ln4SLUBsWDroS57JZkeQQZNReGgsqMcQppWohIQR2lt0ACvqvChDrinQXow3GT/HSkyICERekpU2DaZ4yOOue1ynVVFR2VIJTxaqjtK+8doHsWrcFpAcRHCIXCNRDHdxQkBGKCbtoI3mXn6D3EztCG8IuG84LDShGrEWHCI47/5iUectPAx8JKRRZVQQCqGIGF/Yaq9CSHSA9RRkOIKIKt84I0QIvXDGhSEtCImpKc0rN9avlccJd7wNG714gRHg8PlxdVteQsJjnUSuIcajBA3Fhqw2MFUD/WITw2ih9BsA7TvWMBh9+AmhewJPiJAEJM7IeIdl8C+FJ4ImsyrV1Y9RwviWK+RJYVNvIyYDl12H2f6Aok/PjQWEPDDSwYDvea4NJl5rYamTFBo9GTi/82BFkeVC9BoMLfUxKmAqyqTxJpLsajNJ9DKFVxRIpkeOc4keAQcftHpkmgGDFkNaksvGxnR6plCiubTdmssW07s2RmsLoFWXttmd7hPcD2EgAOCfBqclBBWjCCouWpqa1ciICQNyGSa0DmCwRTrnTCpVma04yMc5MEf0f7uQ3kNA4bwzNbfdWU3E5aANddgRzljAJS9O5ILFWUIBqEmEfBcWkvGZgQCakBVE6rgQReC3ZsB2AjwrT0FP2Afe9A2pB9Czz21SxwXCkOqMJUznXWqVtkCCEHvLQbvimjk6JmJ+yzpmCvg+9qgrHfusgmSb2UIzBiFbrshljO8QuFm4P82XSOvBknLHdp01D1xJHxRuaNzbhltg3rkCME7081AjIlkHdVH6PWvgz3sYk/bFrQes67TbTD3kpkUwhTIY719bhMdezNUImWZ3VAtZk9ZHnfIxRntPQnuQLsIGJJGv8bdjIlP2iBn6Iq7X5ESWhQImif4d7zLMU8zK3oj5o6bzJMBDoD8A+ePNkg3Vj4LpX8DJwTI1sdoW8UBQSc026ICjNfFDjMZlysLToObNaUmAVVYNYxJ+YuQk92C6ORndx6aTCOkmxRFiB3u2QJxrhP5OFE+SXQgleZGn0NO5o52is8dZqZS4PS4OCqiv5vk+4MOP02GcuiKA2Kuk/sxqUv/iK39fWCwQ/PdH3KRi7jU3i7dx0eJRpssFPHtgTSFQ0ZxBO15gVOoghSklIQJEIuwyGF1gey1lDMAhIk11nF4BGwkRK69WpT0TGxcxq8Vwl51WBRERW3sBzfQx7/dWhGw1fPhQT5EA29gxLg8ljgN1kXYIATgoBdEwCwQwFA1RMU03CKoIJoQmg9EWSd4iDuQYCYB4SAk4VB1wSRZlYHNFgxcFKMtIfgMRRHaIAno4BkSoEuJ4EtBFVzEViIoBah1DErkVKmNAG9YGaC1lr5k2QAhRAQYRINNFAiyxGd0k22gyoMI3FGAWK6ky7UURDWgl945DB40GH3kBovcGKJg/0qjCCElVBi45JUnBQqmhKIXvJkgWpeF+AMoHsXgFUKD8RxOaJkG/mB7rAguVpd4bcNSNVEpKlgszt7LVQWAYYqekKJk1NIcmhY7zNdU+JtBQIAqohgmAkA2NoB+odUeFFeMAMiCFVAtYdOj4YGqKZZpSVomAQlapQkW8mG/zIanEVqGmMgn7gcUBmECQOEtREVzBaNfOaGgmEYEQKOCvWIHCqQEOI9iKAKFxRsdXGQVvtYVnkYqVSGazGPxCKOqNJp86EYqOJVQxJpzJNNJjoCJQUhDQqMGBiJBsp5BFpSaUUtQbciauM82MgQjnNqDyUaTASKixUNdvcGsKVAC1P+AtmkBy/njdUnC7V3fJOJJ703l7+mjzXVHwt2iAowCSEQkHkTcPESDIvDBzj1BGGDkjIiBEA7BQ3pBMp0lWd7BHThaKUALa0TBELwjd/yc+a0AIlhUC8BRcrGf5gGkVOYaug3CpdUcxO2lKFYFQoVDTbabCLClu0ngu5WAy32GuH2ZrQlAUKgcr5imzZHSyUlVQmmPOhLQYBxe1FyeGTwCcEWNJoAMJa6MBASe0uzmJ+RmMyQAqx2nCB0D2CynEnwLSgQD1EQn4mVOdX7CdArNc9Jdd3rnd4JneFqNBhxAeZrneaJneh6ABohne9bOAFCAAcjnfNJnfdYnBcCNe+r/5+qcjc/s53+yTn+OgICuDHcC6IEODYGyQX6+S7HUgVVYkxdFgiuciSIExDqNBej9gVsUw/y9wAn0gy/uCxYYqBJQqAi4EsasgU4cxYfChzaNKJ0MJxmc6GQsXhIYjBNknbtBXgjSwiotSoqizDN4BR1pqNkwqBIoaE7KQh3cwV8IQon+UCCcACEYAiJI3cyU5Y0ekT9pUwlgQk5OStCEglAlwm/+wSm0kTOwwg8Ew5jOTJmKwJbSQj84nQm8aanMjC0kA2JiKZpmzJpmaNxgQ5IqwT/OHoKNQzlEqGP+wQyRhZJoSF1YEjJch8KEaGehqHmUgKfJSyTgyd8xRIf1/8hkBN8rad9UkJSReJdI8IGk7gIyOiqtISpTzIRTQMb/reoURtcYeSqXJgGO/EpSbJ1M0ASqRgU57eo59SoJTBKs0kwLTEfQXWoOjNL59cyAGqrTbCslRQZbuMUfSaki8YEtqdE1QodV2FmjGlWVYAkW3I8prlAINkYgQgYs+QhxyAZmIIerlUFe8IEU/UFp0GtEicZFRYGz6esL1mC//hYZfEZofOoneMRvIOy3DodoFAe/aoa/FtJ95YWKzoU9nQRudcxXVcmVkE+2okG3bo3L/lCpbqqidgo3roeEolEXxaRPygN24dd69UqOJCrBMGuHzOvWkcCBJIjMokk95v8lh7GqL1LLq/JsnR7irBZe9jDtVz5tgUXtVLgqOpoTxRqFjvBIsTIMhg2J1/Jqq6KAu0BrdNTKJV7LrkxD0Iqsgi4pnIaJk90s1nrGmZCFrEyRtXhMyJjBxJIegTBLbhwF3zYtquQloZjBSBBuJORDxNSQqLgCqcgBpWQiprVb0hlKNCjuGdhpqECK5zZpcjltGdkk6R7LuVxutIYWx9Ttx9jJWrDsgv4MzE6pwrAFuSwLLcxmyE2LkBbudeXuzpzB6ZrBt0iGvYxmuTio60ou7NoGw5GodylvJKAXm4oLmCIMSC1M6Hbcw3AvnbitvEZCjr7tYfKokr0uQEJMwGj/1/fabiBSK87kkvP2rt4CL4ISsOUIcAEjcOgccAIzMOcscAND8OU8cARTsORMcAVjsOEMwEdwcAeDwwBncAiL8AiTcAmb8AmjcAqr8AqzcAu78AvDcAzL8NLMjwROwdrNcA5DjfCgx/oYz8PqcBAjzffsbPRArxAjcdBcT1qlk9Qm8RMTDRE/j/iQDxRbscykTw+zz5al3hV7ccrUML5+wRF/cRmb8RmjcRqr8RqzcRu78RvDcRzL8RzTcR3b8R3jcR7r8R7zcR/7MdY8wW0O6tKcntS0nekJcuB43te8UCuqTCGfa+nSTaaeLhBpYRy5zOUBrLdmUSKfjOExXpFO/wPhGWfg1RDVPd6jBqwnA65ngm3YtlqAsfLqQTKaZAGesQ0P28BKxuNiRgIpD+kqczK5Bo3ohbKWDc24mkGIuQcr21F9sVQjy7LqAWsto10tY40UJ8EVAFzDUdsmBd0cxtPBRmAp2cApXS96KCvKJasTixQ4gYX4UR5ScIdI7Rw8t8AqtR5VaBIycJKCqR9IUJ9fxB8s4YA/7Jo3gVQR6B4NSESLgNOisAMqZccQVKsOWFRChIafadvr2a0MjMHxhR87awE5XXQ/UULFDF8OeAcLzAAVWOA7V6Bsrm+qFooeRNwYWKAzZF8ZTZyyZmbbWom5/h/3nRQ4zZphvpL4sf/T3+bDMmV012BAF8fjocDUp0HJEYizW8WLTu0JYVDB/D0hk54TSdIGcoxRGl6FWS8G+bDDGQpWGwVAQuNUC8RUVgvAVqszJHhgUfmFHiDVYhDiajXsCSKKbvVpV2Rhbo0yPggGYdwXniTTS4phAXj0x6BEa/wCkyEhckyJu0Y2ElDkCp4Eh87enzkGwDJlIZ7WG36kQjBlXK/FKxqWk/EVEPOGUqmCZOGBCg4iXieWCvX1FE4M8zo2WJVIaEv1nNCQVZLRc12iXisXc3UDdPcqLeabuEwunC1aToyliOCtS1IjjiFHSTXA7hIAdOOKdPMGI9ZiffjBOZZiPQpFj5n/I4boIkzsiIYlbRfkiHtfdgx5onenxtN6DH93I0ts4jQ8ALSwl3+tsnzT7EMM47hEkwKco3h33B6gF9QGoqDYS4XHIt2qmwq5d3YT43etF39jjSvoCyJM7JX1d5Hx4U4mWXLZGFD6LZSlX7pcpFpd5HYDVXcD+Q9WccjMNZPmGjs4JPhAB5HdlWjZuLOhVaNdWYGsNq6VEYoAm4hloTToQPPWeFuvhJWLg+MKeKkWeVxWuJiL1lA+BD/WGDKgW2wnuWITolNSuKpMxrJFgJ3fJbw9SG1vWob01dVWuJmLVsXdRaOtuTvqN1ZLT9fMDxJ8qiUnG7V1ZXWAFJU/FLRJ/5umJybyXpRgsjmfjwBpBno2PWlZ+oTzutw9WzS2Ca+zajqz4YCn84a2XblccNRCe1alfAvvTDQ6Fab/DgFKMAQlaBtoTAGqyZGrq4WpG3ikf5xmqeYMhOVVzsP1JZSqd+UFtq+QE5w3h7uG07Y7jeX98upQm5SqpGUYxKZXlji68Lqpx7u4xtsCXDuwrs3qHYS/z0whAzzRAPMPLF1MaDrUkEhy+mgBJXzhZGnQFLzMnN7EA/KR/uuXGgEQG82O8uYAgfwfk3zJm/znHHLkLe7jLPLJu85ygrLbrbzXNN6ZpDILSd5tzrPLz81yGrPM4zwjO/MWUbXKl0Es8DzUZP8qIuBzLmClUEALSCxrWq3f0/fADbzf9hX0/EFA/VEm/fB08t7iL+TTTjD1U9c6hHiBANacDzrGO5tEXzwTXChgxaDUA7S0QUWgze1Msc8Eq3dVZyY90mDJRalCF24U73iYx6sR4n9hp4RhUxYAGW6FGRK2bKshHb7DUHD2Y0NHHF6+26f1SqpVVGmBQYz2PTSVaQtcBCQlJQ4iYrB2WIjs4BNNeAcgHkTiZnijJLCtjkajM8TlZMLiGEyUMSZnRwmFMq46M27qSH33vksjHpSi6HO3c4gjuZVWgqMJEE6DOJIj7Fu2T8RYXdv+1KwFk1taWGyUKlaxpoQkF7KGF5b/JKacpJip5GS2pILBJAgAACOIABIBUqAIhIgspkgkEPAEDwC9RAMQsGYBiShQACwCDkACiCwERI2GgymSip5aJfaZS9JSAKQAoRA9GLuZ+w2Py+f0uv2Oz+v3/L7/DxgoOCgnFBAgcxiAkFTAEMAgQ1CC89hAcIiwwyCWNQXgCCnj8jYJoMCikHBI1gNwJTNjapiwg6SEgIOweGsSGiBguNvychJrsiJGuyMVsJpm0nCImqSaCVXQVSVw43mYoNBlvQhkqLOEeIsJGaQIZEwYLz9PX29/j5+vf9TZJ1G8T1AOaIFIBXRixNPBhQwbOnwIMWLEXhL1NQM2SAGDhA67/1T8CDKkyJEkS5o8iTKlypUsW7p8CTOmzJk0a9q8iTOnzp08Sw5QBDSoUKADeho9ijSp0ogDivJpujSq1KlUq9KB+tSp1a1cu3qdiXVP2I8Gv5o9i7bq2Dxr9dBqggdTCWpaygbS2G/GChPjjtHxKGjBI0TxElASEQHgjAerArx7e8duIGmK5DE+9E7FJzcOBoMD9UjTHcCAUAElKMiBXxGdv6XpO3ozIcMm1mXGp4jRG9IK77T1rXVPjh0JyNwhMIyaCcl+DOWlccgEhBsr4C6MMIrBoGaHDyk2sSDF8OFOjC+sUi88Dh0A1tEpPqJEhAQRz8hzgPywG/jTNVs/yP+dCGc4oBFH9xAmgHax4fGbHQ3aIQB9QShmWm5u/EAAAXRNwdwfFLnh0Ub8ELGLY9+AwiECuyTgwGUBdCNChZnEIYGCg5iy3Hec6RChgIpJsQsDELAyYXuNASHYIfqh444blOlGzxVt8DaDAzHk0ARpvJjoDIpGYoZDYzCeElQub3S22iAPQICAfq/EMEJCH25JGX11qehMi2LOIOMicOAIARk44ibDQOsQ4MCdK1qZiYs3SNHPg1cF51Yx9sXVgBRCZMOhjh6KUWIsHvVCmAkYNYDGhkGggWaPfSiAgIGBDFokmdPUloJBl3qSBAIvLFFkhigqQIB5ezRgozzF+rL/WahUBPBCF1KgdmqqUUwh7LSu8jHfPagAJE0xpPpVrQKqnqFAqxLygWO7t9lDGKoDOmDYnelG0sW2KEZKKYP94uGqXX2aWRsQQ15b6yAfzhCinP3cYhDCBsWgwJAJ+DXwG2ukCQitHb7yhIAS2tWFKXX5MBcLBaxCQBsiMAkmHFQCQu9tM0vXAJZeEpFExJy2l7K5FmNc5hvK0bNmm29AAISIZTzcs7g/T7xAxc4QDRTBslASKA1u1pPbA+gFkWmnMCwgztBxSDoH23OQBx+mtk7tqR8LMysddViYGjU/J5+9nNZ1nOEyIR576sgxcJtXcgl/m4IKQUznUQsAl8iT/ziIsoHXjQ3xAdAtz7UiDPkQAgpehyvz4Kc051vc0F91ovv8Nzyn74HjgAXqU+qqDlgpQO0xSPGffZDO4Pba/wL8zX91/PAs3YOY8257isgA2+xSC7+AORzLUeIh3+txkZmnOQlUOc0z/InJZpdObKN5HFx5PJSBuU7vajT2WSiiae83bAXNe3mQQuEIoRqN8e81jVkNxLZnNmMQEA/lg45j9qG/QyUqgjGg1yIIeDwTJA8OI0yLCU+IwhQ6aHl1KKEKXwjDGH7FhchjoQxviMMcRoWGIrShDn8IxCCCxYdy4KEQj4jEJEJkAAZoihOfCMUoNlGJVKyiFSVygChqcf+LAzjAFb8IxjCKcYxkLKMZz4jGNKpxjWxsoxvfCMc4ynGOdKyjHe+IxzzqcY987KMf/wjIQApykIQspCEPichEKjKPXGykIx8JyUhKcpKUrKQlL4nJTGpyk5zspCc/CcpQinKUpLSkBvxQylSqcpWsbKUrXwnLWMpylrTc5CkXictc6nKXvOylL38JzGAKc5jELKYxj4nMZCpzmcxspjOfCc1oSnOa1KymNa+JzWweUwMH6KY3vwnOcB7gltos5xcHQAEDqHOd7GxnOylARHPKM4dGBEA954nPtNTznvnsp1f2GU9/CnQeGqmbH2rwB3oxADVvAOhAddkYRVCHf0b/iEBQFGTRXgjBWDE6FCUkwL+OHoIEIjiYd5owGCLNIAEMcB4gcnAYIRwmSRhRwmAokYMxNTSgO33oLi1KCSmwyINiWMGYSvSYAHDUCez5B4o+I4AIWIkNPMDIkIwwpBI8wqUoWuofItDSVygCp126ag7oc9WSmo6EPHUDP32KR6A+KxZLeIdRkeEMBoR1o3CwxGGk4Ze6xshPacWEEbYKh03JAwG3kamAlNqOCPCVr14ogWNr2Ie3wtWOcmVqG84qgruqlRsYoawbYPaCVRSusyNggklrmtIizEAaDAVEMmZwWbluVLeQXU+uatrDzLZ1s3zsLGBfdkHNdKNP9DGt8cYisIsCDCmwyUVFLq46pHcg9g20jQeb3HDZySpVvGTIgVftOdzgEleRnRXq71ZR1Bc9thvRdS5rCBCLZwg1DVGd6g6yWlUJMEoG2wXv3fyACjddFrSGZbBsK9sONzl0vYlkLUi/wRHR7iIhFm2AOdhhgsRgOLQhPcU6SBpgzSw0tozrrSASZJ0rKEJBNKVEjaUzhMuqVyzppbCP4cBSrvIBATr1Q07b1mP0/njJCGaAQQv4YJqxtLaYzQqTr7zDJGsWy1xGyYS7DGad/GQoZBZKksOM5jSrec1sbrOb3wznOMt5znSus53vjOc86xnLIQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Robinson, JM, Cook, JL, Purdam, C, et al. The VISA-A questionnaire: a valid and reliable index of the clinical severity of Achilles tendinopathy. Br J Sports Med 2001; 35:335. Copyright &copy; 2002 BMJ Publishing Group Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2229=[""].join("\n");
var outline_f2_11_2229=null;
var title_f2_11_2230="Aortic dissection on noninvasive imaging";
var content_f2_11_2230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic dissection on noninvasive imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Representative transesophageal echocardiograms (TEE) (panels A and B) and computed tomograms (CT) (panels C and D) of a section of the descending aorta in distal aortic dissection. Panels A and C are acute studies, while B and D are from follow-up evaluation. Both TEE and CT scan show persistence of the intimal flap forming the true lumen (TL) and a markedly dilated false lumen (FL) with the development of thrombi.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Song, JK, Kang, DH, Lim, TH, et al. Different remodeling of descending thoracic aorta after acute event in aortic intramural hemorrage versus aortic dissection. Am J Cardiol 1999; 83:937 with permission from Excerpta Medica Inc.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2230=[""].join("\n");
var outline_f2_11_2230=null;
var title_f2_11_2231="Invasive UC nested variant";
var content_f2_11_2231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Invasive urothelial carcinoma, nested variant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    At low power (A, 10x), the nested variant of urothelial carcinoma is characterized by crowded nests with deceptively bland appearance, irregularly invading muscle fibers. At higher power (B, 20x) the cytologic atypia increases, particularly in the deeper portion of the lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2231=[""].join("\n");
var outline_f2_11_2231=null;
var title_f2_11_2232="Antepartum fetal heart rate assessment";
var content_f2_11_2232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antepartum fetal heart rate assessment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/11/2232/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/11/2232/contributors\">",
"     Bruce K Young, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/11/2232/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/11/2232/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/11/2232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/11/2232/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/11/2232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus' health is evaluated, in part, by assessment of the fetal heart rate (FHR). This assessment involves identification of two general types of FHR patterns: those that may be associated with adverse fetal or neonatal outcomes (ie, nonreassuring patterns) and those that are indicative of fetal well-being (ie, reassuring patterns). The primary goal is to recognize fetuses in whom timely intervention will prevent death. A secondary goal is to avoid fetal neurologic injury.",
"   </p>",
"   <p>",
"    Antepartum FHR evaluation will be reviewed here. Intrapartum fetal evaluation and additional techniques for assessing fetal health are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=see_link\">",
"     \"Intrapartum fetal heart rate assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=see_link\">",
"     \"The fetal biophysical profile\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FETAL CARDIAC DEVELOPMENT AND PHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cardiac development",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal heart and its conduction system develop between three and six weeks post-conception. Factors that regulate fetal heart rate become functional later in gestation, with each factor becoming operational at a different gestational age. Thus, an understanding of the physiological development of the cardiac system is critical for differentiating a normal from an abnormal FHR pattern at each stage of pregnancy.",
"   </p>",
"   <p>",
"    Cardiac output and fetal circulation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=see_link&amp;anchor=H2#H2\">",
"     \"Venous Doppler for fetal assessment\", section on 'Fetal circulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Autonomic nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parasympathetic and sympathetic nervous systems comprise the autonomic nervous system, which regulates the FHR. FHR changes result from moment-to-moment autonomic modulation from medullary cardiorespiratory centers in response to inputs from [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chemoreceptors",
"     </li>",
"     <li>",
"      Baroreceptors",
"     </li>",
"     <li>",
"      Central nervous system activities, such as arousal and sleep",
"     </li>",
"     <li>",
"      Hormonal regulation",
"     </li>",
"     <li>",
"      Blood volume control",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623156015\">",
"    <span class=\"h3\">",
"     Parasympathetic nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parasympathetic innervation of the heart is primarily mediated by the vagus nerve (tenth cranial nerve), which originates in the medulla oblongata. Fibers from this nerve supply the sinoatrial (SA) and atrioventricular (AV) nodes. The two parasympathetic influences on the heart are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A chronotropic effect that slows FHR. Stimulation of the vagus nerve results in a relative slowing of SA node firing and a decrease in FHR, while medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      ) that block the release of acetylcholine from the vagus nerve lead to a relative increase in SA node firing and acceleration of the FHR (by approximately 20 beats per minute [bpm] at term).",
"     </li>",
"     <li>",
"      An oscillatory effect that alters R wave intervals, resulting in FHR variability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623156022\">",
"    <span class=\"h3\">",
"     Sympathetic nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sympathetic nerves are distributed throughout the myocardium of the term fetus. Sympathetic stimulation results in release of norepinephrine, which accelerates the FHR and improves inotropy. Blockade of sympathetic activity decreases baseline FHR and blunts accelerations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect of gestational age on FHR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parasympathetic nervous system exerts a progressively greater influence on FHR as gestational age advances (ie, advancing gestational age is associated with slowing of the baseline heart rate) (",
"    <a class=\"graphic graphic_figure graphicRef62797 \" href=\"UTD.htm?30/58/31661\">",
"     figure 1",
"    </a>",
"    ). As an example, at 20 weeks of gestation the average FHR is 155",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    while at 30 weeks it is 144",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"   </p>",
"   <p>",
"    FHR",
"    variability is rarely present before 24 weeks of gestation, while the absence of variability is abnormal after 28 weeks of gestation since the parasympathetic nervous system is consistently developed by the third trimester. Regardless of gestational age, loss of variability is an abnormal finding once a fetus has demonstrated that its heart rate responds to the oscillatory input of the parasympathetic nervous system.",
"   </p>",
"   <p>",
"    Advancing gestational age is also associated with increased frequency and amplitude of FHR accelerations, which are modulated by the sympathetic nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Fifty percent of normal fetuses demonstrate accelerations with fetal movements at 24 weeks; this proportion rises to over 95 percent at 30 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/4\">",
"     4",
"    </a>",
"    ]. Before 30 weeks, however, accelerations are typically only 10 beats per minute for 10 seconds rather than the 15 beats per minute sustained for 15 seconds noted after 30 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiovascular response to hypoxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal oxygenation depends upon adequate maternal oxygenation, uteroplacental and fetoplacental blood flow, and distribution of oxygenated blood to fetal tissues. Therefore, reduced fetal oxygenation may result from a variety of sources including maternal disorders (eg, respiratory insufficiency, hypotension, vasoconstrictors, alkalosis), acute or chronic placental dysfunction (eg, abruptio placentae, infarction, confined placental mosaicism), uterine factors (eg, rupture, tachysystole), and fetal factors (eg, arrhythmia, fetal hydrops, umbilical cord compression).",
"   </p>",
"   <p>",
"    Transient, mild hypoxemia associated with contractions causes stimulation of chemoreceptors in the fetal carotid arteries. These receptors signal the fetal brainstem to improve blood flow for better perfusion of brain, heart, adrenals, and placenta. The brainstem responds with sympathetic stimulation to increase catecholamine levels, which first increase heart rate and variability and then, if hypoxemia persists or worsens, constrict peripheral arterial beds, resulting in systemic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/5\">",
"     5",
"    </a>",
"    ]. Baroreceptors then respond by sending a signal to the brainstem that leads to stimulation of the vagus nerve and consequent slowing of the fetal heart related to the contractions. The bradycardia can manifest as early, late or variable decelerations, depending upon the etiology of the transient hypoxia (eg, fetal head compression reduces cerebral blood flow which can lead to early decelerations, uterine contractions reduce placental blood flow which can lead to late decelerations, and compression of the umbilical cord reduces blood flow in the umbilical vein and arteries which can cause variable decelerations) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=see_link&amp;anchor=H18#H18\">",
"     \"Intrapartum fetal heart rate assessment\", section on 'Management of fetal heart rate patterns'",
"    </a>",
"    .) This sequence is the probable pathogenesis of a positive contraction stress test and is largely derived from fetal sheep studies (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Contraction stress test'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    There is also a nonadrenergic component to the fetal response. It appears to be mediated by humoral substances, such as vasoconstrictor hormones, released from the adrenal as a direct result of hypoxemia.",
"   </p>",
"   <p>",
"    As hypoxemia worsens, the normal efferent sympathetic response to fetal movement is abolished so that accelerations of the FHR disappear. This stage is reflected by nonreactivity of the nonstress test (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Nonstress test'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Prolonged",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe hypoxemia results in persistent bradycardia or repetitive late decelerations related to myocardial depression. Variability is also lost. Ultimately there is a loss of fetal biophysical activities, such as breathing, movement, and body tone. At this stage, the fetus may be acidotic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EQUIPMENT FOR FHR MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hand-held Doppler ultrasound probe can be used to calculate and display, but not record, the FHR. Electronic fetal monitors are used to both determine the FHR and continuously record it in graphical form. In external FHR monitoring systems, the FHR is measured by focusing an ultrasound beam on the fetal heart from a small Doppler ultrasound device placed on the maternal abdomen. A bedside monitor interprets the Doppler signals, which reflect the frequency of heart valve movement as well as atrial and ventricular systole. The complex wave generated is analyzed and the peak detected and used for calculations. An internal computer then calculates the FHR by averaging several consecutive beat-to-beat frequencies (to minimize artifact). This process of averaging is called \"autocorrelation.\" It produces a FHR pattern closely resembling that derived from a fetal electrocardiogram (ECG), although there is more baseline variability inherent with the Doppler technique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27592?source=see_link&amp;anchor=H31630829#H31630829\">",
"     \"Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology\", section on 'External fetal heart rate monitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Auscultation of the FHR using a fetal stethoscope is also possible, but more cumbersome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INTERPRETATION OF FHR TRACINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The types and significance of FHR",
"    <span class=\"nowrap\">",
"     changes/patterns",
"    </span>",
"    that may be observed antepartum or during labor are discussed in detail separately. These patterns are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef65859 \" href=\"UTD.htm?3/5/3165\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=see_link&amp;anchor=H18#H18\">",
"     \"Intrapartum fetal heart rate assessment\", section on 'Management of fetal heart rate patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FHR always needs to be interpreted in the context of the gestational age, prior results of fetal assessment, maternal conditions (including medications), and fetal condition (eg, growth restriction, anemia, arrhythmia).",
"   </p>",
"   <p>",
"    In general, FHR accelerations and variability are reassuring findings that suggest the fetus is neither hypoxemic nor acidotic. Short, shallow decelerations are mediated by fetal chemoreceptors and typically reflect a mild reduction in fetal oxygen tension [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/8\">",
"     8",
"    </a>",
"    ]. Repetitive, deep, prolonged decelerations reflect a more severe abnormality that eventually may become associated with development of metabolic acidosis and hypotension. A higher baseline rate and loss of variability are additional signs of fetal decompensation, bearing in mind the effects of gestational age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANTEPARTUM FHR MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence from randomized trials that proves antepartum FHR monitoring results in a decreased risk of fetal death (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Utility of antepartum FHR monitoring'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/9\">",
"     9",
"    </a>",
"    ]. Nevertheless, antepartum fetal monitoring of pregnancies deemed to be at high risk of adverse fetal outcome is a routine obstetric practice in the United States, and elsewhere, based upon circumstantial evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/10\">",
"     10",
"    </a>",
"    ]. For liability exposure reasons, it is impossible to abandon use of these tests in the United States while awaiting data from well-designed randomized trials, which may never be performed.",
"   </p>",
"   <p>",
"    Currently, antepartum FHR monitoring is generally performed in pregnancies in which the risk of fetal demise is known to be increased (",
"    <a class=\"graphic graphic_table graphicRef61128 \" href=\"UTD.htm?33/51/34619\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/10\">",
"     10",
"    </a>",
"    ]. These pregnancies are complicated by maternal medical or obstetrical conditions potentially associated with placental dysfunction or poor uteroplacental perfusion. They also include fetal disorders or any other conditions potentially associated with an increased risk of fetal death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nonstress test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nonstress test (NST) is the most common cardiotocographic method of antepartum fetal assessment. Unlike the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    challenge test, it is noninvasive and can be performed in any setting with an electronic fetal monitor. There are no direct maternal or fetal risks from nonstress testing.",
"   </p>",
"   <p>",
"    Testing may be initiated when the fetal neurological maturity enables FHR accelerations to occur (typically at 26 to 28 weeks) and the fetus is believed to be at increased risk of death. There is no high-quality evidence regarding the optimal frequency of testing [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/9\">",
"     9",
"    </a>",
"    ]. Testing is performed at daily to weekly intervals as long as the indication for testing persists. The frequency of testing is based on clinical judgment, taking into consideration whether the test is being performed to screen for fetal hypoxemia in a high risk pregnancy or to monitor a fetus with suspected, but compensated, fetal hypoxemia. Deterioration of maternal or fetal status requires reevaluation despite recent reassuring test results. As discussed above, the presence of a reassuring pattern indicates that there is no fetal hypoxemia only at the time of testing. Because of the low prevalence of stillbirth, the assertion that a reactive nonstress test assures fetal survival for another seven days is unproven, but the odds are 99 percent that the fetus will survive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23600030\">",
"    <span class=\"h3\">",
"     Reactive tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The test is reactive if there are two or more fetal heart rate accelerations reaching a peak of at least 15 bpm above the baseline rate and lasting for at least 15 seconds from onset to return in a 20-minute period (",
"    <a class=\"graphic graphic_figure graphicRef72845 \" href=\"UTD.htm?41/26/42406\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65859 \" href=\"UTD.htm?3/5/3165\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/7,10,11\">",
"     7,10,11",
"    </a>",
"    ]. A reactive test is reassuring of fetal well-being and is reassuring regardless of the length of observation time necessary to demonstrate reactivity (for observation times up to 120 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/12\">",
"     12",
"    </a>",
"    ]. Different criteria have been used for fetuses prior to 32 weeks given the physiological immaturity of the fetal heart at this stage of gestation. Reactivity prior to 32 weeks may be defined as two accelerations of at least 10 beats per minute, lasting 10 seconds or more, over a 20-minute interval [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Effect of gestational age on FHR'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23600276\">",
"    <span class=\"h4\">",
"     Reactive with decelerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The significance of a reactive NST associated with FHR decelerations is unclear. Multiple observational studies have described an increased frequency of intrapartum FHR decelerations and operative delivery when this combination occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/14-19\">",
"     14-19",
"    </a>",
"    ], except when the decelerations are brief [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/20\">",
"     20",
"    </a>",
"    ]; however, outcomes are usually good.",
"   </p>",
"   <p>",
"    We suggest sonographic evaluation of these pregnancies to look for factors that have been associated with FHR decelerations, such as oligohydramnios, nuchal cord or other compromise of the umbilical cord, or intrauterine growth restriction. Other causes, such as intermittent fetal cardiac arrhythmias, may also be diagnosed by sonography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=see_link\">",
"     \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further assessment by biophysical profile, and Doppler ultrasound of the umbilical and middle cerebral vessels if intrauterine growth restriction is detected, can offer further reassurance of fetal well-being for continuing conservative management of the preterm fetus. In the absence of a clinical basis for an increased risk of fetal compromise and when other fetal assessment testing is reassuring, the pregnancy can be followed with at least twice weekly monitoring by biophysical profile and nonstress testing until there is evidence of fetal deterioration or until fetal lung maturity is documented. Delivery for a persistent reactive NST associated with decelerations is reasonable when fetal pulmonary maturity is attained. If the patient&rsquo;s cervix is favorable, the NST is reactive, and the biophysical profile is reassuring, induction with continuous FHR monitoring is reasonable. As discussed above, cesarean or instrumental delivery is common because of the increased frequency of nonreassuring FHR patterns during labor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=see_link\">",
"     \"Oligohydramnios\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25815?source=see_link\">",
"     \"Nuchal cords\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29494?source=see_link&amp;anchor=H496167#H496167\">",
"     \"Umbilical cord prolapse\", section on 'Pregnancies with funic presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23600037\">",
"    <span class=\"h3\">",
"     Nonreactive tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nonreactive NST is defined as one that does not show such accelerations over a 40-minute period. Nonreactivity may be a sign of fetal hypoxemia or acidosis and thus is nonreassuring of fetal well-being. Fetuses with a nonreactive NST have a mean umbilical vein pH of 7.28 &plusmn; 0.11, while those with low biophysical profile (BPP) scores have a mean pH of 7.16 &plusmn; 0.08 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/21\">",
"     21",
"    </a>",
"    ]. (The normal range of antepartum fetal umbilical vein pH has been established by cordocentesis (",
"    <a class=\"graphic graphic_table graphicRef76880 \" href=\"UTD.htm?9/1/9245\">",
"     table 3",
"    </a>",
"    )).",
"   </p>",
"   <p>",
"    However, nonreactivity may be benign and temporary due to fetal immaturity, quiet fetal sleep, or maternal smoking (women who smoke should not smoke proximate to an NST) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/22\">",
"     22",
"    </a>",
"    ]. In one study of late preterm fetuses from uncomplicated pregnancies, quiescence (no eye movements, no somatic movements except for the occasional startle, and a FHR pattern with little baseline variability) occurred at least once in 30 percent of fetuses within the 100-minute observation time, but 96 percent of the fetuses cycled between quiescence and active states during the period of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/23\">",
"     23",
"    </a>",
"    ]. Nonreactivity can also be related to fetal neurological or cardiac anomalies, sepsis, or maternal ingestion of drugs with cardiac effects.",
"   </p>",
"   <p>",
"    Ancillary tests may prove useful in avoiding a premature iatrogenic delivery, since the false positive rate of an isolated nonreactive NST may be as high as 50 to 60 percent. Some options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Performing vibroacoustic stimulation (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Vibroacoustic stimulation'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Performing additional tests not based on FHR assessment (eg, BPP, Doppler velocimetry). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=see_link\">",
"       \"The fetal biophysical profile\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"       \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=see_link\">",
"       \"Fetal blood sampling\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Modifying factors potentially causing abnormal test results, if possible (eg, correction of diabetic ketoacidosis or maternal hypotension).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cordocentesis carries a procedure related risk of fetal loss of at least 1 percent; therefore, it is rarely used as an ancillary test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Vibroacoustic stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vibroacoustic stimulation is useful for decreasing the number of nonreactive NSTs related to quiet fetal sleep cycles. This test is performed by placing an auditory source, such as an artificial larynx, on or just above the maternal abdomen and delivering a short burst of sound to the fetus. The procedure stimulates the fetus to move and thus shortens the duration of time needed to produce an acceleration (weighted mean difference -4.55 minutes, 95% CI -5.96 to -3.14 minutes) and reduces the frequency of nonreactive NSTs (OR 0.61, 95% CI 0.49-0.75), without compromising the predictive value of a reactive NST [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/24\">",
"     24",
"    </a>",
"    ]. It can be performed antepartum or intrapartum.",
"   </p>",
"   <p>",
"    There are no evidence-based standards for performing this procedure. It has been performed as soon as 5 minutes after initiation of the NST. A stimulus of one to five seconds is given, and may be repeated. The optimal placement of the stimulus also has not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although commonly practiced, meta-analyses have reported that neither maternal glucose administration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/25\">",
"     25",
"    </a>",
"    ] nor manual fetal manipulation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/26\">",
"     26",
"    </a>",
"    ] significantly decrease the incidence of nonreactive test results related to quiet fetal sleep. The meta-analysis of manual fetal manipulation included only two trials and reported no significant change in incidence of nonreactive NST with fetal manipulation compared to no or mock stimulation (OR 1.28, 95% CI 0.94-1.74). However, subsequent to this analysis, the first randomized trial showing that manual fetal stimulation significantly reduced the time to reactivity and increased the frequency of reactivity when compared to performing the NST alone was published [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/27\">",
"     27",
"    </a>",
"    ]. Further analysis of the value of manual stimulation is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Contraction stress test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contraction stress test (CST) is usually performed using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    (also called an oxytocin challenge test [OCT]). A dilute solution of oxytocin is infused until three contractions occur within 10 minutes. Relative contraindications include preterm labor, patients at high risk of preterm delivery, preterm premature rupture of membranes, placenta previa, and previous classical cesarean delivery or extensive uterine surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CST is interpreted as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Positive (nonreassuring)",
"      </strong>",
"      - A positive (nonreassuring) test is defined by the presence of late decelerations following 50 percent or more of the contractions (such a test is considered positive even if the contraction frequency is less than three in 10 minutes).",
"     </li>",
"     <li>",
"      <strong>",
"       Negative (reassuring)",
"      </strong>",
"      - A negative (reassuring) test has no late or significant variable decelerations [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Equivocal",
"      </strong>",
"      - An equivocal-suspicious pattern consists of intermittent late or significant variable decelerations, while an equivocal-tachysystolic pattern refers to fetal heart rate decelerations occurring with contractions more frequent than every two minutes or lasting longer than 90 seconds.",
"     </li>",
"     <li>",
"      <strong>",
"       Unsatisfactory",
"      </strong>",
"      - An unsatisfactory test is one in which the tracing is uninterpretable or contractions are fewer than three in 10 minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CST is also interpreted as described above in women who are having spontaneous contractions of adequate frequency.",
"   </p>",
"   <p>",
"    A positive (nonreassuring) CST may indicate decreased fetal reserve and correlates with a 20 to 40 percent incidence of abnormal FHR patterns during labor. An equivocal-suspicious test with repetitive variable decelerations is also associated with abnormal FHR patterns in labor, which are often related to cord compression due to oligohydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies have suggested that the CST is more predictive of adverse outcome than the NST [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/28\">",
"     28",
"    </a>",
"    ]. However, other reports have not demonstrated any improvement in predicting perinatal morbidity compared to the NST even when both tests are combined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Results from comparative trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence from comparative trials on which to base a recommendation for use of one method of fetal assessment over another. CSTs are invasive (an intravenous line and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    are needed), costly, and potentially risky since contractions are induced. The only randomized trial comparing use of the BPP (which includes an NST) versus the NST alone in management of 652 high-risk pregnancies was inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/29\">",
"     29",
"    </a>",
"    ]. Costs were not considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Utility of antepartum FHR monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a seminal observational study, the stillbirth rates (corrected for lethal congenital anomalies and unpredictable causes of demise) after a reactive or nonreactive NST were 1.9 and 26 per 1000 births, respectively. The stillbirth rates after a negative CST, reactive positive CST, or nonreactive positive CST were 0.3, 0, and 88 per 1000 births, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/30\">",
"     30",
"    </a>",
"    ]. These findings suggest that abnormal test results are concerning, but should be interpreted with regard to the clinical situation, given the high false positive rate (ie, up to 60 percent of fetuses with a positive CST tolerate labor and have no FHR changes necessitating intervention).",
"   </p>",
"   <p>",
"    A 2012 Cochrane review attempted to determine whether nonstress testing can improve maternal or perinatal outcome by identifying pregnancies at high risk in which prompt induction of labor or immediate delivery by cesarean are required [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/31\">",
"     31",
"    </a>",
"    ]. Six randomized trials involving 2105 women were included. Tested patients were compared to controls in whom nonstress testing was not performed or test results were concealed. There were no significant differences between groups in maternal outcomes, such as frequency of induction of labor or cesarean delivery, or in infant outcomes, including perinatal mortality, low 5 minute Apgar, neonatal intensive care unit admission, and neonatal seizures. Perinatal mortality (adjusted for lethal anomalies) in the monitored group was higher than in controls (2.3 versus 1.1 percent, four studies, N = 1627; OR 2.05, 95% CI 0.95-4.42).",
"   </p>",
"   <p>",
"    There are many limitations to the trials in this meta-analysis, which prevent making as assessment of the value of this test in current practice. Randomization methods were suboptimal, which could have created bias. The total number of adverse events, such as perinatal mortality and abnormal neurological signs, was too low to determine whether small, but statistically significant, differences in outcome might result from testing. Furthermore, these trials were conducted in the early 1980s when these tests were just being introduced into clinical practice and clinicians were inexperienced in test interpretation and subsequent pregnancy management. It is possible that the tests would be interpreted and acted upon differently today, with different outcomes. Lastly, fetal assessment and neonatal care have changed since the 1980s; the combined use of ultrasound and fetal heart rate monitoring may be more predictive of fetal status and need for intervention than either test alone.",
"   </p>",
"   <p>",
"    Computerized fetal heart rate analysis systems allow an automated evaluation of the FHR tracing. When the authors of the meta-analysis compared computerized cardiotocography versus traditional cardiotocography, computerized cardiotocography was associated with a significant reduction in perinatal mortality (RR 0.20, 95% CI 0.04-0.88, two trials, 0.9 versus 4.2 percent, 469 women), but no significant difference in potentially preventable deaths (RR 0.23, 95% CI 0.04-1.29, two trials, N = 469), although the meta-analysis was underpowered to assess this outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Management of pregnancies with nonreassuring antepartum testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of the fetus with nonreassuring antepartum FHR testing depends upon the clinical context. At term, delivery, rather than further evaluation, is usually warranted since fetal hypoxemia cannot be definitively excluded when these tests are nonreassuring. Depending on the FHR pattern, induction of labor with continuous FHR and contraction monitoring may be attempted in the absence of obstetrical contraindications. Repetitive late decelerations or severe variable decelerations generally mandate expeditious delivery by cesarean [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2232/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonreassuring antepartum FHR test results in a preterm gestation pose a greater dilemma. After weighing the potential risks of fetal hypoxemia versus the maternal and neonatal risks associated with iatrogenic preterm birth, preterm delivery may be indicated for persistent nonreassuring testing that has been confirmed by additional tests of fetal well-being (eg, BPP, NST, CST), particularly when there is known uteroplacental insufficiency, such as in the setting of fetal growth restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal well-being is evaluated, in part, by assessment of the fetal heart rate (FHR). The FHR pattern is interpreted as reassuring (no fetal",
"      <span class=\"nowrap\">",
"       hypoxemia/acidosis)",
"      </span>",
"      or nonreassuring (possible fetal",
"      <span class=\"nowrap\">",
"       hypoxemia/acidosis).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FHR patterns reflect the fetal response to input from chemoreceptors, baroreceptors, central nervous system activities, hormonal regulation, and blood volume control. Gestational age is a factor in interpretation of FHR patterns. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Fetal cardiac development and physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interpretation of FHR tracings is subjective and not very reproducible. Criteria have been developed for characterizing FHR",
"      <span class=\"nowrap\">",
"       changes/patterns,",
"      </span>",
"      and determining whether these",
"      <span class=\"nowrap\">",
"       changes/patterns",
"      </span>",
"      are reassuring or nonreassuring. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Interpretation of FHR tracings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that pregnancies in which the risk of fetal demise is known to be increased undergo antepartum FHR monitoring (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Given its safety and convenience, we suggest fetal assessment by nonstress testing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The frequency of testing depends upon the maternal and fetal status. Vibroacoustic stimulation is useful for decreasing the number of nonreactive nonstress tests related to quiet fetal sleep cycles. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Nonstress test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonreassuring test results may be due to fetal hypoxemia or acidosis, but should be interpreted with regard to the clinical situation, given the high false positive rate. Additional testing with Doppler ultrasound, vibroacoustic stimulation, or other techniques may be helpful in making clinical decisions. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Utility of antepartum FHR monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Parer, JT. Fetal Heart Rate. In: Maternal Fetal Medicine: Principles and Practice. Creasy and Resnik (Eds), W.B. Saunders Company, Philadelphia, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/2\">",
"      Sadovsky G, Nicolaides KH. Reference ranges for fetal heart rate patterns in normoxaemic nonanaemic fetuses. Fetal Ther 1989; 4:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/3\">",
"      Park MI, Hwang JH, Cha KJ, et al. Computerized analysis of fetal heart rate parameters by gestational age. Int J Gynaecol Obstet 2001; 74:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/4\">",
"      Pillai M, James D. The development of fetal heart rate patterns during normal pregnancy. Obstet Gynecol 1990; 76:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/5\">",
"      Young BK, Katz M, Klein SA. Pregnancy after spinal cord injury: altered maternal and fetal response to labor. Obstet Gynecol 1983; 62:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/6\">",
"      Antoine C, Young BK, Silverman F. Simultaneous measurement of fetal tissue pH and transcutaneous pO2 during labor. Eur J Obstet Gynecol Reprod Biol 1984; 17:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/7\">",
"      Electronic fetal heart rate monitoring: research guidelines for interpretation. National Institute of Child Health and Human Development Research Planning Workshop. Am J Obstet Gynecol 1997; 177:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/8\">",
"      Westgate JA, Wibbens B, Bennet L, et al. The intrapartum deceleration in center stage: a physiologic approach to the interpretation of fetal heart rate changes in labor. Am J Obstet Gynecol 2007; 197:236.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/9\">",
"      Rouse DJ, Owen J, Goldenberg RL, Cliver SP. Determinants of the optimal time in gestation to initiate antenatal fetal testing: a decision-analytic approach. Am J Obstet Gynecol 1995; 173:1357.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Antepartum Fetal Surveillance. ACOG Practice Bulletin #9, American College of Obstetricians and Gynecologists, Washington DC 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/11\">",
"      Evertson LR, Gauthier RJ, Schifrin BS, Paul RH. Antepartum fetal heart rate testing. I. Evolution of the nonstress test. Am J Obstet Gynecol 1979; 133:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/12\">",
"      Brown R, Patrick J. The nonstress test: how long is enough? Am J Obstet Gynecol 1981; 141:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/13\">",
"      Macones GA, Hankins GD, Spong CY, et al. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Obstet Gynecol 2008; 112:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/14\">",
"      Hoskins IA, Frieden FJ, Young BK. Variable decelerations in reactive nonstress tests with decreased amniotic fluid index predict fetal compromise. Am J Obstet Gynecol 1991; 165:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/15\">",
"      Begum F, Buckshee K. Foetal compromise by spontaneous foetal heart rate deceleration in reactive non-stress test and decreased amniotic fluid index. Bangladesh Med Res Counc Bull 1998; 24:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/16\">",
"      Glantz C, D'Amico ML. Lack of relationship between variable decelerations during reactive nonstress tests and oligohydramnios. Am J Perinatol 2001; 18:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/17\">",
"      Judge NE, Mann LI, Lupe P, Amini S. Clinical associations of variable decelerations during reactive nonstress tests. Obstet Gynecol 1989; 74:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/18\">",
"      Phelan JP, Lewis PE Jr. Fetal heart rate decelerations during a nonstress test. Obstet Gynecol 1981; 57:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/19\">",
"      Bruce SL, Petrie RH, Davison J. Prediction of abnormal umbilical cord position and intrapartum cord problems from the nonstress test. Diagn Gynecol Obstet 1980; 2:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/20\">",
"      Meis PJ, Ureda JR, Swain M, et al. Variable decelerations during nonstress tests are not a sign of fetal compromise. Am J Obstet Gynecol 1986; 154:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/21\">",
"      Manning FA, Snijders R, Harman CR, et al. Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH. Am J Obstet Gynecol 1993; 169:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/22\">",
"      Oncken C, Kranzler H, O'Malley P, et al. The effect of cigarette smoking on fetal heart rate characteristics. Obstet Gynecol 2002; 99:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/23\">",
"      Pillai M, James D. Behavioural states in normal mature human fetuses. Arch Dis Child 1990; 65:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/24\">",
"      Tan KH, Smyth R. Fetal vibroacoustic stimulation for facilitation of tests of fetal wellbeing. Cochrane Database Syst Rev 2001; :CD002963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/25\">",
"      Tan KH, Sabapathy A. Maternal glucose administration for facilitating tests of fetal wellbeing. Cochrane Database Syst Rev 2012; 9:CD003397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/26\">",
"      Tan KH, Sabapathy A. Fetal manipulation for facilitating tests of fetal wellbeing. Cochrane Database Syst Rev 2001; :CD003396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/27\">",
"      Piyamongkol W, Trungtawatchai S, Chanprapaph P, Tongsong T. Comparison of the manual stimulation test and the nonstress test: a randomized controlled trial. J Med Assoc Thai 2006; 89:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/28\">",
"      Freeman RK, Anderson G, Dorchester W. A prospective multi-institutional study of antepartum fetal heart rate monitoring. II. Contraction stress test versus nonstress test for primary surveillance. Am J Obstet Gynecol 1982; 143:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/29\">",
"      Platt LD, Walla CA, Paul RH, et al. A prospective trial of the fetal biophysical profile versus the nonstress test in the management of high-risk pregnancies. Am J Obstet Gynecol 1985; 153:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/30\">",
"      Freeman RK, Anderson G, Dorchester W. A prospective multi-institutional study of antepartum fetal heart rate monitoring. I. Risk of perinatal mortality and morbidity according to antepartum fetal heart rate test results. Am J Obstet Gynecol 1982; 143:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2232/abstract/31\">",
"      Grivell RM, Alfirevic Z, Gyte GM, Devane D. Antenatal cardiotocography for fetal assessment. Cochrane Database Syst Rev 2012; 12:CD007863.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 409 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-1201EFFE29-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2232=[""].join("\n");
var outline_f2_11_2232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FETAL CARDIAC DEVELOPMENT AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cardiac development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Autonomic nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H623156015\">",
"      - Parasympathetic nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H623156022\">",
"      - Sympathetic nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect of gestational age on FHR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiovascular response to hypoxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EQUIPMENT FOR FHR MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INTERPRETATION OF FHR TRACINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANTEPARTUM FHR MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nonstress test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23600030\">",
"      - Reactive tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23600276\">",
"      Reactive with decelerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23600037\">",
"      - Nonreactive tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vibroacoustic stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Contraction stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Results from comparative trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Utility of antepartum FHR monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Management of pregnancies with nonreassuring antepartum testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/409\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/409|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/58/31661\" title=\"figure 1\">",
"      Baseline FHR by gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/26/42406\" title=\"figure 2\">",
"      Reactive nonstress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/409|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/5/3165\" title=\"table 1\">",
"      NICHHD FHR interpretation guide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/51/34619\" title=\"table 2\">",
"      Indications for antepartum fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/1/9245\" title=\"table 3\">",
"      Umbilical Vein and Artery pH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27592?source=related_link\">",
"      Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=related_link\">",
"      Doppler ultrasound of the umbilical artery for fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=related_link\">",
"      Intrapartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25815?source=related_link\">",
"      Nuchal cords",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=related_link\">",
"      Oligohydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=related_link\">",
"      Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=related_link\">",
"      The fetal biophysical profile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29494?source=related_link\">",
"      Umbilical cord prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=related_link\">",
"      Venous Doppler for fetal assessment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_11_2233="Oxaliplatin: Drug information";
var content_f2_11_2233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxaliplatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/31/33269?source=see_link\">",
"    see \"Oxaliplatin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/49/33558?source=see_link\">",
"    see \"Oxaliplatin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eloxatin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6821523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eloxatin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F204285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Platinum Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F204263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Advanced colorectal cancer:",
"     </b>",
"     I.V.: 85 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks until disease progression or unacceptable toxicity (in combination with fluorouracil/leucovorin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stage III colon cancer (adjuvant):",
"     </b>",
"     I.V.: 85 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks for 6 months (12 cycles; in combination with fluorouracil/leucovorin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Colon/colorectal cancer (unlabeled doses or combinations):",
"     </b>",
"     I.V.: 85 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on days 1, 15, and 29 of an 8-week treatment cycle in combination with fluorouracil/leucovorin (Kuebler, 2007)",
"     <b>",
"      or",
"     </b>",
"     85 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks in combination with fluorouracil/leucovorin/irinotecan (Falcone, 2007)",
"     <b>",
"      or",
"     </b>",
"     130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks in combination with capecitabine (Cassidy, 2008; Haller, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Esophageal/gastric cancers (unlabeled use; as part of a combination chemotherapy regimen):",
"     </b>",
"     I.V.: 85 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks (Al-Batran, 2008; Conroy, 2010)",
"     <b>",
"      or",
"     </b>",
"     130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (Cunningham, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Gastric cancer:",
"     </i>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks (Louvet, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hepatobiliary cancer, advanced (unlabeled use; as part of a combination chemotherapy regimen):",
"     </b>",
"     I.V.: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks (Andre, 2004)",
"     <b>",
"      or",
"     </b>",
"     130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (Nehls, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Non-Hodgkin's lymphoma, refractory (unlabeled use; as part of a combination chemotherapy regimen):",
"     </b>",
"     I.V.: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days every 4 weeks (Tsimberidou, 2008)",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (Lopez, 2008; Rodriguez, 2007)",
"     <b>",
"      or",
"     </b>",
"     130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (Chau, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer, advanced (unlabeled use):",
"     </b>",
"     I.V.: 130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (Dieras, 2002; Piccart, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pancreatic cancer, advanced (unlabeled use; as part of a combination chemotherapy regimen):",
"     </b>",
"     I.V.: 85 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks (Conroy, 2005; Conroy, 2011; Pelzer, 2011)",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks (Louvet, 2005)",
"     <b>",
"      or",
"     </b>",
"     110-130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (Xiong, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Testicular cancer, refractory (unlabeled use; in combination with gemcitabine):",
"     </b>",
"     I.V.: 130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (Bokemeyer, 2008; Kollmannsberger, 2004; Pectasides, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F204264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F204265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Manufacturer's recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Reduce dose from 85 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 65 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternate recommendations: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;20 mL/minute: In a study with a limited number of patients with mild-to-moderate impairment, defined by the authors as Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-59 mL/minute (determined using 24-hour urine collection), oxaliplatin was well-tolerated, suggesting a dose reduction may not be necessary in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;20 mL/minute receiving every-3-week dosing (dose range: 80-130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks) (Takimoto, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6821524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mild, moderate, or severe impairment: No dosage adjustment necessary (Doroshow, 2003; Synold, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F204286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Acute toxicities: Longer infusion time (6 hours) may mitigate acute toxicities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neurosensory events:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Persistent (&gt;7 days) grade 2 neurosensory events:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Adjuvant treatment of stage III colon cancer: Reduce dose to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Advanced colorectal cancer: Reduce dose to 65 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Consider withholding oxaliplatin for grade 2 neuropathy lasting &gt;7 days despite dose reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Persistent grade 3 neurosensory events: Consider discontinuing oxaliplatin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Other toxicities (grade 3/4 gastrointestinal toxicity, grade 4 neutropenia, or grade 3/4 thrombocytopenia): After recovery from toxicity, oxaliplatin dose reductions are recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adjuvant treatment of stage III colon cancer: Reduce dose to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; delay next dose until neutrophils recover to &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets recover to &ge;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Advanced colorectal cancer: Reduce dose to 65 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; delay next dose until neutrophils recover to &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets recover to &ge;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Pulmonary toxicity (unexplained respiratory symptoms including nonproductive cough, dyspnea, crackles, pulmonary infiltrates): Discontinue until interstitial lung disease or pulmonary fibrosis have been excluded.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate, preservative free]: 5 mg/mL (10 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eloxatin&reg;: 5 mg/mL (10 mL, 20 mL, 40 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F204244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as I.V. infusion over 2 hours; extend infusion time to 6 hours for acute toxicities. Flush infusion line with D",
"     <sub>",
"      5",
"     </sub>",
"     W prior to administration of any concomitant medication. Patients should receive an antiemetic premedication regimen. Avoid mucositis prophylaxis with ice chips during oxaliplatin infusion (may exacerbate acute neurological symptoms). Do not use needles or administration sets containing aluminum.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F204292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W;",
"     <b>",
"      incompatible",
"     </b>",
"     with alkaline solutions (eg, fluorouracil) and chloride-containing solutions. Flush infusion line with D",
"     <sub>",
"      5",
"     </sub>",
"     W prior to, and following, administration of concomitant medications via same I.V. line.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, aminophylline, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, chlorpromazine, cimetidine, cyclophosphamide, dexamethasone, diphenhydramine, dobutamine, docetaxel, dolasetron, dopamine, doxorubicin, droperidol, enalaprilat, epirubicin, etoposide phosphate, famotidine, fentanyl, furosemide, gemcitabine, granisetron, haloperidol lactate, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, ifosfamide, irinotecan, leucovorin calcium, lorazepam, magnesium sulfate, mannitol, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, mitoxantrone, morphine, nalbuphine, ondansetron, paclitaxel, palonosetron, potassium chloride, prochlorperazine, promethazine, ranitidine, sodium bicarbonate, theophylline, topotecan, verapamil, vincristine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diazepam.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F204243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of stage III colon cancer (adjuvant) after complete resection of primary tumor; treatment of advanced colorectal cancer",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F204281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of esophageal cancer, gastric cancer, hepatobiliary cancer (advanced), non-Hodgkin's lymphoma (refractory), ovarian cancer (advanced, platinum-pretreated), pancreatic cancer (advanced), testicular cancer (refractory)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F204295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Oxaliplatin may be confused with Aloxi&reg;, carboplatin, cisplatin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F204283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported with monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (61%), fever (25%), pain (14%), headache (13%), insomnia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (64%), diarrhea (46%), vomiting (37%), abdominal pain (31%), constipation (31%), anorexia (20%), stomatitis (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (64%; grades 3/4: 1%), thrombocytopenia (30%; grades 3/4: 3%), leukopenia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (54%; grades 3/4: 4%), ALT increased (36%; grades 3/4: 1%), total bilirubin increased (13%; grades 3/4: 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (may be dose limiting; 76%; acute 65%; grades 3/4: 5%; persistent 43%; grades 3/4: 3%), back pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (13%), cough (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (10%), chest pain (5%), peripheral edema (5%), flushing (3%),  thromboembolism (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (5%), alopecia (3%), hand-foot syndrome (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (5%), hypokalemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (7%), taste perversion (5%), flatulence (3%), mucositis (2%), gastroesophageal reflux (1%), dysphagia (acute 1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (9%; redness/swelling/pain)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Rigors (9%), arthralgia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal lacrimation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (5% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: URI (7%), rhinitis (6%), epistaxis (2%), pharyngitis (2%), pharyngolaryngeal dysesthesia (grades 3/4: 1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions (3%); hypersensitivity (includes urticaria, pruritus, facial flushing, shortness of breath, bronchospasm, diaphoresis, hypotension, syncope: grades 3/4: 2% to 3%); hiccup (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening; reported with mono- and combination therapy): Acute renal failure, alkaline phosphatase increased, anaphylactic/anaphylactoid reactions, anaphylactic shock, angioedema, aphonia, ataxia, colitis, cranial nerve palsies, deep tendon reflex loss, deafness, diplopia, dysarthria, dysphonia, eosinophilic pneumonia, extravasation (including necrosis), fasciculations, gait abnormal, hematuria, hemolysis, hemolytic anemia (immuno-allergic), hemolytic uremia syndrome, hemorrhage, hepatic failure, hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease), hepatitis, hepatotoxicity, hypertension, hypomagnesemia, hypoxia, ileus, INR increased, interstitial lung disease, interstitial nephritis (acute), intestinal obstruction, intracerebral bleeding, Lhermittes' sign, metabolic acidosis, myoclonus, neutropenic fever, neutropenic sepsis, neutropenic typhlitis, nodular regenerative hyperplasia, optic neuritis, pancreatitis, peliosis, prothrombin time increased, ptosis, rectal hemorrhage, reversible posterior leukoencephalopathy syndrome (RPLS), rhabdomyolysis, seizure, sepsis, thrombocytopenia (immuno-allergic), trigeminal neuralgia, tubular necrosis (acute),  visual disturbance (acuity decreased, field disturbance, transient loss)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F204247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxaliplatin, other platinum-containing compounds, or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Pregnancy, breast-feeding; severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F204232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactoid reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Anaphylactic/anaphylactoid reactions have been reported with oxaliplatin (may occur within minutes of administration); symptoms may be managed with epinephrine, corticosteroids, antihistamines,",
"     </b>",
"     and discontinuation; oxygen and bronchodilators have also been used (Kim, 2009). Grade 3 or 4 hypersensitivity has been observed. Allergic reactions are similar to reactions reported with other platinum analogs, and may occur with any cycle. Reactions typically occur after multiple cycles; in retrospective reviews, reaction occurred at a median of 7-9 cycles, with an onset of 5-70 minutes (Kim, 2009; Polyzos, 2009). Symptoms may include bronchospasm (rare), erythema, hypotension (rare), pruritus, rash, and/or urticaria; previously-untreated patients have also experienced flushing, diaphoresis, diarrhea, shortness of breath, chest pain, hypotension, syncope, and disorientation. According to the manufacturer, rechallenge is contraindicated (deaths due to anaphylaxis have been associated with platinum derivatives). In patients rechallenged after mild hypersensitivity, reaction recurred at a higher level of severity; for patients with severe hypersensitivity, rechallenge (with 2-3 days of antihistamine and corticosteroid premedication, and prolongation of infusion time) allowed for 2-4 additional oxaliplatin cycles; however, rechallenge was not feasible in nearly two-thirds of patients due to the severity of the initial reaction (Polyzos, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropathy: Two different types of peripheral sensory neuropathy may occur: First, an acute (within hours to 1-2 days), reversible (resolves within 14 days), with primarily peripheral symptoms that are often exacerbated by cold (may include pharyngolaryngeal dysesthesia); avoid mucositis prophylaxis with ice chips during oxaliplatin infusion (may exacerbate symptoms); this acute neuropathy commonly recurs with subsequent doses. Secondly, a more persistent (&gt;14 days) presentation that often interferes with daily activities (eg, writing, buttoning, swallowing) may occur; these symptoms may improve in some patients upon discontinuing treatment. In a retrospective evaluation of patients treated with oxaliplatin for colorectal cancer, the incidence of peripheral sensory neuropathy was similar between diabetic and nondiabetic patients (Ramanathan, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Hepatotoxicity (including rare cases of hepatitis and hepatic failure) has been reported. Liver biopsy has revealed peliosis, nodular regenerative hyperplasia, sinusoidal alterations, perisinusoidal fibrosis, and veno-occlusive lesions. The presence of hepatic vascular disorders (including veno-occlusive disease) should be considered, especially in individuals developing portal hypertension or who present with increased liver function tests.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary fibrosis: May cause pulmonary fibrosis; withhold treatment for unexplained pulmonary symptoms (eg, crackles, dyspnea, nonproductive cough, pulmonary infiltrates) until interstitial lung disease or pulmonary fibrosis are excluded.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reversible posterior leukoencephalopathy syndrome: Cases of reversible posterior leukoencephalopathy syndrome (RPLS) have been reported. Signs/symptoms include headache, mental status changes, seizure, blurred vision, blindness and/or other vision changes; may be associated with hypertension. Diagnosis is confirmed with brain imaging.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; increased toxicity may occur. Reduce initial dose in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluorouracil (5-FU): Risk of adverse hematologic effects or adverse GI effects associated with severe diarrhea/emesis (eg, dehydration, hypokalemia, ileus) may be increased with concomitant use of 5-FU.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Taxane derivatives: When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before platinum derivatives (carboplatin, cisplatin, oxaliplatin) to limit myelosuppression and enhance efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Elderly patients are more sensitive to adverse events, particularly diarrhea, dehydration, hypokalemia, leukopenia, fatigue, and syncope.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: Platinum Derivatives may enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: Platinum Derivatives may enhance the adverse/toxic effect of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased fetal weight, decreased ossification, and increased fetal deaths were observed in animal reproduction studies at one-tenth the equivalent human dose. Women of childbearing potential should be advised to avoid pregnancy and use effective contraception during treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Use in pregnant women is contraindicated in the Canadian labeling. Males should be advised not to father children during and for up to 6 months following therapy. May cause permanent infertility in males. Prior to initiating therapy, advise males desiring to father children, to seek counseling on sperm storage.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F204270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3017308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue breast-feeding or to discontinue oxaliplatin should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Eloxatin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/10 mL (10 mL): $1448.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/20 mL (20 mL): $2896.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/40 mL (40 mL): $5793.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Oxaliplatin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/10 mL (10 mL): $203.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/20 mL (20 mL): $407.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Oxaliplatin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $210.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $420.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F204240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, blood chemistries (including serum creatinine, ALT, AST, and bilirubin); INR and prothrombin time (in patients on oral anticoagulant therapy); signs of neuropathy, hypersensitivity, respiratory effects, and/or RPLS",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Crisapla (UY);",
"     </li>",
"     <li>",
"      Dacotin (IN);",
"     </li>",
"     <li>",
"      Dacplat (AR);",
"     </li>",
"     <li>",
"      Eloxatin (AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, GB, GT, HK, HN, ID, IE, IL, IT, KP, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, SE, SG, SV, TH, TR, TW);",
"     </li>",
"     <li>",
"      Eloxatine (FR, RU, VE);",
"     </li>",
"     <li>",
"      Entia (TH);",
"     </li>",
"     <li>",
"      Henplatin (PH);",
"     </li>",
"     <li>",
"      Liplatin (KP);",
"     </li>",
"     <li>",
"      Olipcis (MX);",
"     </li>",
"     <li>",
"      Oplat (CO);",
"     </li>",
"     <li>",
"      Oxalem (PH);",
"     </li>",
"     <li>",
"      Oxalip (TH);",
"     </li>",
"     <li>",
"      Oxaltic (AR);",
"     </li>",
"     <li>",
"      Oxaltie (EC, PK);",
"     </li>",
"     <li>",
"      Oxapla (KP);",
"     </li>",
"     <li>",
"      Oxerin (CO);",
"     </li>",
"     <li>",
"      Oxitan (TH);",
"     </li>",
"     <li>",
"      Oxitel (PH);",
"     </li>",
"     <li>",
"      Oxol (TH);",
"     </li>",
"     <li>",
"      OXP (KP);",
"     </li>",
"     <li>",
"      Platinox (PH);",
"     </li>",
"     <li>",
"      Pleoxtin (KP);",
"     </li>",
"     <li>",
"      Rexta (ID);",
"     </li>",
"     <li>",
"      Riptam (MX);",
"     </li>",
"     <li>",
"      Sindoxplatin (HK, PH);",
"     </li>",
"     <li>",
"      Xaliplat (PY);",
"     </li>",
"     <li>",
"      Zildox (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F204231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oxaliplatin, a platinum derivative, is an alkylating agent. Following intracellular hydrolysis, the platinum compound binds to DNA forming cross-links which inhibit DNA replication and transcription, resulting in cell death. Cytotoxicity is cell-cycle nonspecific.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F204246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 440 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;90% primarily albumin and gamma globulin (irreversible binding to platinum)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Nonenzymatic (rapid and extensive), forms active and inactive derivatives",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 391 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~54%); feces (~2%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Al-Batran SE, Hartmann JT, Probst S, et al, &ldquo;Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(9):1435-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/18349393/pubmed\" id=\"18349393\" target=\"_blank\">",
"        18349393",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andre P, Cisternino S, Roy AL, et al, &ldquo;Stability of Oxaliplatin in Infusion Bags Containing 5% Dextrose Injection,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2007, 64(18):1950-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/17823107/pubmed\" id=\"17823107\" target=\"_blank\">",
"        17823107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andre T, Boni C, Mounedji-Boudiaf L, et al, &ldquo;Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(23):2343-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/15175436/pubmed\" id=\"15175436\" target=\"_blank\">",
"        15175436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andre T, Boni C, Navarro M, et al, &ldquo;Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(19):3109-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/19451431/pubmed\" id=\"19451431\" target=\"_blank\">",
"        19451431",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andre T, Tournigand C, Rosmorduc O, et al, &ldquo;Gemcitabine Combined With Oxaliplatin (GEMOX) in Advanced Biliary Tract Adenocarcinoma: A GERCOR Study,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2004, 15(9):1339-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/15319238/pubmed\" id=\"15319238\" target=\"_blank\">",
"        15319238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al, &ldquo;Biweekly Intensified Ambulatory Chronomodulated Chemotherapy With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Metastatic Colorectal Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(11):2950-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/8918492/pubmed\" id=\"8918492\" target=\"_blank\">",
"        8918492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhargava P, Gammon D, and McCormick MJ, &ldquo;Hypersensitivity and Idiosyncratic Reactions to Oxaliplatin,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 100(1):211-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/14692042/pubmed\" id=\"14692042\" target=\"_blank\">",
"        14692042",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bokemeyer C, Oechsle K, Honecker F, et al, &ldquo;Combination Chemotherapy With Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Cisplatin-Refractory or Multiply Relapsed Germ-Cell Tumors: A Study of the German Testicular Cancer Study Group,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2008, 19(3):448-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/18006893/pubmed\" id=\"18006893\" target=\"_blank\">",
"        18006893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brandi G, Pantaleo MA, Galli C, et al, &ldquo;Hypersensitivity Reactions Related to Oxaliplatin (OHP),&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2003, 89(3):477-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/12888815/pubmed\" id=\"12888815\" target=\"_blank\">",
"        12888815",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cassidy J and Misset JL, &ldquo;Oxaliplatin-Related Side Effects: Characteristics and Management,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2002, 29(5 Suppl 15):11-20.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cassidy J, Clarke S, D&iacute;az-Rubio E, et al, &ldquo;Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin as First-Line Therapy for Metastatic Colorectal Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(12):2006-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/18421053/pubmed\" id=\"18421053\" target=\"_blank\">",
"        18421053",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cersosimo RJ, &ldquo;Oxaliplatin-Associated Neuropathy: A Review,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(1):128-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/15590869 /pubmed\" id=\"15590869 \" target=\"_blank\">",
"        15590869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chau I, Webb A, Cunningham D, et al, &ldquo;An Oxaliplatin-Based Chemotherapy in Patients With Relapsed or Refractory Intermediate and High-Grade Non-Hodgkin's Lymphoma,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2001, 115(4):786-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/11843810/pubmed\" id=\"11843810\" target=\"_blank\">",
"        11843810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conroy T, Desseigne F, Ychou M, et al, &ldquo;FOLFIRINOX Versus Gemcitabine for Metastatic Pancreatic Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(19):1817-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/21561347/pubmed\" id=\"21561347\" target=\"_blank\">",
"        21561347",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conroy T, Paillot B, Fran&ccedil;ois E, et al, &ldquo;Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer -- A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(6):1228-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/15718320/pubmed\" id=\"15718320\" target=\"_blank\">",
"        15718320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conroy T, Yatagh&egrave;ne Y, Etienne PL, et al, \"Phase II Randomised Trial of Chemoradiotherapy With FOLFOX4 or Cisplatin Plus Fluorouracil in Oesophageal Cancer,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2010, 103(9):1349-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/20940718/pubmed\" id=\"20940718\" target=\"_blank\">",
"        20940718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cunningham D, Starling N, Rao S, et al, &ldquo;Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(1):36-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/18172173/pubmed\" id=\"18172173\" target=\"_blank\">",
"        18172173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Lemos ML and Walisser S, &ldquo;Management of Extravasation of Oxaliplatin,&rdquo;",
"      <i>",
"       J Oncol Pharm Pract",
"      </i>",
"      , 2005, 11(4):159-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/16595069/pubmed\" id=\"16595069\" target=\"_blank\">",
"        16595069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dieras V, Bougnoux P, Petit T, et al, &ldquo;Multicentre Phase II Study of Oxaliplatin as a Single-Agent in Cisplatin/Carboplatin +/- Taxane-Pretreated Ovarian Cancer Patients,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2002, 13(2):258-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/11886003/pubmed\" id=\"11886003\" target=\"_blank\">",
"        11886003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doroshow JH, Synold TW, Gandara D, et al, &ldquo;Pharmacology of Oxaliplatin in Solid Tumor Patients With Hepatic Dysfunction: A Preliminary Report of the National Cancer Institute Organ Dysfunction Working Group,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2003, 30(4 Suppl 15):14-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/14523790/pubmed\" id=\"14523790\" target=\"_blank\">",
"        14523790",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Falcone A, Ricci S, Brunetti I, et al, &ldquo;Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(13):1670-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/17470860 /pubmed\" id=\"17470860 \" target=\"_blank\">",
"        17470860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graham MA, Lockwood GF, Greenslade D, et al, &ldquo;Clinical Pharmacokinetics of Oxaliplatin: A Critical Review,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2000, 6(4):1205-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/10778943/pubmed\" id=\"10778943\" target=\"_blank\">",
"        10778943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grothey A, Nikcevich DA, Sloan JA, et al, &ldquo;Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(4):421-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/21189381/pubmed\" id=\"21189381\" target=\"_blank\">",
"        21189381",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haller DG, Tabernero J, Maroun J, et al, &ldquo;Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid as Adjuvant Therapy for Stage III Colon Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(11):1465-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/21383294/pubmed\" id=\"21383294\" target=\"_blank\">",
"        21383294",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, &ldquo;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khushalani NI, Leichman CG, Proulx G, et al, &ldquo;Oxaliplatin in Combination with Protracted-Infusion Fluorouracil and Radiation: Report of a Clinical Trial for Patients With Esophageal Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(12):2844-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/12065561/pubmed\" id=\"12065561\" target=\"_blank\">",
"        12065561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kim BH, Bradley T, Tai J, et al, &ldquo;Hypersensitivity to Oxaliplatin: An Investigation of Incidence and Risk Factors, and Literature Review,&rdquo;",
"      <i>",
"       Oncology",
"      </i>",
"      , 2009, 76(4):231-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/19246947/pubmed\" id=\"19246947\" target=\"_blank\">",
"        19246947",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kollmannsberger C, Beyer J, Liersch R, et al, &ldquo;Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(1):108-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/14701772/pubmed\" id=\"14701772\" target=\"_blank\">",
"        14701772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      KueblerJP, Wieand HS, O'Connell MJ, et al, &ldquo;Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin as Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(16):2198-204.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/17470851/pubmed\" id=\"17470851\" target=\"_blank\">",
"        17470851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levi F, Metzger G, Massari C, et al, &ldquo;Oxaliplatin: Pharmacokinetics and Chronopharmacological Aspects,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2000, 38(1):1-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/10668856/pubmed\" id=\"10668856\" target=\"_blank\">",
"        10668856",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      L&oacute;pez A, Guti&eacute;rrez A, Palacios A, et al, &ldquo;GEMOX-R Regimen is a Highly Effective Salvage Regimen in Patients With Refractory/Relapsing Diffuse Large-Cell Lymphoma: A Phase II Study,&rdquo;",
"      <i>",
"       Eur J Haematol",
"      </i>",
"      , 2008, 80(2):127-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/18005385/pubmed\" id=\"18005385\" target=\"_blank\">",
"        18005385",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Louvet  C, Andr&eacute; T, Tigaud JM, et al, &ldquo;Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(23):4543-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/12454110/pubmed\" id=\"12454110\" target=\"_blank\">",
"        12454110",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Louvet C, Labianca R, Hammel P, et al, &ldquo;Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(15):3509-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/15908661/pubmed\" id=\"15908661\" target=\"_blank\">",
"        15908661",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nehls O, Oettle H, Hartmann JT, et al, &ldquo;Capecitabine Plus Oxaliplatin as First-Line Treatment in Patients With Advanced Biliary System Adenocarcinoma: A Prospective Multicentre Phase II Trial,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2008, 98(2):309-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/18182984/pubmed\" id=\"18182984\" target=\"_blank\">",
"        18182984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oechsle K, Kollmannsberger C, Honecker F, et al, &ldquo;Long-Term Survival After Treatment With Gemcitabine and Oxaliplatin With and Without Paclitaxel Plus Secondary Surgery in Patients With Cisplatin-Refractory and/or Multiply Relapsed Germ Cell Tumors,&rdquo;",
"      <i>",
"       Eur Urol",
"      </i>",
"      , 2011, 60(4):850-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/21704446/pubmed\" id=\"21704446\" target=\"_blank\">",
"        21704446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pectasides D, Pectasides M, Farmakis D, et al, &ldquo;Gemcitabine and Oxaliplatin (GEMOX) in Patients With Cisplatin-Refractory Germ Cell Tumors: A Phase II Study,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2004, 15(3):493-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/14998855/pubmed\" id=\"14998855\" target=\"_blank\">",
"        14998855",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pelzer U, Schwaner I, Stieler J, et al, &ldquo;Best Supportive Care (BSC) Versus Oxaliplatin, Folinic Acid and 5-Fluorouracil (OFF) Plus BSC in Patients for Second-Line Advanced Pancreatic Cancer: A Phase III-Study from the German CONKO-Study Group,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2011, 47(11):1676-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/21565490/pubmed\" id=\"21565490\" target=\"_blank\">",
"        21565490",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(Suppl 7):167-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/22997449/pubmed\" id=\"22997449\" target=\"_blank\">",
"        22997449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piccart MJ, Green JA, Lacave AJ, et al, &ldquo;Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(6):1193-202.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/10715288/pubmed\" id=\"10715288\" target=\"_blank\">",
"        10715288",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Polyzos A, Tsavaris N, Gogas H, et al, &ldquo;Clinical Features of Hypersensitivity Reactions to Oxaliplatin: A 10-Year Experience,&rdquo;",
"      <i>",
"       Oncology",
"      </i>",
"      , 2009, 76(1):36-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/19033714/pubmed\" id=\"19033714\" target=\"_blank\">",
"        19033714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramanathan PK, Rothenberg ML, de Gramont A, et al, &ldquo;Incidence and Evolution of Oxaliplatin-Induced Peripheral Sensory Neuropathy in Diabetic Patients With Colorectal Cancer: A Pooled Analysis of Three Phase III Studies,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(4):754-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/19887466/pubmed\" id=\"19887466\" target=\"_blank\">",
"        19887466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodr&iacute;guez J, Gutierrez A, Palacios A, et al, &ldquo;Rituximab, Gemcitabine and Oxaliplatin: An Effective Regimen in Patients With Refractory and Relapsing Mantle Cell Lymphoma,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2007, 48(11):2172-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/17990179/pubmed\" id=\"17990179\" target=\"_blank\">",
"        17990179",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saltz LB, Clarke S, D&iacute;az-Rubio E, et al, &ldquo;Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(12):2013-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/18421054/pubmed\" id=\"18421054\" target=\"_blank\">",
"        18421054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suenaga M, Mizunuma N, Shinozaki E, et al, &ldquo;Management of Allergic Reactions to Oxaliplatin in Colorectal Cancer Patients,&rdquo;",
"      <i>",
"       J Support Oncol",
"      </i>",
"      , 2008, 6(8):373-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/19149322/pubmed\" id=\"19149322\" target=\"_blank\">",
"        19149322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Synold TW, Takimoto CH, Doroshow JH, et al, &ldquo;Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients With Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2007, 13(12):3660-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/17575231/pubmed\" id=\"17575231\" target=\"_blank\">",
"        17575231",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Takimoto CH, Graham MA, Lockwood G, et al, &ldquo;Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer patients With Impaired Renal Function,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2007, 13(16):4832-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/17699862/pubmed\" id=\"17699862\" target=\"_blank\">",
"        17699862",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Takimoto CH, Remick SC, Sharma S, et al, &ldquo;Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      ,  2003,  21(14):2664-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/12860942/pubmed\" id=\"12860942\" target=\"_blank\">",
"        12860942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA, Saenz CA, Ingram DS, et al, &ldquo;Compatibility Screening of Oxaliplatin During Simulated Y-Site Administration With Other Drugs,&rdquo;",
"      <i>",
"       J Oncol Pharm Practice",
"      </i>",
"      , 2002, 8(1):33-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tsimberidou AM, Wierda WG, Plunkett W, et al, &ldquo;Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(2):196-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/18182662/pubmed\" id=\"18182662\" target=\"_blank\">",
"        18182662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiseman LR, Adkins JC, Plosker GL, et al, &ldquo;Oxaliplatin: A Review of Its Use in the Management of Metastatic Colorectal Cancer,&rdquo;",
"      <i>",
"       Drugs Aging",
"      </i>",
"      , 1999, 14(6):459-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/10408744/pubmed\" id=\"10408744\" target=\"_blank\">",
"        10408744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Xiong HQ, Varadhachary GR, Blais JC, et al, &ldquo;Phase 2 Trial of Oxaliplatin Plus Capecitabine (XELOX) as Second-Line Therapy for Patients With Advanced Pancreatic Cancer,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2008, 113(8):2046-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/11/2233/abstract-text/18756532/pubmed\" id=\"18756532\" target=\"_blank\">",
"        18756532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10180 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2233=[""].join("\n");
var outline_f2_11_2233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709183\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204261\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821523\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204285\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204263\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204264\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204265\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821524\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204286\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204242\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204229\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204244\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204292\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204243\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204281\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204295\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204283\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204247\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204232\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299798\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204236\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204238\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204249\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204270\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3017308\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323568\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204240\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539908\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204231\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204246\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10180\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10180|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/31/33269?source=related_link\">",
"      Oxaliplatin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/49/33558?source=related_link\">",
"      Oxaliplatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_11_2234="Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis";
var content_f2_11_2234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/11/2234/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/11/2234/contributors\">",
"     Peter C Taylor, MA, PhD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/11/2234/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/11/2234/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/11/2234/contributors\">",
"     James R O'Dell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/11/2234/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/11/2234/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/11/2234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with rheumatoid arthritis (RA) follow a variable disease course with regard to outcome measures such as functional status or radiological assessment of joint damage. Early identification of patients with RA and, in particular, of those likely to assume a more rapidly destructive form of disease is important because of the possible benefit from early, aggressive intervention with disease modifying agents. This realization has prompted the investigation and measurement of numerous biologic &ldquo;markers&rdquo; in blood and joint fluids that may serve as indicators of prognosis and the response to therapy. Although some of the markers under consideration are accessible in routine practice, many are in the stage of experimental evaluation and require access to specialized technology and customized reagents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICALLY USEFUL MARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the many biologic markers that have been assessed for usefulness in estimating disease activity and prognosis of rheumatoid arthritis, only a few have found a role in clinical practice. The main clinically useful biologic markers in patients with RA include rheumatoid factors, anti-cyclic citrullinated peptide (anti-CCP) antibodies, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). These tests and their clinical use in diagnosis and assessment of disease outcome are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL MARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential biologic markers that remain investigational can be considered in four categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immunologic (or serologic) abnormalities",
"     </li>",
"     <li>",
"      Genetic factors, such as HLA class II",
"     </li>",
"     <li>",
"      The acute phase response elicited by hepatocytes as part of the inflammatory process, other than CRP or those assessed indirectly by ESR",
"     </li>",
"     <li>",
"      Macromolecules specific for joint associated tissues that are released into the circulation or excreted in the urine as part of degenerative and reparative processes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although not measured clinically, the pattern of cytokine activation may be important in the pathogenesis of RA. This topic is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immunologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several immunologic abnormalities, particularly autoantibodies, are associated with the presence of rheumatoid arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Autoantibodies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28680421\">",
"    <span class=\"h4\">",
"     Antiperinuclear factor and antikeratin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characterization of the antigenic targets recognized by antikeratin and antiperinuclear antibodies led to the recognition of citrullinated peptides as important antigenic targets for antibodies present in the sera of patients with RA. Commercially available assays for the detection of anti-citrullinated peptide antibodies (ACPA), including antibodies to cyclic citrullinated peptides (anti-CCP), are widely used clinically in the evaluation of rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-citrullinated peptide antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antikeratin antibodies (AKA) were originally identified in 1979 in patients with rheumatoid arthritis (RA) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/1\">",
"     1",
"    </a>",
"    ]. A related antibody, antiperinuclear factor antibody (APF), is also associated with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/2\">",
"     2",
"    </a>",
"    ]. Study of antibodies to perinuclear factor (APF) and keratin (AKA) led to the appreciation that both types of antibodies recognize epidermal filaggrin, an intermediate filament associated protein involved in cornification of the epidermis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A major determinant of antibody binding to filaggrin is the presence of citrulline, formed by a post-translational modification of arginine. Citrullination is catalyzed by peptidylarginine deiminase [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/5\">",
"     5",
"    </a>",
"    ]. Antibodies against this antigen had higher specificity for RA than did rheumatoid factor. However, assays for these antibodies were technically demanding and never widely available.",
"   </p>",
"   <p>",
"    Identification of these and other post-translationally modified peptides and proteins containing the amino acid citrulline led to the development of the more convenient and standardized assays for antibodies to citrullinated proteins, including enzyme-linked immunosorbent (ELISA) assays for anti-CCP antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-citrullinated peptide antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing for antibodies to other citrullinated proteins has been an active area of investigation. As examples, the presence of antibodies to citrullinated fibrinogen, to citrullinated vimentin (anti-Sa, see below), to citrullinated synthetic type I or type II collagen telopeptides, and to alpha-enolase may have sensitivity and specificity similar to that of anti-CCP testing [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/6-13\">",
"     6-13",
"    </a>",
"    ]. A commercial assay for anti-mutated citrullinated vimentin is also available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-MCV antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion of APF and AKA is, therefore, of mainly historical interest.",
"   </p>",
"   <p>",
"    The sensitivity and specificity of APF and AKA vary depending on the laboratory means of detection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      APF detected by means of indirect immunofluorescence using buccal epithelium has a reported specificity for RA of 73 to 99 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/2,14,15\">",
"       2,14,15",
"      </a>",
"      ] and a sensitivity of 49 to 87 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/2,14,16\">",
"       2,14,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The reported specificity of AKA, detected by the use of rat esophagus as a substrate [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/1\">",
"       1",
"      </a>",
"      ], generally exceeds 90 percent with a sensitivity between 40 and 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/14,17\">",
"       14,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An immunoblotting method for the detection of AKA, using three protein antigens extracted from rat esophagus epithelium and separated by non-denaturing polyacrylamide gel electrophoresis, found that AKA had a sensitivity of 43 to 50 percent and a specificity of 99 percent for RA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/18\">",
"       18",
"      </a>",
"      ]. The intensity of labeling of the three rat esophagus protein antigens, and that of human epidermal filaggrin when RA sera are tested by immunoblotting, correlates with the APF titers of the sera [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the lack of widespread availability of tests to detect AKA and APF (and anti-filaggrin antibodies), identifying their presence in a given patient may have important implications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AKA have been reported in RF-negative RA, although the prevalence is only one third that in RF-positive cases [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/14\">",
"       14",
"      </a>",
"      ]. Similarly, APF has been reported in cases of RA that are repeatedly RF-negative [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The prognostic significance of AKA and APF has been studied in three cohorts of early RA with follow-ups of three and eight years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. All patients with detectable AKA developed at least some erosions by the end of the eight-year follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/21\">",
"       21",
"      </a>",
"      ]. One cohort with recent onset RA was followed by the same investigators; the initial presence of AKA was associated with active and treatment-resistant disease at up to three years but did not predict radiologic progression [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/22\">",
"       22",
"      </a>",
"      ]. Others have reported similar findings [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/19\">",
"       19",
"      </a>",
"      ]. Furthermore, among patients with chronic erosive RA, APF and AKA do not define any subgroup with a particularly aggressive course.",
"     </li>",
"     <li>",
"      Similar to RF, the presence of AKA, APF, or antifilaggrin antibodies may antedate clinical RA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. In addition, detection of either AKA or APF in a healthy individual with a positive sensitized sheep red blood cell agglutination test further increases the relative risk of developing RF-positive RA by a factor of five [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/24\">",
"       24",
"      </a>",
"      ]. However, a significant number of antibody positive patients do not develop disease. As an example, in the study just quoted, 12 of 70 RF positive patients who did not develop RA tested positive for either AKA, APF, or both antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A negative AKA may help exclude a diagnosis of RA in patients who are RF-positive and present with symptoms suggestive of RA but who have other disorders. In one study, for example, the prevalence of AKA was 8 percent among patients with hepatitis C virus (HCV) infection, RF positivity, and arthralgia or arthritis, compared with 61 percent for those diagnosed with RA who were RF-positive and were not infected with HCV [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Positive RF, AKA, or APF tests prior to clinical disease may also indicate that initiation of disease antedates symptoms by many years. This possibility has profound implications for epidemiologic studies seeking an initiating cause of RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28680428\">",
"    <span class=\"h4\">",
"     Anti-Sa antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-Sa antibodies, similar to a number of other autoantibodies linked to RA, recognize a citrulline-containing epitope located on vimentin, an intermediate filament that is widely expressed on mesenchymal cells and macrophages that is not normally citrullinated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/27\">",
"     27",
"    </a>",
"    ]. Antibodies to mutated citrullinated vimentin (anti-MCV) may be associated with more severe disease than anti-CCP antibodies and may be comparable to anti-CCP in predicting radiographic progression [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/9,28\">",
"     9,28",
"    </a>",
"    ]. A commercial assay for antibodies to MCV is available, and the information below is presented for historical perspective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-MCV antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations suggested that the presence of anti-Sa antibodies may be an accurate diagnostic and predictive test for RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 489 patients with inflammatory joint disease, of whom 154 had RA, anti-Sa antibodies were 68 percent sensitive and 79 percent specific for RA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/29\">",
"       29",
"      </a>",
"      ]. Anti-Sa antibodies also helped predict which patients would eventually develop late severe radiologic damage.",
"     </li>",
"     <li>",
"      A second study compared the use of anti-Sa and anti-CCP antibodies in an outpatient clinic population comprised of patients with RA, other connective tissue diseases, and spondyloarthritides [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/30\">",
"       30",
"      </a>",
"      ]. Anti-Sa antibodies were much less sensitive (44 versus 72 percent) with a similar specificity (96 versus 94 percent). Anti-Sa and anti-CCP antibodies were discordant in 47 of 87 patients with RA. Thus, assays for anti-Sa antibodies were proposed as being useful when anti-CCP antibodies are negative but RA is still suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28680483\">",
"    <span class=\"h4\">",
"     Other autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other autoantibodies have also been the subject of investigation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-p68 (BiP) antibodies &mdash; A protein that serves as a chaperone in the endoplasmic reticulum and binds to immunoglobulin heavy chains is a p68 autoantigen named BiP. Increased T-cell proliferative responses against BiP have been noted in patients with RA, and antibodies directed against the protein may be a marker for the disease. As an example, in one study of 400 patients with RA, 200 patients with other rheumatic diseases, and 150 healthy donors, antibodies with anti-BiP specificity had a 68 and 96 percent sensitivity and specificity for RA, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-RA33 antibodies &mdash; Immunoblot analysis using soluble nuclear extracts from HeLa cells demonstrated the presence of an autoantibody to a 33 kD antigen (anti RA33) in 4 of 14 patients with RA in a report from Austria; no positive tests were noted in patients with ankylosing spondylitis or psoriatic arthropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/32\">",
"       32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The RA33 antibody is directed against a functional component of the spliceosome and is also found in systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD); however, the pattern on immunoblot is distinguishable from RA by the simultaneous presence of Sm bands (BB', D) and U1 RNP (A, C), respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=see_link\">",
"       \"Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2743?source=see_link\">",
"       \"Anti-U1 RNP antibodies in mixed connective tissue disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Anti-RA33 antibodies are associated with prominent arthritis in patients with MCTD and SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/34\">",
"       34",
"      </a>",
"      ], suggesting a relationship of this antibody to autoimmune inflammatory joint disease in general. Furthermore, it has been postulated that anti-RA33 antibodies are an early and stable marker of RA, since all seven patients in the Austrian study who had initially unclassified anti-RA33 positive arthritis went on to develop RA within three years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/32\">",
"       32",
"      </a>",
"      ]. However, the presence of anti-RA33 antibodies is not associated with an increased risk of progressive radiographic joint damage [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ANCA &mdash; Patients with rheumatoid arthritis may have antineutrophil cytoplasmic antibodies, usually atypical (non-MPO) P-ANCA. Nonvasculitic aspects of RA activity, severity, and chronicity have not consistently correlated with ANCA status. One report found that patients with RA who were P-ANCA positive had an increased rate of radiographic progression of joint damage [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/35\">",
"       35",
"      </a>",
"      ]. However, until this is confirmed, it is our opinion that there is little clinical utility for ANCA testing in patients with RA in whom the presence of an ANCA-associated systemic vasculitis is not suspected on clinical grounds. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Nonvasculitic rheumatic disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gal O glycoforms &mdash; RA is associated with a marked increase in IgG lacking galactose (designated as Gal 0 glycoforms) and terminating in N-acetyl glucosamine in the Fc region [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/36\">",
"       36",
"      </a>",
"      ]. Gal 0 levels correlate with disease severity in RA and revert to normal during the course of pregnancy-induced remissions [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/37\">",
"       37",
"      </a>",
"      ]. Agalactosyl immunoglobulins (Gal 0 IgG) activate complement by means of a mannose binding protein dependent pathway in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/38\">",
"       38",
"      </a>",
"      ]. More rapid radiographic progression of RA has been associated with low serum levels of mannose-binding lectin, which is determined genetically [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. Furthermore, the finding of mannose binding protein and enrichment of Gal 0 IgG in RA synovial fluids has prompted the suggestion that these events are of pathologic significance in the joint destruction of RA.",
"      <br/>",
"      <br/>",
"      Gal 0 IgG and RF were measured at presentation and at a two-year follow-up in a prospective study of 60 British patients with a history of synovitis of less than one year's duration [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/41\">",
"       41",
"      </a>",
"      ]. Over the study period, 39 patients developed RA as defined by the 1987 American College of Rheumatology classification criteria for RA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"       \"Clinical features of rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link&amp;anchor=H15#H15\">",
"       \"Diagnosis and differential diagnosis of rheumatoid arthritis\", section on 'Classification criteria'",
"      </a>",
"      .) The initial Gal 0 IgG correctly predicted the development of RA, or otherwise, in 47 of the 60 patients. The combination of Gal 0 IgG and RF status gave a test with 90 percent sensitivity, 95 percent specificity, and 94 percent predictive value.",
"     </li>",
"     <li>",
"      Antibodies to alpha-enolase &mdash; Among 255 patients with early arthritis, elevated serum levels of antibodies to an enzyme in the glycolytic pathway, alpha-enolase, were found in 25 percent of those who were later determined to have rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/42\">",
"       42",
"      </a>",
"      ]. One-half of those with RA and anti-enolase antibodies did not have serum rheumatoid factor or antifilaggrin antibodies. Among 40 patients whose arthritis remained undifferentiated after one year of observation, 10 percent had antibodies to alpha-enolase.",
"     </li>",
"     <li>",
"      Antibodies to glucose phosphate isomerase (GPI) &mdash; Antibodies to the ubiquitous enzyme, glucose phosphate isomerase, which have been implicated as pathogenically important in an animal model of inflammatory arthritis, may be associated with the presence of extraarticular manifestations of RA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=see_link&amp;anchor=H27#H27\">",
"       \"Pathogenesis of rheumatoid arthritis\", section on 'Antibodies to glucose-6-phosphate isomerase'",
"      </a>",
"      .) These autoantibodies are more often present in those patients with RA complicated by rheumatoid vasculitis and Felty syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies to ferritin &mdash; Antibodies to the heavy chain of ferritin may be associated with RA. This association in a predominantly Caucasian population is suggested by the finding in one study of a higher prevalence of such antibodies in those with established RA and early RA (16 and 19 percent, respectively) than in healthy blood donors, osteoarthritic subjects, or those with systemic lupus erythematosus (2.7, 2.1, and 2.1 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies to PADI4 &mdash; It is known that the enzyme peptidyl-arginine deiminase 4 (PADI4) converts arginine to citrulline and that genetic variants of this enzyme are associated with RA. The presence of antibodies to PADI4 in patients with RA and in controls was examined in Chinese patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/45\">",
"       45",
"      </a>",
"      ]. Levels of antibodies to PAD4 were assessed in 109 patients with RA, in 232 patients with related rheumatic diseases, and in 106 healthy controls. Antibodies to PAD4 were observed in 45 percent of patients with RA and in 0 to 13 percent of controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Cell surface expression of CD40 ligand",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CD40 ligand (CD154) is expressed on activated T cells and underlies many interactions between these and other hematopoietic cells. Enhanced surface expression of the CD40 ligand on circulating T cells is associated with more active disease in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Complement activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Markers of complement activation, possibly due to immune complexes present in synovium or plasma, have been proposed as a possible indicator of RA disease activity. As an example, the concentration of covalently linked C1q-C4 complement components was correlated with disease activity in 84 patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing RA is associated with carriage of particular HLA alleles. A patient's HLA DR type and other genetic factors may also play a role in determining the severity of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Shared epitope",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA is positively associated with certain HLA DR alleles (particularly HLA DR4) encoding a conserved amino acid sequence in the third hypervariable region of the DRb1 chain. A number of studies have suggested the potential usefulness of HLA typing in predicting disease severity and as a guide to early aggressive therapy. This area of investigation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23546?source=see_link\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Matrix metalloproteinase genotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Matrix metalloproteinases can degrade collagen and can contribute to cartilage and bone destruction in RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    .) Carriage of a polymorphism in the promoter region of the gene for matrix metalloproteinase 3 (MMP-3) may be associated with more severe disease. This was illustrated in one study of 103 patients with early RA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/48\">",
"     48",
"    </a>",
"    ]. Homozygous carriage of a particular polymorphism in the promoter region of the MMP-3 gene",
"    <span class=\"nowrap\">",
"     (6A/6A)",
"    </span>",
"    was associated with the presence of more severe joint damage at baseline and, after four years of follow-up, was associated with more progression of joint erosions and joint space narrowing than carriage of one or more alleles of a different type (5A).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Interleukin-10 promoter genotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association may exist between an interleukin-10 (IL-10) promoter polymorphism and the severity of, though not the susceptibility to, RA. This was illustrated in a study in 283 Dutch patients who were prospectively followed for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/49\">",
"     49",
"    </a>",
"    ]. There was no difference between the patients with RA and healthy controls in the prevalence of two IL-10 promoter polymorphisms (-2849 G and A), and there was no significant difference in the baseline radiographic severity of their joint disease. However, among the 152 patients with at least one allele associated with an increased production of IL-10, there was a significantly higher mean joint damage score by the end of the study than among the 31 patients without such an allele.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Sulphoxidation status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inherited ability to oxidize the sulphur compound S-carboxy-methyl-L-cysteine varies widely among individuals. The prevalence of individuals with poor sulphoxidation status is increased in patients with established RA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/50\">",
"     50",
"    </a>",
"    ]. Furthermore, one study suggested that a defective sulphoxidation status correlates strongly with persistent clinical disease in early RA. In this report, the S-oxidation capacity was evaluated in 54 patients with recent onset symmetrical polyarthritis, and the clinical course was monitored at for four years. At four years, 74 percent of patients with a diagnosis of RA were poor S-oxidizers compared with 31 percent of those who were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acute phase response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Markers of the acute phase response, such as C reactive protein, the erythrocyte sedimentation rate (ESR), and interleukin-6, have been evaluated as potential markers of disease activity in RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Interleukin-6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin-6 (IL-6) has a major stimulatory effect on hepatic synthesis of acute phase proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/51\">",
"     51",
"    </a>",
"    ] and is known to play a regulatory role in platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/52\">",
"     52",
"    </a>",
"    ]. Furthermore, there is evidence to suggest that IL-6 has an etiopathologic role in the anemia of chronic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inflamed synovium is thought to be the principal source of plasma IL-6 in RA, since IL-6 is often detected in high concentration in the synovial fluid. Thus, it was postulated that plasma IL-6 concentrations might reflect joint inflammation better than acute phase protein levels. However, in one study of 51 patients with early RA, there was no relationship between radiologic progression and time integrated values of plasma IL-6 concentration even though there was a significant correlation between IL-6 and the acute phase response [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/54\">",
"     54",
"    </a>",
"    ]. This finding contrasts with the relationship between radiologic findings and time integrated values of CRP and ESR discussed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Tissue-specific markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of biochemical markers of joint damage have been described in RA. These molecules may be synthetic or degradative, their presence in body fluids arising as a consequence of metabolism of the tissue of origin. They are predominantly derived from a single tissue such as cartilage, bone, or synovium and can be detected principally by immunoassay of joint fluid, serum, or urine. Appropriate assays are not routinely available, and joint fluids are not readily available (apart from knee joints), in comparison with serum or urine. There is, as yet, limited information regarding the usefulness of tissue-specific markers as measures of disease activity or response to therapy in RA. However, some markers may be of prognostic value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Synovium-specific markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The synovium is thought to be the dominant source of serum hyaluronan, a marker that is strikingly elevated in the serum of patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. In vitro studies demonstrate that synovial lining cells of rheumatoid joints produce detectable amounts of hyaluronan, while lining cells from normal joints do not [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/57\">",
"     57",
"    </a>",
"    ]. Despite a short half-life of 15 minutes or less, serum hyaluronan concentrations correlate with disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/56\">",
"     56",
"    </a>",
"    ], and at least one prospective study has suggested that, in early RA, serum hyaluronan may reflect ongoing joint destruction and may even predict subsequent joint damage [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/58\">",
"     58",
"    </a>",
"    ]. However, elevated serum levels of hyaluronan may be nonspecific since they may vary with physical activity independent of the degree of synovitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other markers that may be predominantly released from the synovium are matrix metalloproteinase 1 and 3 (MMP-1 and MMP-3), enzymes that fragment matrix collagen. Elevated levels of MMP-3 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/60\">",
"     60",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MMP-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/61\">",
"     61",
"    </a>",
"    ] may correlate with increased radiographic joint damage. Elevated serum levels of immunoglobulin soluble receptor (Fc gamma RIIIa) in RA are thought to be due to synovial macrophages",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    NK cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Cartilage-specific markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Markers of cartilage metabolism may have some prognostic value in patients with RA. In early RA, for example, high serum levels of cartilage oligomeric matrix protein (COMP), a member of the thrombospondin protein family, predict severe disease characterized by subsequent large and small joint destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. In one study, increased serum concentrations of COMP were found in all patients who developed rapid hip joint destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The aggrecan content of synovial fluid in knee joints is also reported to be predictive of knee and hip joint destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/65\">",
"     65",
"    </a>",
"    ]. The chondroitin sulphate-rich region of aggrecan is most abundantly detected in synovial fluids recovered from joints with little radiologic evidence of destruction, whereas the hyaluronan binding region of core protein is released in more severely damaged joints [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The same study that measured serum level of COMP in patients with RA (see above) also measured serum levels of a putative marker of cartilage aggrecan synthesis, epitope 846, located on the chondroitin sulphate rich area of the aggrecan molecule. The epitope 846 levels were found to be elevated only in a group of patients with slow joint destruction, as compared with a group matched for age, gender, and disease duration but with more destructive joint disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/64\">",
"     64",
"    </a>",
"    ]. These data indicate the presence of cartilage reparative processes in the group with a more benign course and suggest that elevated 846 epitope is indicative of a more favorable prognosis.",
"   </p>",
"   <p>",
"    Measurement of crosslinked c-terminal peptides from type II collagen (CTX-II) in urine may provide some prognostic information. A correlation between the excretion of these peptides and radiographic progression up to five years was noted in a prospective study of 110 patients with early RA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Similarly, urinary excretion of a peptide derived from the helical portion of type II collagen (HELIX-II) also correlates with radiographic progression and is independent of other variables, including baseline CRP levels, joint damage, and urinary CTX-II excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/69\">",
"     69",
"    </a>",
"    ]. When studied in 89 patients with early RA, patients with increased levels of both HELIX-II and CTX-II had the highest risk of radiographic progression compared with those without an elevation of either of these markers (OR 17.5, 95% CI 3.1-99).",
"   </p>",
"   <p>",
"    The combination of cartilage and synovial biomarkers may have a better ability to predict radiographic progression than either alone. This was illustrated in a study of 118 patients in which several biomarkers were measured in blood samples and in which radiographs were obtained at baseline and after two years of treatment with synthetic disease modifying antirheumatic drugs but not with biologic agents; multivariable analysis indicated that the combinations of serum biomarkers that included both MMP-3 and CTX-II levels were better than any individual biomarker in predicting radiographic progression [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Bone-specific markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with cartilage, several bone specific markers are available and may have a useful purpose in patients with RA.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone sialoprotein is an osteoblast-derived protein preferentially expressed in juxtaarticular bone. Bone sialoprotein levels in synovial fluid correlate with knee joint destruction in both RA and osteoarthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/71\">",
"       71",
"      </a>",
"      ]. By contrast, bone sialoprotein levels are elevated in RA serum without a correlation between concentration and joint destruction.",
"     </li>",
"     <li>",
"      Bone degradation, assessed by detection of pyridinoline cross-links in urine, correlates with disease activity in RA and diminishes after treatment with pulsed glucocorticoids and DMARDs [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immunoassays are available for measurement of cross-linked carboxyterminal telopeptides of type I collagen (ICTP), a larger serum marker for bone collagen degradation. A three-year prospective study of 66 patients with early RA found that 51 percent initially had elevated levels of serum ICTP compared with healthy controls. Throughout the follow-up, serum ICTP levels correlated with inflammatory parameters and, from the first year on, with the radiologic changes assessed annually. Initial ICTP levels correlated better than the other variables of disease activity with the subsequent erosive progression of joints, suggesting that its measurement may serve as a prognostic marker for joint damage in early RA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/73\">",
"       73",
"      </a>",
"      ]; this observation was independently confirmed in a group of 110 patients with early RA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/67\">",
"       67",
"      </a>",
"      ]. Subsequent studies found that ICTP levels in synovial fluid correlated better with prognosis than did serum levels [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/74\">",
"       74",
"      </a>",
"      ] and that higher ICTP levels after six months of treatment with a combination of antirheumatic drugs was predictive of increased radiographic progression [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The initial ratio of serum levels of an inhibitor of osteoclast differentiation (osteoprotegerin) and a stimulatory protein (Receptor Activator of Nuclear factor Kappa B ligand [RANKL]) may be a predictor of joint destruction in patients with early RA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Vascular markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum vascular endothelial factor (VEGF) concentrations are elevated in RA patients when compared with healthy controls and with patients with osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. Furthermore, in patients with early RA, there is a significant correlation between serum VEGF levels at presentation and radiographically assessed joint damage over the subsequent year [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Plasma proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a proteomic approach, 163 plasma proteins were evaluated in 44 patients with RA to determine which were associated with disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/11/2234/abstract/80\">",
"     80",
"    </a>",
"    ]. Plasma proteins whose concentrations were correlated with disease activity included IL-6, oncostatin M, IL-2, M-CSF, TNF receptor superfamily member 9, CCL23, TGF alpha, and CXCL13.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26882544\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early identification of patients with RA and, in particular, of those likely to assume a more rapidly destructive form of disease is important because of the possible benefit from early, aggressive intervention with disease-modifying agents. This realization has prompted the investigation and measurement of numerous biologic &ldquo;markers&rdquo; in blood and joint fluids that may serve as indicators of prognosis and the response to therapy. Although some of the markers under consideration are accessible in routine practice, many are in the stage of experimental evaluation and require access to specialized technology and customized reagents. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main clinically useful biologic markers in patients with RA include rheumatoid factors, anti-cyclic citrullinated peptide (anti-CCP) antibodies, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinically useful markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biologic markers that remain investigational can be considered in four categories (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Investigational markers'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Immunologic (or serologic) abnormalities",
"     </li>",
"     <li>",
"      Genetic factors, such as HLA class II",
"     </li>",
"     <li>",
"      The acute phase response elicited by hepatocytes as part of the inflammatory process, other than CRP or those assessed indirectly by ESR",
"     </li>",
"     <li>",
"      Macromolecules specific for joint-associated tissues that are released into the circulation or excreted in the urine as part of degenerative and reparative processes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several immunologic abnormalities, particularly autoantibodies, are associated with the presence of rheumatoid arthritis. Such autoantibodies include antiperinuclear factor, antikeratin antibodies, and anti-Sa, which have all been found to be directed against citrullinated peptides. These antibodies, which are now mainly of historical interest since the development of commercial tests for anti-citrullinated",
"      <span class=\"nowrap\">",
"       peptide/protein",
"      </span>",
"      antibodies, may have both diagnostic and prognostic significance. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Autoantibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other markers of interest include levels of CD154, measures of complement activation, and other autoantibodies, including (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Autoantibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Cell surface expression of CD40 ligand'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Complement activation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Anti-p68 (BiP) antibodies, which target a protein that serves as a chaperone in the endoplasmic reticulum and binds to immunoglobulin heavy",
"     </li>",
"     <li>",
"      Anti-RA33 antibodies, directed against a functional component of the spliceosome and also found in systemic lupus and mixed connective tissue disease",
"     </li>",
"     <li>",
"      Antineutrophil cytoplasmic antibody (ANCA), usually atypical (non-myeloperoxidase) p-ANCA",
"     </li>",
"     <li>",
"      Agalactosyl immunoglobulins (Gal 0 IgG), which activate complement by means of a mannose binding protein dependent pathway in vitro",
"     </li>",
"     <li>",
"      Antibodies to alpha-enolase",
"     </li>",
"     <li>",
"      Antibodies to glucose phosphate isomerase",
"     </li>",
"     <li>",
"      Antibodies to ferritin",
"     </li>",
"     <li>",
"      Antibodies to PADI4",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic factors that may influence the severity of RA include the shared epitope, matrix metalloproteinase genotype, interleukin-10 promoter genotype, and sulphoxidation status. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Markers of the acute phase response, such as C reactive protein, the erythrocyte sedimentation rate (ESR), and interleukin-6, have been evaluated as markers of disease activity in RA. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Acute phase response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of experimental biochemical markers of joint damage have been described in RA. These molecules may be synthetic or degradative, their presence in body fluids arising as a consequence of metabolism of the tissue of origin. They are predominantly derived from a single tissue such as cartilage, bone, or synovium and can be detected principally by immunoassay of joint fluid, serum, or urine. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Tissue-specific markers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/1\">",
"      Young BJ, Mallya RK, Leslie RD, et al. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979; 2:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/2\">",
"      NIENHUIS RL, MANDEMA E. A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR. Ann Rheum Dis 1964; 23:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/3\">",
"      Sebbag M, Simon M, Vincent C, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995; 95:2672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/4\">",
"      Palosuo T, Lukka M, Alenius H, et al. Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int Arch Allergy Immunol 1998; 115:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/5\">",
"      Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/6\">",
"      Nielen MM, van der Horst AR, van Schaardenburg D, et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005; 64:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/7\">",
"      Vander Cruyssen B, Cantaert T, Nogueira L, et al. Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Res Ther 2006; 8:R122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/8\">",
"      Dejaco C, Klotz W, Larcher H, et al. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006; 8:R119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/9\">",
"      Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/10\">",
"      Koivula MK, Heli&ouml;vaara M, Ramberg J, et al. Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis. Ann Rheum Dis 2007; 66:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/11\">",
"      Lundberg K, Kinloch A, Fisher BA, et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008; 58:3009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/12\">",
"      Nicaise Roland P, Grootenboer Mignot S, Bruns A, et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther 2008; 10:R142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/13\">",
"      Snir O, Widhe M, von Spee C, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 2009; 68:736.",
"     </a>",
"    </li>",
"    <li>",
"     Hoet R, van Venroijj WJ. The antiperinuclear factor (APF) and antikeratin antibodies (AKA) in rheumatoid arthritis. In: Rheumatoid Arthritis, Smolen JS, Kalden JR, Maini RN (Eds), Springer-Verlag, Berlin 1992. p.299.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/15\">",
"      Vivino FB, Maul GG. Histologic and electron microscopic characterization of the antiperinuclear factor antigen. Arthritis Rheum 1990; 33:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/16\">",
"      Janssens X, Veys EM, Verbruggen G, Declercq L. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. J Rheumatol 1988; 15:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/17\">",
"      Hoet RM, Boerbooms AM, Arends M, et al. Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis 1991; 50:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/18\">",
"      Gom&egrave;s-Daudrix V, Sebbag M, Girbal E, et al. Immunoblotting detection of so-called 'antikeratin antibodies': a new assay for the diagnosis of rheumatoid arthritis. Ann Rheum Dis 1994; 53:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/19\">",
"      Combe B, Dougados M, Goupille P, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001; 44:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/20\">",
"      von Essen R, Kurki P, Isom&auml;ki H, et al. Prospect for an additional laboratory criterion for rheumatoid arthritis. Scand J Rheumatol 1993; 22:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/21\">",
"      Kurki P, von Essen R, Kaarela K, et al. Antibody to stratum corneum (antikeratin antibody) and antiperinuclear factor: markers for progressive rheumatoid arthritis. Scand J Rheumatol 1997; 26:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/22\">",
"      Paimela L, Palosuo T, Aho K, et al. Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis. Ann Rheum Dis 2001; 60:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/23\">",
"      Kurki P, Aho K, Palosuo T, Heli&ouml;vaara M. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992; 35:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/24\">",
"      Aho K, von Essen R, Kurki P, et al. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol 1993; 20:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/25\">",
"      Aho K, Palosuo T, Heli&ouml;vaara M, et al. Antifilaggrin antibodies within \"normal\" range predict rheumatoid arthritis in a linear fashion. J Rheumatol 2000; 27:2743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/26\">",
"      Kessel A, Rosner I, Zuckerman E, et al. Use of antikeratin antibodies to distinguish between rheumatoid arthritis and polyarthritis associated with hepatitis C infection. J Rheumatol 2000; 27:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/27\">",
"      Vossenaar ER, Despr&eacute;s N, Lapointe E, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004; 6:R142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/28\">",
"      Innala L, Kokkonen H, Eriksson C, et al. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008; 35:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/29\">",
"      Hayem G, Chazerain P, Combe B, et al. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol 1999; 26:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/30\">",
"      L&oacute;pez-Longo FJ, Rodr&iacute;guez-Mahou M, S&aacute;nchez-Ram&oacute;n S, et al. Anti-cyclic citrullinated peptide versus anti-Sa antibodies in diagnosis of rheumatoid arthritis in an outpatient clinic for connective tissue disease and spondyloarthritis. J Rheumatol 2006; 33:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/31\">",
"      Bl&auml;ss S, Union A, Raymackers J, et al. The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum 2001; 44:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/32\">",
"      Hassfeld W, Steiner G, Graninger W, et al. Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol 1993; 32:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/33\">",
"      Hassfeld W, Steiner G, Studnicka-Benke A, et al. Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum 1995; 38:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/34\">",
"      Isenberg DA, Steiner G, Smolen JS. Clinical utility and serological connections of anti-RA33 antibodies in systemic lupus erythematosus. J Rheumatol 1994; 21:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/35\">",
"      Mustila A, Paimela L, Leirisalo-Repo M, et al. Antineutrophil cytoplasmic antibodies in patients with early rheumatoid arthritis: an early marker of progressive erosive disease. Arthritis Rheum 2000; 43:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/36\">",
"      Parekh RB, Dwek RA, Sutton BJ, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985; 316:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/37\">",
"      Rook GA, Steele J, Brealey R, et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun 1991; 4:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/38\">",
"      Malhotra R, Wormald MR, Rudd PM, et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995; 1:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/39\">",
"      Graudal NA, Madsen HO, Tarp U, et al. The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2000; 43:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/40\">",
"      Ip WK, Lau YL, Chan SY, et al. Mannose-binding lectin and rheumatoid arthritis in southern Chinese. Arthritis Rheum 2000; 43:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/41\">",
"      Young A, Sumar N, Bodman K, et al. Agalactosyl IgG: an aid to differential diagnosis in early synovitis. Arthritis Rheum 1991; 34:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/42\">",
"      Saulot V, Vittecoq O, Charlionet R, et al. Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum 2002; 46:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/43\">",
"      van Gaalen FA, Toes RE, Ditzel HJ, et al. Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis. Arthritis Rheum 2004; 50:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/44\">",
"      Mewar D, Moore DJ, Young-Min S, et al. Antiferritin antibodies discovered by phage display expression cloning are associated with radiographic damage in rheumatoid arthritis. Arthritis Rheum 2005; 52:3868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/45\">",
"      Zhao J, Zhao Y, He J, et al. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J Rheumatol 2008; 35:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/46\">",
"      Berner B, Wolf G, Hummel KM, et al. Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis. Ann Rheum Dis 2000; 59:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/47\">",
"      Wouters D, Voskuyl AE, Molenaar ET, et al. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products. Arthritis Rheum 2006; 54:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/48\">",
"      Constantin A, Lauwers-Canc&egrave;s V, Navaux F, et al. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: Association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum 2002; 46:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/49\">",
"      Lard LR, van Gaalen FA, Schonkeren JJ, et al. Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum 2003; 48:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/50\">",
"      Emery P, Bradley H, Arthur V, et al. Genetic factors influencing the outcome of early arthritis--the role of sulphoxidation status. Br J Rheumatol 1992; 31:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/51\">",
"      Gauldie J, Richards C, Harnish D, et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987; 84:7251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/52\">",
"      van Gameren MM, Willemse PH, Mulder NH, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994; 84:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/53\">",
"      Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/54\">",
"      van Leeuwen MA, Westra J, Limburg PC, et al. Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis 1995; 54:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/55\">",
"      Engstr&ouml;m-Laurent A, H&auml;llgren R. Circulating hyaluronate in rheumatoid arthritis: relationship to inflammatory activity and the effect of corticosteroid therapy. Ann Rheum Dis 1985; 44:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/56\">",
"      Poole AR, Witter J, Roberts N, et al. Inflammation and cartilage metabolism in rheumatoid arthritis. Studies of the blood markers hyaluronic acid, orosomucoid, and keratan sulfate. Arthritis Rheum 1990; 33:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/57\">",
"      Dahl IM, Husby G. Hyaluronic acid production in vitro by synovial lining cells from normal and rheumatoid joints. Ann Rheum Dis 1985; 44:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/58\">",
"      Paimela L, Heiskanen A, Kurki P, et al. Serum hyaluronate level as a predictor of radiologic progression in early rheumatoid arthritis. Arthritis Rheum 1991; 34:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/59\">",
"      Manicourt DH, Poilvache P, Nzeusseu A, et al. Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest. Arthritis Rheum 1999; 42:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/60\">",
"      Yamanaka H, Matsuda Y, Tanaka M, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000; 43:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/61\">",
"      Green MJ, Gough AK, Devlin J, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003; 42:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/62\">",
"      Masuda M, Morimoto T, De Haas M, et al. Increase of soluble FcgRIIIa derived from natural killer cells and macrophages in plasma from patients with rheumatoid arthritis. J Rheumatol 2003; 30:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/63\">",
"      Forslind K, Eberhardt K, Jonsson A, Saxne T. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol 1992; 31:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/64\">",
"      M&aring;nsson B, Carey D, Alini M, et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995; 95:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/65\">",
"      M&aring;nsson B, Geborek P, Saxne T. Cartilage and bone macromolecules in knee joint synovial fluid in rheumatoid arthritis: relation to development of knee or hip joint destruction. Ann Rheum Dis 1997; 56:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/66\">",
"      Saxne T, Heineg&aring;rd D. Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions. Arthritis Rheum 1992; 35:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/67\">",
"      Garnero P, Landew&eacute; R, Boers M, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002; 46:2847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/68\">",
"      Landew&eacute; R, Geusens P, Boers M, et al. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004; 50:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/69\">",
"      Charni N, Juillet F, Garnero P. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2005; 52:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/70\">",
"      Young-Min S, Cawston T, Marshall N, et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007; 56:3236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/71\">",
"      Saxne T, Zunino L, Heineg&aring;rd D. Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis. Arthritis Rheum 1995; 38:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/72\">",
"      Kollerup G, Hansen M, H&oslash;rslev-Petersen K. Urinary hydroxypyridinium cross-links of collagen in rheumatoid arthritis. Relation to disease activity and effects of methylprednisolone. Br J Rheumatol 1994; 33:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/73\">",
"      Paimela L, Leirisalo-Repo M, Risteli L, et al. Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up. Br J Rheumatol 1994; 33:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/74\">",
"      Aman S, Risteli J, Luukkainen R, et al. The value of synovial fluid analysis in the assessment of knee joint destruction in arthritis in a three year follow up study. Ann Rheum Dis 1999; 58:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/75\">",
"      Hakala M, Risteli J, Aman S, et al. Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression. Scand J Rheumatol 2008; 37:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/76\">",
"      Geusens PP, Landew&eacute; RB, Garnero P, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006; 54:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/77\">",
"      Harada M, Mitsuyama K, Yoshida H, et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998; 27:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/78\">",
"      Ballara S, Taylor PC, Reusch P, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001; 44:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/79\">",
"      Nagashima M, Wauke K, Hirano D, et al. Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/11/2234/abstract/80\">",
"      Rioja I, Hughes FJ, Sharp CH, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 2008; 58:2257.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7488 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-D141E0F7E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2234=[""].join("\n");
var outline_f2_11_2234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26882544\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICALLY USEFUL MARKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INVESTIGATIONAL MARKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immunologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28680421\">",
"      Antiperinuclear factor and antikeratin antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28680428\">",
"      Anti-Sa antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28680483\">",
"      Other autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Cell surface expression of CD40 ligand",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Complement activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Shared epitope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Matrix metalloproteinase genotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Interleukin-10 promoter genotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Sulphoxidation status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acute phase response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Interleukin-6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Tissue-specific markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Synovium-specific markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Cartilage-specific markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Bone-specific markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Vascular markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Plasma proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26882544\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2743?source=related_link\">",
"      Anti-U1 RNP antibodies in mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=related_link\">",
"      Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23546?source=related_link\">",
"      HLA and other susceptibility genes in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_11_2235="Histopathology atropic rhinitis";
var content_f2_11_2235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histopathologic findings in atrophic rhinitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Epithelium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrophy of serous and mucinous glands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of cilia and goblet cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metaplasia of pseudostrafied columnar to islands of squamous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoplasmacytic inflammatory cell infiltrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Submucosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory cell infiltrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endarteritis obliterans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilation of capillaries",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2235=[""].join("\n");
var outline_f2_11_2235=null;
var title_f2_11_2236="Karnofsky performance status scale";
var content_f2_11_2236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Karnofsky performance status scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Value",
"       </td>",
"       <td class=\"subtitle1\">",
"        Level of functional capacity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        Normal, no complaints, no evidence of disease",
"       </td>",
"       <td rowspan=\"3\">",
"        Able to carry on normal activity and to work; no special care needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        Able to carry on normal activity, minor signs or symptoms of disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        Normal activity with effort, some signs or symptoms of disease",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        Cares for self, unable to carry on normal activity or to do active work",
"       </td>",
"       <td rowspan=\"3\">",
"        Unable to work; able to live at home and care for most personal needs; various degrees of assistance needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        Requires occasional assistance, but is able to care for most needs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        Requires considerable assistance and frequent medical care",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        Disabled, requires special care and assistance",
"       </td>",
"       <td rowspan=\"5\">",
"        Unable to care for self; requires equivalent of institutional or hospital care; disease may be progressing rapidly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Severely disabled, hospitalization is indicated although death is not imminent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        Hospitalization is necessary, very sick, active supportive treatment necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        Moribund, fatal processes progressing rapidly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Dead",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2236=[""].join("\n");
var outline_f2_11_2236=null;
var title_f2_11_2237="Banff diagnostic criteria reject allograft nephropathy";
var content_f2_11_2237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Banff diagnostic criteria for rejection and allograft nephropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        1. Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\">",
"        2. Antibody-mediated rejection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Rejection: due, at least in part, to documented",
"anti-donor antibody (suspicious for if antibody not demonstrated). May",
"coincide with categories 3, 4 and 5 - see below",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Type (grade)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. ATN-like - C4d+, minimal inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Capillary - C4d+, capillary margination and/or thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.&nbsp;Arterial - C4d+, transmural arteritis (v3) (see section 4, grade III below)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        3. Borderline changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Suspicious for acute cellular rejection. No",
"intimal arteritis ispresent, but there are foci of mile tubulitis (1-4",
"mononuclear cells/tubular cross-section). May coincide with categories",
"2 and 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        4. Acute/active cellular rejection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        T-cell mediated rejection; may coincide with categories 2 and 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type (grade) of histopathological findings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1A Cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of moderate tubulitis (&gt;4",
"mononuclear cells/tubular cross section or group of 10 tubular cells)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1B Cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of severe tubulitis (&gt;10",
"mononuclear cells/tubular cross-section or group of 10 tubular cells)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2A Cases with mild to moderate intimal arteritis (v1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2B Cases with severe intimal arteritis comprising &gt;25% of the luminal area (v2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3 Cases with transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation (v3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        5. Chronic/sclerosing allograft nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Fibrosing changes in the allograft, with or",
"without features of true alloimmune injury to the graft; may coincide",
"with categories 2, 3 and 4.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Mild interstitial fibrosis and tubular atrophy without (a) or with (b) specific changes suggesting chronic (mild) rejection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderate interstitial fibrosis and tubular atrophy (a) or (b) (moderate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Severe interstitial fibrosis and tubular atrophy and tubular loss (a) or (b) (severe)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        6. Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Changes not considered to be due to rejection; may coincide with categories 2, 3, 4 and 5.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Racusen, CR, Solez, K, Mihatsch, MJ, et al. Am J Transplant 2003; 3:708.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2237=[""].join("\n");
var outline_f2_11_2237=null;
var title_f2_11_2238="Inherited metabolic disease";
var content_f2_11_2238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Transplantation of allogeneic hepatocytes in patients with inherited metabolic diseases (n=16)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnosis, [reference]",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Procedure and outcome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Alpha-1 antitrypsin-deficiency (with cirrhosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [1,2]",
"       </td>",
"       <td>",
"        4.5 months",
"       </td>",
"       <td>",
"        Intraportal infusion. OLT after 4 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Crigler-Najjar syndrome type 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [3]",
"       </td>",
"       <td>",
"        10 years",
"       </td>",
"       <td>",
"        Intraportal (7.5x10",
"        <sup>",
"         9",
"        </sup>",
"        hepatocytes). Total bilirubin 50 percent &darr;. Bilirubin glucuronides detected in bile up to 3.5 years. Auxilliary liver transplantation at 4 years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [4]",
"       </td>",
"       <td>",
"        2 weeks-3 months",
"       </td>",
"       <td>",
"        4.3x10",
"        <sup>",
"         9",
"        </sup>",
"        (cryopreserved): 9 infusions at 2 weeks; 1 infusion at 3 months. At 9 months total bilirubin  40 percent &darr;.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [5]",
"       </td>",
"       <td>",
"        9 years",
"       </td>",
"       <td>",
"        Intraportal (3.5x10",
"        <sup>",
"         9",
"        </sup>",
"        + 4x10",
"        <sup>",
"         9",
"        </sup>",
"        cells over 2 hours), total bilirubin 50 percent &darr;. OLT after 4.6 months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [1]",
"       </td>",
"       <td>",
"        8 years",
"       </td>",
"       <td>",
"        Intraportal (1.5x10",
"        <sup>",
"         9",
"        </sup>",
"        cells over 1 hour). Total bilirubin 30 percent &darr;.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Factor VII deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [6]",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Intraportal in two brothers (1x10",
"        <sup>",
"         9",
"        </sup>",
"        fresh cells and 2.2x10",
"        <sup>",
"         9",
"        </sup>",
"        cryopreserved cells). Exogenous FVII reqirement 80 percent &darr;. OLT after 6 months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Glycogen storage disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [7]",
"       </td>",
"       <td>",
"        Child",
"       </td>",
"       <td>",
"        Intraportal infusion. On normal diet with no hypoglycemic episode after transplantation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [1]",
"       </td>",
"       <td>",
"        18 years",
"       </td>",
"       <td>",
"        Intraportal (3x10",
"        <sup>",
"         9",
"        </sup>",
"        cells), 3 infusions at one-week intervals, one infusion (3x10",
"        <sup>",
"         9",
"        </sup>",
"        cells) after 1 month from a second donor. Glucose-6-phosphatase activity normal 3 weeks and 7 months later.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Infantile refsum's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [8]",
"       </td>",
"       <td>",
"        4 years",
"       </td>",
"       <td>",
"        Intraportal (2x10",
"        <sup>",
"         9",
"        </sup>",
"        cells, 8 infusions). Pipecholic acid &darr;. Engrafted hepatocyte mass 0.25 percent (by SRY-PCR).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Progressive familial intrahepatic cholestasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [4]",
"       </td>",
"       <td>",
"        Two children",
"       </td>",
"       <td>",
"        Intraportal (3x10",
"        <sup>",
"         8",
"        </sup>",
"        fresh cells, each). No improvement. OLT at 5 and 14 months, respectively.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Ornithine transcarbamylase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [9]",
"       </td>",
"       <td>",
"        5 years",
"       </td>",
"       <td>",
"        Intraportal (1x10",
"        <sup>",
"         9",
"        </sup>",
"        fresh cells). OTC 0.5 percent of normal on biopsy at day 28. Died of sepsis at day 42.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [10]",
"       </td>",
"       <td>",
"        Two infants",
"       </td>",
"       <td>",
"        Intraportal (4x10",
"        <sup>",
"         9",
"        </sup>",
"        fresh cells). NH",
"        <sub>",
"         3",
"        </sub>",
"        &darr; for 11 days. OLT.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [11]",
"       </td>",
"       <td>",
"        Newborn",
"       </td>",
"       <td>",
"        Infused through  umbilical vein (1.9x10",
"        <sup>",
"         9",
"        </sup>",
"        cells). Normal NH",
"        <sub>",
"         3",
"        </sub>",
"        on normal protein diet. OLT at 7 months with no neurological abnormality.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Citrulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [1]",
"       </td>",
"       <td>",
"        2 years and 1 month",
"       </td>",
"       <td>",
"        Intraportal (1x10",
"        <sup>",
"         9",
"        </sup>",
"        cells, 3 months later, 2x10",
"        <sup>",
"         9",
"        </sup>",
"        cells from a second donor). Citruline and NH",
"        <sub>",
"         3",
"        </sub>",
"        &darr; at 2 weeks and 6 months.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Fisher RA, Strom SC. Human hepatocyte Transplantation: Worldwide results. Transplantation 2006; 82:441.",
"     <br>",
"      2. Strom SC, Chowdhury JR, Fox IJ. Hepatocyte transplantation for the treatment of human disease. Semin Liver Dis 1999; 19:39.",
"      <br>",
"       3. Fox IJ, Roy-Chowdhury J, Kaufman SS, et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 1998; 338:1422.",
"       <br>",
"        4. Hughes RD, Mitry RR, Dhawan A. Hepatocyte transplantation for metabolic liver disease: UK experience. J Royal Soc Med 2005; 98:341.",
"        <br>",
"         5. Ambrosino G, Varotto S, Strom SC, et al. Isolated hepatocyte transplantation for Crigler-Najjar Syndrome Type 1. Cell Transplantation 2005; 14:151.",
"         <br>",
"          6. Dhawan A, Mitry RR, Hughes RD, et al. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 2004; 78:1812.",
"          <br>",
"           7. Muraca M, Gerunda G, Neri D, et al. Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet 2002; 359:317.",
"           <br>",
"            8. Sokal EM, Smets F, Bourgois A, et al. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. Transplantation 2003; 76:735.",
"            <br>",
"             9. Strom SC, Fisher RA, Rubinstein WS, et al. Transplantation of human hepatocytes. Transplant Proc 1997; 29:2103.",
"             <br>",
"              10. Horslen SP, McCowan TC, Goertzen TC, et al. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 2003; 111:1262.",
"              <br>",
"               11. Mitry RR, Dhawan A, Hughes RD, et al. One liver, three recipients-segment IV from split liver procedure as a source of hepatocytes for cell transplantation. Transplantation 2004; 77:1614.",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2238=[""].join("\n");
var outline_f2_11_2238=null;
var title_f2_11_2239="Adult three part humerus fracture";
var content_f2_11_2239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Three-part proximal humerus fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior radiograph shows a fracture of the surgical neck of the humerus. A portion of the surgical neck and the greater tuberosity are displaced from head and shaft. In the Neer classification system this is categorized as a three-part proximal humerus fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_11_2239=[""].join("\n");
var outline_f2_11_2239=null;
